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CHAPTER 1
INTRODUCTION
1.1 Abstract
cis-Diamminedichloridoplatinum(II), or cisplatin (1), is a widely used platinumcontaining anticancer drug.1 Cisplatin is only effective against certain cancers, including
testicular and ovarian cancer.2 Although cisplatin in its mono- or bis-aquated form can
coordinate to RNA, enzymes, and other sulfur-containing proteins, its anticancer activity
is attributed to DNA binding.3 Despite its effectiveness against certain cancers, clinical
usage of cisplatin is restricted by a number of dose-dependent side effects such as
nephrotoxicity and neurotoxicity.4 Additionally, certain cancers showed intrinsic or
developed resistance to cisplatin therapy.5,6 Over the past few decades, scientists have
been trying to develop new platinum-based anticancer drugs that can overcome these
problems. This chapter summarizes the mechanism of action, binding targets, and
drawbacks of cisplatin and cisplatin analogs.

2
1.2 Cisplatin in cancer therapy
1.2.1 Discovery of cisplatin
Cisplatin (cis-diamminedichloridoplatinum(II)) is one of the most commonly used
anticancer drugs in the world with a high success rate.7 The serendipitous discovery of
the antitumor activity of cisplatin in the 1960s opened up a field of metallodrug
development for cancer treatment. Dr. Barnett Rosenberg, a physicist at Michigan State
University, was interested in studying the impact of electric currents on cellular division
in bacteria.8 He carried out experiments using an apparatus with platinum electrodes
immersed in ammonium chloride buffer, and he monitored Escherichia coli (E. coli) cell
growth. After a period of time, E. coli cells were viewed under a microscope and found to
have a long and filamentous shape instead of their normal length. This shape difference
was found to be due to inhibition of cellular division.8 With further experiments, the
compound that causes the inhibition was found to be a platinum(IV) complex with the
formula [PtCl4(NH3)2] in its cis form.9 Because of the observed antiproliferative
properties, it was of interest to test platinum compounds for their anticancer activity.
Rosenberg and coworkers used the platinum(IV) complex cis-[PtCl4(NH3)2] and
platinum(II) complex cis-[PtCl2(NH3)2] against Sarcoma 180 tumors in mice.10 The cis
form of the platinum(II) complex cisplatin (cis-[PtCl2(NH3)2]) was found to be the active
isomer; whereas, the trans complex was inactive (Figure 1.1). The treatment of tumors
was a success, with mice showing no signs of cancer after 6 months.10 Following that
result, cisplatin entered clinical trials and was approved for clinical usage in 1978. 11
Since then, it is been used to treat testicular cancer with over a 90% cure rate.1
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Furthermore, cisplatin has been widely used to treat several other cancer types, including
ovarian, cervical, head and neck, and non-small-cell lung cancer.1

Figure 1.1. Structures of cisplatin (1) and transplatin (2). Both compounds have
square planar geometry.
1.2.2 The structural components of cisplatin
The structure of cisplatin (1) (Figure 1.1) was first discovered by an Italian
doctor, Michel Peyrone, in 1845.12 It has a square planar geometry with two chlorido
ligands and two ammine ligands coordinated to the platinum metal center in the cis form.
The transition metal platinum is in the +2 oxidation state, giving an overall charge of zero
to the complex. Based on the mechanism of action, the chlorido ligands are displaced by
water (aqua ligand) and the ammine ligands remain coordinated to the platinum center.
Therefore, chlorido ligands are referred to as the “leaving groups”, whereas the ammine
ligands are referred to as the “carrier ligands” or “non-leaving groups.” As shown in
Figure 1.1, two isomers exist, referred to as cisplatin (1) and transplatin (2).
1.2.3 Mechanism of action of cisplatin
The anticancer activity of cisplatin is generally believed to be derived from its
interactions with DNA.12 When cisplatin is administered intravenously, it encounters a
relatively high Cl- concentration (around 100 mM) in the blood. The higher Clconcentration (compared to cytoplasm) prevents displacement of the chlorido ligand on 1
by water, and the complex remains in the neutral state. Cisplatin can enter cells via

4
passive diffusion or via active transport using Cu-transporting proteins.13,14 Inside the
cell, the Cl- concentration is lower (4-20 mM) than outside, causing the cisplatin to
undergo aquation and yielding a positively charged species, [PtCl(H2O)(NH3)2]+.15 The
aquation is the rate-determining step of cisplatin coordination to DNA with a rate of 10.2
× 10-5 s-1(Figure 1.2).16

Figure 1.2. Ligand exchange equilibria for cisplatin. The chlorido ligands of cisplatin
are displaced by one or two aqua ligands to produce cationic mono- and diaqua
complexes, respectively. The monoaqua complex readily coordinates to the N7 position
of a guanine base in DNA. A bifunctional DNA adduct is formed after the second
chlorido ligand is replaced with an aqua ligand. The rates shown are from the literature.16
Monoaquation leads to generation of the charged reactive species of cisplatin
(Figure 1.3, 3) and also prevents the molecule from diffusing out of the cell.17
Electrostatic interactions favor attraction of the positively charged 3 to the negatively
charged nucleic acid backbone. Upon interaction near a purine base, the aqua ligand is
displaced from 3 and cross-linking to the nucleic acid occurs.3 After subsequent
displacement of the second chlorido ligand by a neighboring purine base, a stable adduct
is generated.15 Cisplatin preferentially coordinates to the N7 position of deoxyguanosine
(dG) residues in DNA and makes 1,2-intrastrand d(GpG) adducts (Figure 1.3).18 The
compound is also known to make 1,2-intrastrand d(ApG) (dA is deoxyadenosine), 1,3-
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intrastrand d(GpXpG), in which X is an intervening deoxynucleotide, and interstrand
adducts with DNA.3 The adduct formation distorts the DNA structure because of the
structural constraints of the Pt atom. In particular, the 1,2-intrastrand adducts unwind and
bend the DNA towards the major groove, exposing the minor groove.1 Proteins, such as
those belonging to the high-mobility group (HMG) class, repair enzymes, and
transcription factors, preferentially bind to the exposed shallow and wide minor groove
and initiate DNA repair processes or signaling cascades for apoptosis.19,20

Figure 1.3. A general pathway of cisplatin mechanism of action.17 Cisplatin (1)
undergoes aquation and produces a positively charged species (3) inside the cell.
Compound 3 coordinates to DNA and forms different adducts as shown. The adducts
distort the DNA structure and initiate signaling cascades for cell death.
There is evidence to suggest that cisplatin reacts with many other cellular
components in the cell other than DNA.17 RNA, proteins, and other small molecules,
particularly those that contain thiol groups such as glutathione, are some of the cellular
targets of cisplatin (more details will be given in Sections 1.3 and 1.4.2). The nature of
these reactions and their contributions toward the overall anticancer activity of cisplatin
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are not fully understood due to the complexity of the intracellular environment and the
lack of methodologies to investigate these processes.17 Experiments are often carried out
under in vitro conditions using activated cisplatin (aquated) and conditions that mimic the
cellular environment to understand cisplatin accumulation on cellular components and
how the resulting adducts affect normal cellular functions.15
1.3 DNA as a target of cisplatin
Numerous studies have focused on DNA as the main biological target of cisplatin
that triggers the anticancer activity.12 There is extensive evidence that points to DNA as
the primary target of cisplatin. Bacteria treated with cisplatin have shown phenotypic
characteristics that are similar to the effects caused by DNA-damaging agents.21
Moreover, DNA repair-deficient cells have shown more sensitivity towards cisplatin,
strongly supporting DNA as the major cellular target.22
Cisplatin enters the cell, undergoes mono- and/or bisaquation, and forms the
activated species such as 3. These species need to cross into the nucleus in order to react
with DNA. Once inside the nucleus, due to the high nucleotide concentration, aquated
cisplatin readily reacts with DNA. Isolated and purified DNA from leukocytes of cancer
patients following cisplatin treatment showed the presence of approximately 65% of 1,2d(GpG), 25% of 1,2-d(ApG), and 5-10% of 1,3-d(GpXpG) intrastrand cross-links.19,23
Monofunctional adducts and interstrand adducts were also present in a smaller
percentage. A significant structural effect on DNA was observed with the intrastrand
adducts. The major 1,2-intrastrand cross-links unwind the DNA duplex and cause
bending towards the major groove to generate a widened and shallow minor groove
(Figure 1.4a).24 The cis-GG bend angle caused by 3 coordination (1,2-adduct) has been
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quantified to be 32° using a gel electrophoresis mobility shift assay, and the angle for cisAG adducts is 34°.24 Another study reported bending of 33-35° and an unwinding angle
of 15-20° in a DNA double helix.25 The interstrand cross-links also cause detrimental
effects to the DNA structure by bending the helix towards the minor groove as shown in
the X-ray crystal structure of a short DNA oligomer. (Figure 1.4c).26 Overall, cisplatin
binding impacts the duplex DNA structure to a level that significantly affects replication,
transcription, and repair.17 A variety of cellular proteins recognize and bind to the
platinated DNA.17 Depending on the recognition selectivity and processing of the
platinum adducts by cellular proteins, cytotoxicity of cisplatin would be mediated.
(a)

(b)

(c)

Figure 1.4. Different adducts of cisplatin on double-stranded DNA. A cisplatin 1,2d(GpG) intrastrand cross-link on an 12-mer DNA (PDB ID: 1AIO) (a) is shown in
comparison to a 1,3-d(GpTpG) intrastrand cross-link (PDB ID: 1DA4) (b), and an
interstrand cross-link (PDB ID: 1A2E) (c). The DNA sequences (grey) for the 1,2d(GpG) and 1,3-d(GpTpG) intrastrand adducts are d(CCTCTGGTCTCC) and
d(CTCTAGTGCTCAC), respectively, with their complementary sequences. The
interstrand cross-link is shown at the DNA duplex with the sequence
(CCTCG*CTCTC)d(GAGAG*CGAGG), where the adduct formation sites are indicated
by asterisks. The C residues that are complementary to the Gs shown in asterisks are
exposed to solvent in the crystal structure 1A2E. The cisplatin adduct is shown in red.

8
Inhibition of DNA replication by cisplatin was discovered by using partially
purified human DNA polymerase  and  with template DNA.27 Further experiments
showed inhibition of activity of DNA polymerase I and III, as well as T4 DNA
polymerase, caused by cisplatin adducts.28 Both DNA and RNA polymerases are strongly
blocked by the bifunctional adducts compared to monofunctional adducts. Inhibition of
transcription by cisplatin adducts was shown in in vitro studies using wheat germ RNA
polymerase II, E. coli T7, and SP6 RNA polymerases.29,30 Since RNA polymerase II is an
abundant protein in the cell and the main enzyme used to produce mRNA, it has been
studied extensively with regard to cisplatin damage.30 In vitro experiments done using
purified RNA polymerase II, transcription factors, and DNA templates have shown that
the elongation is blocked by cisplatin 1,2-(GpG) and 1,3-(GpTpG) intrastrand cross-links
(Figures 1.4a and 1.4b).17 In addition, RNA polymerase II stalling at the platination site
has been shown to act as a signal to initiate transcription-coupled repair or programmed
cell death.31
In eukaryotes, DNA is associated with histone proteins and compacted into
chromatin.32 Cisplatin has shown preferred binding to the open form of chromatin.33
Cisplatin binding also blocks transcription factor binding and chromatin remodeling,34 as
well as inducing phosphorylation and hyperacetylation in histone H3 and H4 proteins in
HeLa cells, respectively.35 Furthermore, a recent structural analysis of a nucleosome
containing a site-specific 1,3-(GXG) intrastrand adduct showed that the adduct changes
the rotational setting of the DNA wrapped around the histone proteins.36
Cisplatin adducts on DNA can be removed by different repair pathways. The
primary process for cisplatin-damaged DNA repair is the nucleotide excision repair
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pathway (NER).17 Transcription-coupled repair (TCR) and global genomic repair (GGR)
are the two key initial mechanisms of NER (Figure 1.5). Xeroderma pigmentosum
proteins (XPA, XPB, XPC, XPD, XPF, XPE, and XPG) are involved in these
mechanisms. As mentioned earlier, the signal to initiate TCR is RNA polymerase II
stalling at the platination site and interactions with cockayne syndrome proteins, CSA
and CSB.37 For GGR, XPC-HR23B is the damage recognition protein.17 After the initial
recognition, both TCR and GGR follow the same path to repair the DNA. First, proteins
XPA, replication protein A (RPA), and transcription factor TFIIH assemble on the DNA
in a cooperative fashion.17 XPB and XPD helicases, which are components of TFIIH, are
responsible for DNA unwinding, and XPG binds to the unwound DNA. This step is
followed by XPF-ERCC1 binding and removal of oligonucleotides containing the
platinum adducts by a dual incision. RPA then recruits DNA resynthesis factors to fill the
gap. This pathway of DNA repair has been well studied, and supported by the fact that
Xeroderma pigmentosum cell lines lacking components of NER are more sensitive to
cisplatin than normal cells.38
Overall, the significant effect and outcomes of cisplatin binding to DNA on
replication, transcription, and repair processes are evidence to confirm that DNA is a
major target of cisplatin. However, there are still many problems associated with the
drug, which will be discussed later in Section 1.4.
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Figure 1.5. Nucleotide excision repair pathway for removing cisplatin lesions. The
proteins involved in the transcription-coupled repair pathway or global genome repair
pathway initially recognize the Pt lesion (red), which is then removed by the NER
pathway. The Pt adduct is removed along with a flanking DNA region that is 24 to 32
nucleotides in length.
1.4 RNA as a target of cisplatin
The idea of cisplatin binding to DNA as the main driver for cancer cell apoptosis
has been challenged by a variety of studies that show cisplatin binding to RNA, proteins,
peptides, and lipids.39-41 These studies point to cisplatin toxicity originating from multiple
sources rather than solely from binding to DNA. Among these, RNA is a poorly
characterized target considering its important regulatory roles in the cell. Particularly
considering cisplatin coordination modes with purine bases, RNA could also be a target,
possibly leading to some of the toxicity caused by the drug. Various regulatory roles of
RNA suggest that its platination could have negative impacts on biological systems.
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Experiments have been done to characterize cisplatin binding sites on RNA and
determine rates of reactions with RNA compared to DNA. For example, cisplatin binding
sites in ribosomal RNA hairpins were analyzed using radioactive labeling and enzymatic
footprinting.42,43 The binding preference of cisplatin for certain RNA secondary
structures was analyzed by the Elmroth group using full-length tRNAAla and hairpin
models of its acceptor stem and anticodon loop, and the results showed that platinum
coordination to RNA is highly sequence and structure dependent.44,45 In a recent report by
the DeRose lab, RNA-Pt adducts in cisplatin-treated Saccharomyces cerevisiae were
quantified by using inductively coupled plasma mass spectrometry (ICP-MS).46 These
results suggested that cisplatin accumulates faster and is retained more on RNA
compared to DNA. These studies also showed that cisplatin could interfere with several
enzymatic activities, including exonuclease, endonuclease, and reverse transcriptase,
even with a single adduct on the RNA strand. A number of studies focused on evaluating
the reaction kinetics of cisplatin on DNA and RNA.47-50 In one of those studies, cisplatin
and its derivatives were reacted with RNA and DNA hairpins of similar sequence,
namely r(CGCGUUGUUCGCG) and d(CGCGTTGTTCGCG), and found to have higher
platination rates with the RNA hairpin.51
Very few crystal structures of platinum compounds bound RNA were available up
to 2016. A low-resolution structure of yeast tRNAPhe showed two major cisplatin binding
sites.52 The first nearly atomic resolution crystal structure of cisplatin bound to the
Thermus thermophilus 70S ribosome was reported in 2016.40 This 2.6 Å-resolution X-ray
structure reported nine cisplatin binding sites on the ribosome out of 2200 potential
modification sites (Figure 1.6). Among these sites, two were found on the 30S small
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subunit, six were on the 50S large subunit, and one was bound to the L9 ribosomal
protein. When comparing the cisplatin coordination sites, three were located at the N7
position of adenosine nucleotides (A790 of 16S rRNA; A1848 and A2531 of the 23S
rRNA), and five were at the N7 atoms of guanosines (G1300 of 16S rRNA; and G27,
G425, G1606, and G2220-2221 of 23S rRNA). These crystal structure data shed light on
our understanding of the RNA-cisplatin interactions and patterns, such as base preference
and site of modification.
(a)

(b)

50S

30S

Figure 1.6. The crystal structure of Thermus thermophilus ribosomal subunits with
cisplatin binding sites (PDB ID: 5J4B).40 (a) The 50S subunit is shown with six
cisplatin adducts (red) on 23S rRNA (grey) and one adduct on the L9 ribosomal protein
(green). (b) The 30S subunit has two cisplatin binding sites. Examples of cisplatin
binding at different residues, namely (c) G26, (d) A2531, and (e) Met1 of the L9 protein
are shown. The A-, P-, and E-site bound tRNAs are shown in orange.
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The previous work mentioned above led to the hypothesis that RNA-related
processes may be inhibited by cisplatin and its derivatives. An earlier study done with
platinated messenger RNA showed inhibition of in vitro translation activity.53
Concentration and time-dependent inhibition of peptide synthesis were observed by
cisplatin in this study, and maximum inhibition was detected after 30 min drug exposure.
Furthermore, inhibition of peptide synthesis was observed at cisplatin concentrations as
low as 3 M. Another study showed that cisplatin is capable of making cross-links in
structurally complex RNAs such as the internal loop region of spliceosomal RNAs.54
Moreover, a cisplatin derivative was used to introduce a site-specific cross-link within the
active site of a hammerhead ribozyme.55 These studies showed that platinum compounds
have the ability to introduce distance constraints for dynamic and complex RNA
structures, therefore impacting the RNA function. Another study revealed inhibition of
telomerase activity caused by cisplatin binding in human testicular cancer cells.56
Telomerase is a ribonucleoprotein that adds TTAGGG tandem repeat sequences to
telomeres using the RNA component of the enzyme. The telomere, the RNA component
of the telomerase enzyme, and the gene encoding the RNA component all contain G-rich
sequences; therefore, cisplatin is capable of making cross-links and inhibiting the
telomerase activity through multiple mechanisms. Reduced telomerase activity is
observed in a concentration-dependent manner by cisplatin; whereas, there weren’t any
effects from chemotherapy drugs known to target DNA, such as doxorubicin, bleomycin,
methotrexate, and melphalan.56
As discussed above, cisplatin and platinum(II) compounds have been studied in
order to identify their RNA binding sites and to determine their effects on RNA activity,
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including the impact on mRNA, tRNA, rRNA, spliceosomal, and telomeric RNA
function. However, the underlying mechanism of RNA recognition by cisplatin and
thereby the inactivation of RNA is still not fully understood. Considering the fact that
cisplatin and its derivatives are capable of inactivating a number of essential RNA-related
functions, determining the link between RNA and cisplatin toxicity seems worthwhile.
1.5 Drawbacks associated with platinum-based anticancer drugs
Despite its significant success, cisplatin is not a perfect anticancer drug. The side
effects caused by cisplatin are a significant limitation.57 Common side effects include
nausea, vomiting, diarrhea, temporary hair loss, signs of dehydration, neurotoxicity,
nephrotoxicity, and ototoxicity.57 The severe side effects of cisplatin result in part from
its inability to distinguish tumor cells from normal cells. Therefore, a major concern for
next-generation anticancer drug development is achieving selectivity for tumors over
normal cells in humans.
On another note, cisplatin is successful for treatment of only certain cancers, and
is therefore not universally employed for all cancers. For example, cisplatin cures
testicular cancer with a rate of 90%, and nearly 100% if the cancer is found in the early
stages.17 With ovarian cancer, there is an initial cure rate of up to 70% with cisplatin;
however, the five-year patient survival rate is about 15-20%.58 With small cell lung
cancer, the relapse rate could be as high as 95%.58 This relapse occurs as cancer cells
develop resistance to cisplatin therapy over time.59 Some cancers could be intrinsically
resistant to cisplatin and other platinum-based drugs, whereas others acquire resistance
over time.59 The cross-resistance of tumors to diverse antitumor drugs suggests that they
could share common mechanisms of resistance.58 Therefore, it is important to understand
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these resistance mechanisms to refine therapeutic approaches to battle cancer. Figure 1.7
summarizes the major pathways that cancer cells could use to develop resistance towards
cisplatin and other platinum drugs. Such resistance mechanisms arise as a result of
intracellular changes that prevent cisplatin from binding to DNA, activating the apoptotic
signal pathway, or both. These pathways include changing the amount of cisplatin uptake
and efflux, detoxification of the drug, platinum adduct repair in the cell, and inhibition of
apoptosis. These mechanisms are discussed below in detail.

Figure 1.7. Cisplatin resistance mechanisms.60 The level of cisplatin in the cell and
how the cell responds to the drug in the cytoplasm and nucleus determine the anticancer
activity of cisplatin.
1.5.1 Decreased uptake and increased efflux
The level of drug accumulation inside the cell determines the anticancer activity
of the molecule. Drug accumulation changes as a result of reduced drug uptake, increased
efflux, or both.58 Tumor cells that are resistant to cisplatin have shown a higher
expression of the MRP2 membrane protein, which is associated with cellular efflux of the
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drug.61 Cells overexpressing the MRP2 gene have demonstrated a 10-fold higher
resistance to cisplatin than cells with normal levels of MRP2.61 Cells overexpressing
ATP7B, a copper-transporting P-type ATPase protein, demonstrated a 9-fold greater
resistance to cisplatin due to higher efflux.62 Some studies also showed that cells with
increased levels of p-glycoprotein or the major vault/lung resistance-related protein
(MVP/LRP) also have poor outcomes towards cisplatin therapy.58 However, further work
is required to confirm the role of these proteins in cisplatin resistance.
1.5.2 Detoxification by thiol-containing molecules
After activation in the cell, the aquated form of cisplatin is very reactive towards
cellular components, particularly the abundant glutathione (GSH) and cysteine-rich
metallothioneins.58 Based on the hard-soft acid-base (HSAB) principle, Pt(II) is a
relatively soft acid that can readily coordinate with soft bases such as RS-.63 Coordination
of cisplatin with cellular thiol-containing molecules decreases the level of available
complex to react with DNA, therefore promoting cisplatin resistance. This correlation
between increasing levels of GSH and resistance was confirmed with a panel of resistant
ovarian tumor models and in clinical studies.64,65 Metallothioneins also have S-containing
reactive centers that participate in cisplatin coordination; therefore, it is not surprising to
see elevated metallothionein levels in cisplatin-resistant tumor cells.66 Increased GSH
expression level is a result of increased expression of the γ-glutamylcysteine synthetase
(γ-GCS) gene, which is an important enzyme for GSH biogenesis.67 Higher expression of
GSH and metallothionine following cisplatin treatment could result from their
involvement in controlling drug-induced oxidative stress in the cell.68
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1.5.3 Increase in DNA damage repair
Cisplatin-induced DNA damage repair is explained in the Section 1.2. NER is the
main mechanism used to remove the platinum adducts from DNA. Since DNA adduct
formation is believed to be the lead mechanism for anticancer activity of cisplatin,
removal of these adducts could be another pathway to acquire resistance. ERCC1 is one
of the core proteins associated with the NER pathway, and up regulation of this protein is
associated with cisplatin-based resistance due to increased DNA damage repair.69 DNA
mismatch repair (MMR) is another pathway for DNA damage repair in cells.70 The down
regulation or mutations in the MMR genes and the proteins (MutSα and MutSβ) in the
MMR pathway are associated with cisplatin resistance.71 Base excision repair (BER) has
been proposed to play a role in cisplatin resistance in cells as well.72 Low-fidelity DNA
polymerase β, which is a part of the BER machinery, is capable of bypassing cisplatin
intrastrand adducts, which might lead to cisplatin DNA-damage tolerance.70 Overall,
increased removal of cisplatin adducts in the NER pathway, reduced cytotoxicity due to
poor recognition of the adducts, and bypassing cisplatin intrastrand adducts in the MMR
and the BER pathways lead to cisplatin resistance in cancer cells. To overcome the
cisplatin-associated resistance, new drugs need to be developed with different anticancer
mechanisms.
1.6 Other platinum-based anticancer compounds
Since its introduction as a cancer therapeutic, cisplatin has made a major impact
in cancer medicine as a successful drug and also as a model for platinum-based
anticancer drug development.7 Unfortunately, cisplatin is not universally effective on
every cancer type and also has drawbacks as discussed in Section 1.4, thus emphasizing
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the need for new drug development. The general structural features of the platinum
compounds are shown in Figure 1.8.73 Varying ligands contribute to the anticancer
properties of the drug differently; therefore, it is important to understand these features to
strategically modify or synthesize novel compounds. The non-leaving group, L, has the
ability to interact with DNA and is usually a nitrogen donor. This group will determine
the nature of the Pt adduct, structural impacts, and the resistance profile. The leaving
group, X, will be removed upon aquation and governs the aquation kinetics and toxicity
profiles. Typically, platinum(II)-based drugs have two L groups and two X groups in the
cis configuration. By strategically modifying the ligands, the lipophilicity and solubility
of the complex can be altered. Platinum(IV) complexes have additional axial ligands (R
groups) that govern cell targeting, lipophilicity, and solubility.

Figure 1.8. Different components of classical platinum anticancer drugs. The
properties determine by each group are listed. Platinum(II) drugs have two X and two L
groups in the cis configuration. Platinum(IV) compounds have two additional groups, R.
1.6.1 Clinically available platinum drugs
Out of more than thousands of molecules that have been synthesized and tested
for anticancer properties, only two have been approved for clinical use worldwide along
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with cisplatin. They are carboplatin and oxaliplatin (Figure 1.9).73 Nedaplatin, lobaplatin,
and heptaplatin are approved for regional use in Asia (Figure 1.9).73 Overall, these
molecules bind to DNA and have a similar mechanism of action as cisplatin leading to
apoptosis. However, differences in the non-leaving group ligands result in different DNA
adduct profiles, and therefore could be repaired at different rates.
The success of cisplatin led to a systematic development of new platinum-based
drugs. Carboplatin is one such outcome that was approved for medical use in 1989.74 It is
widely used to treat ovarian cancers, but has also been used for brain, breast, testes,
cervix, and lung cancers. It has a relatively stable 1,1-cyclobutanedicarboxylato
(CBDCA) ligand as its leaving group that has a lower aquation rate (rate-determining
step in the mechanism) and lower toxicity than cisplatin.75 It therefore has lower reaction
kinetics with cellular components compared to cisplatin, thus limiting off-target effects.
Because of these reasons, higher doses of carboplatin can be administered. 76 On the other
hand, it has the same ammine groups as non-leaving group ligands; therefore, carboplatin
has a similar mechanism of action and resistance profile as cisplatin.75
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Figure 1.9. Structures of clinically approved platinum(II) drugs. Carboplatin and
oxaliplatin are second-generation Pt(II) drugs, and nedaplatin, heptaplatin, and lobaplatin
are third-generation drugs.
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Oxaliplatin gained approval for international marketing in 1996 for combination
chemotherapy for colon cancer.77 It has an oxalate leaving group and R,Rdiamminocyclohexane (DACH) non-leaving group ligand. Experimental data revealed
that oxaliplatin utilizes organic cation transporters (OCT) for cell penetration, and the
overexpression of OCTs in colon cancer provides a rationale for effectiveness of this
drug against colon cancer.77
Nedaplatin was developed in Japan and approved for clinical use in 1995.78 The
glycolate leaving group confers higher water solubility to the molecule compared to
cisplatin. Nedaplatin has the same non-leaving ammine ligands as cisplatin and
carboplatin. It is primarily used to treat esophagus, head and neck, small cell lung
cancers, and non-small cell lung cancers.79
Heptaplatin and lobaplatin are third-generation cancer drugs. Hepataplatin was
developed in Korea to treat gastric cancer.7 As shown in Figure 1.9, it has a malonate
leaving group and 2-(1-methylethyl)-1,3-dioxolane-4,5-dimethanammine as the nonleaving group ligand, which forms a seven-membered chelate ring.80
Lobaplatin was initially developed in Germany, but only has regulatory approval
for clinical use in China.7 Initially it was used to treat chronic myelogenous leukemia, but
is now used to also treat small cell lung cancers and metastatic breast cancer.7 Lobaplatin
is a heptaplatin derivative, but with different L and X ligands.
1.6.2 Other Pt(II) complexes
A large number of platinum(II) complexes has been developed and tested for their
anticancer activity in both academia and industry. Conjugation of biologically available
molecules is a common approach scientists are using in the hopes of lowering the toxicity
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and achieving selectivity of platinum-based drugs. For example, glycoconjugation has
been introduced to selectively target cancer cells with higher glucose transporter
expression. Furthermore, these compounds have increased water solubility and reduced
toxicity. There are a variety of platinum-containing molecules with sugar groups attached
as non-leaving groups or leaving groups that are analogous to cisplatin and oxaliplatin
(Figure 1.10).81-83 Primarily, the work in this area has been limited to synthesis of the
complexes and testing for cytotoxicity. The first Pt(II) complex with an attached amino
sugar is shown in Figure 1.10a.84 Recently, some effort has been made to establish a link
between platinum-sugar conjugation and uptake using specific receptors in cancer cells.83
The first experimental evidence of sugar-linked oxaliplatin analogs exploiting the glucose
receptor was reported in 2013.81
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Figure 1.10. Structures of carbohydrate-linked Pt(II) complexes. (a) PtCl2(methyl
2,3-diammino-2,3-dideoxy-α-D-mannopyranoside84 and (b) cis-dichlorido[(2-β-Dglucopyranosidyl)propane-1,3-diammine]platinum(II)82 are cisplatin derivatives with
sugar groups attached as non-leaving group ligands. (c) (trans-R,R-cyclohexane-1,2diammine)-malonatoplatinum(II)81 and (d) glucose-Pt(II) complex83 are oxaliplatin
derivatives, in which sugar groups are attached to the leaving group.
Another class of Pt(II) complexes that has been synthesized contains a steroid
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group (estrogen and testosterone) attached as the non-leaving group ligand (Figure
1.11).85 Steroids have been used as targeting groups that utilize the overexpressed steroid
receptors on certain cancer cells. For example, estrogen receptor is overexpressed in
breast cancers to stimulate proliferation.86 The rationale for attaching steroids is that they
can kill the cancer cells by either enhanced uptake of the platinum drug or by blocking
the steroid receptor from its biological function.
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Figure 1.11. Structures of estrogen receptor ligands attached to Pt(II) complexes.
(a) cis-dichlorido[N-(4-(17α-ethynylestradiolyl)-benzyl)-ethylenediammine]platinum(II) and
(b) cis-diammino[2-(4-(17α-ethynylestradiolyl)-benzoylamino)-malonato] platinum(II)
have the estrogen receptor group attached to the leaving group or the non-leaving group,
respectively.85
Conjugating amino acids or peptides to make platinum(II) complexes is another
idea that has been explored (Figure 1.12). Earlier studies showed that conjugation of
netropsin and distamycin peptides, which are minor groove DNA binders, change the
overall complex binding preference to poly(dA) over poly(dG).87 Altered specificity for
A residues on RNA was also observed for some amino-acid-linked cisplatin analogs with
lysine,
ornithine,
and
arginine
as
the
non-leaving
group
88
ligands.

23
(a)

(b)

+
H 2N

H2
N

Cl
Pt

O

(c)

Cl
H2N

Pt

O_

H 2N

H2
N

N
H

Cl

Cl
Pt

O

O_

Cl

Cl
N

HN

NH
2
O

+
NH2

O

H
N

HN

H
N
N
O

N

N

O

Figure 1.12. Structures of Pt(II) complexes attached to amino acids and peptides. (a)
Lysine-Pt(II) or Kplatin, (b) arginine-Pt(II) or Rplatin, and (c) peptide-Pt(II) complexes
are shown.87,88
In hopes of altering the spectrum of activity and thereby circumventing the
drawbacks associated with clinically available drugs, researchers are introducing large
changes to the general structure of platinum(II) compounds as shown in Figure 1.12.
Another expectation of this search for new ligands is to find platinum drugs that are
effective against other cancer types. Furthermore, trans,89 monofunctional,90 and
polynuclear platinum(II) complexes91,92 are some of the non-classical compounds being
explored.
1.6.3 Platinum(IV) complexes
Platinum(IV) complexes have octahedral geometries, which differs from the
square planar platinum(II) complexes. The two extra ligands in the complex can be used
to tune cellular targeting, lipophilicity, uptake, and delivery.7 Although the platinum(IV)
complexes have been in discussion since the discovery of cisplatin activity, their clinical
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significance was only recognized recently.93 Platinum(IV) complexes are more resistant
to ligand substitution than the platinum(II) complexes; therefore, they can be used as
prodrugs to minimize unwanted side reactions before reaching target DNA. When
reacting, Pt(IV) will undergo reduction to yield Pt(II) reactive species. Some of the
Pt(IV) drugs that have reached clinical trials are tetraplatin, satraplatin, and iproplatin
(Figure 1.13).7 Out of these, satraplatin is the first orally active platinum complex to be
synthesized.
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Figure 1.13. Chemical structures of Pt(IV) complexes. Structures of tetraplatin,
iproplatin, and satraplatin are shown.
1.7 Platinum complexes as chemical probes
Cisplatin and a large number of platinum compounds have been synthesized and
tested for their anticancer activity over the years.7 The possibility of attaching different
ligands to the platinum center as discussed in the above sections could be utilized to
introduce new functionalities to the drug. While these modifications are introduced to
improve the anticancer properties of the drug, there are some instances in which the
modifications introduce other properties to the complex that allow for example
visualization and purification.94 Such properties allow the derivatives to be used as
probes in biochemical studies. In this section, a new role of platinum complexes as
chemical probes will be discussed.
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A chemical probe is a small molecule that interacts with specific targets to
provide information about that target. The reaction could also provide information about
the environment, in which the target resides. Cisplatin forms stable and inert bonds with
purine residues, allowing the adducts to be analyzed using a variety of techniques. For
example at the nucleoside level, adducts can be detected and analyzed using high
performance liquid chromatography (HPLC) and mass spectrometry (LC-MS).95 In the
context of nucleic acids, the adducts can be analyzed using gel electrophoresis techniques
as well.95 Cisplatin is a small molecule with a +1/+2 charge depending on aquation. As
mentioned earlier, cisplatin’s size, charge, and reactivity can be altered by changing the
non-leaving group ligands. For example, fluorophores have been attached to detect the
drug localization within complex cellular environments.94,96 Furthermore, attachment of a
reactive handle such as a “clickable” group to the Pt complex provides ways to
incorporate a variety of functional groups (Figure 1.14).94 This approach could be used
for detection, isolation, and purification of Pt-bound targets.
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Figure 1.14. Chemical structures for cisplatin derivatives with “clickable” groups. 94
The (a) azide-appended and (b) alkyne-appended complexes can undergo click
modification with another molecule with the counter-reactive part.
The information gained from cisplatin binding sites reflects how other small
molecules find their targets, and could be used for novel drug development. Cisplatin can
readily penetrate the cell membrane, allowing it to be used for in vivo probing as well.43
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Additionally, cisplatin reactivity can be quenched using high chloride concentrations,
which allows it to be used for monitoring binding kinetics. Differences in platination
rates upon changes in the reaction medium (for example, salt, pH, and the presence of
other ligands) give information about the microenvironment of the target and how those
affect drug-target interactions.50
For the purpose of this thesis work, we were particularly interested in exploring
cisplatin and its derivatives as probes for RNA structure. RNA plays important regulatory
roles in the life cycle of a cell by modulating gene expression. Therefore, RNA has
received much attention by scientists as a promising target for drug development. As the
protein synthesis machinery in the cell, the ribosome has been a validated target for both
anticancer and antibacterial drugs, and still has great potential for further exploration.97 In
order to find possible target sites, selective chemical reagents are needed to probe the
structural details of rRNA in vivo and in vitro.98 Figure 1.15 shows some of the chemical
probes that are available for RNA structure studies. Chemical probing techniques are
useful in studying RNA structure at near physiological solution conditions and reveal
information at the nucleotide level.99 Compared to some other structure probing methods
such as NMR spectroscopy and X-ray crystallography, only small amounts of sample
(pmoles) are needed for chemical probing.99,100 One limitation of this method is that only
a few compounds have been applied to in vivo (dimethylsulfate (DMS), hydroxyl
radicals, and Pb2+) probing.98 Additionally, these reagents are reactive at specific sites;
therefore, they cannot detect some of the desired sites or need additional steps for
detection at their reactive sites such as reverse transcription. For example, to detect N7-G
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modification by DMS, aniline treatment has to be done, as methylation at this site doesn’t
directly inhibit reverse transcription.101
The use of cisplatin as a chemical probe for RNA has been reported previously by
our lab previously.43 By changing the non-leaving ligand to amino acids, the reactivity of
the platinum complex has been altered, and this method has provided information about
accessibility of rRNA towards various ligands.88 Moreover, cisplatin has been used for
both in vitro and in vivo probing, and adducts are identified by reverse transcription stops.
Studies from our lab have also shown the feasibility of using cisplatin kinetics to
investigate the impact of RNA microenvironments on drug binding.50
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Figure 1.15. The chemical probes and their target sites. Certain modifications (e.g.,
methylation or alkylation at N1-A, N3-C, N1-G, and N3-U) are detected by reverse
transcription (RT) analysis. Modifications at the N7-G position by DMS are detected by
aniline-induced strand scission and RT analysis.98-100
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1.8 Aminoglycosides: RNA targeting antibiotics
Aminoglycosides are small molecule, broad-spectrum antibiotics that target
bacterial ribosome and inhibit translation.102 Commonly, aminoglycosides are composed
of a 2-deoxystreptoamine (2-DOS) subunit that is connected to different amino sugar
rings via glycosidic linkages (Figure 1.16). Streptomycin is an example of an
aminoglycoside without a 2-DOS moiety.102

Figure 1.16. Chemical structures of aminoglycosides. Neomycin, paromomycin,
gentamycin and kanamycin have the common 2-DOS moiety (red), whereas streptomycin
does not.
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Aminoglycosides inhibit protein synthesis by binding to the A site (helix 44, or
h44) of the 16S ribosomal RNA with a moderate (μM) affinity.103 Binding of the
aminoglycosides induces or stabilizes an extrahelical conformation of residues A1492
and A1493.104,105 These residues are important for aminoacyl tRNA recognition and
mRNA translocation.106,107 Aminoglycoside binding stabilizes the h44-mRNA-tRNA
complex and induces codon misreading, translocation abortion, and decreased translation
fidelity.108,109 Crystal structures have also shown a secondary binding site for neomycin,
paromomycin, and gentamycin at helix 69 (H69) of 23S rRNA as well.106,110,111 The
interactions in the H69 major groove can inhibit the recycling and translocation steps in
protein synthesis.112
With the emergence of the antibiotic resistance, it is important to understand the
underlying principles of drug-target interactions in order to develop novel drugs.
Chemical tools are necessary to understand the electrostatics and salt-dependent
properties in aminoglycoside-nucleic acid interactions. Chapter 6 of this thesis describes
the feasibility of using cisplatin kinetics to investigate these RNA-drug interactions.
1.9 Thesis overview and specific aims of the research
Serendipitous discovery of cisplatin opened up a field of metallodrug
development for cancer treatment.8 Strategic development of platinum and other metalcontaining drugs has led to successful approval of treatments for several cancer types.
Notably, platinum-containing drugs such as carboplatin and oxaliplatin, which were
developed based on cisplatin, are prevailing in the treatment of cancer.113,114 However,
new platinum-based anticancer agents are only slowly being introduced to the clinic.
With a deeper understanding of the mechanistic details of these drugs, many strategies

30
can be explored to develop next-generation platinum drugs that overcome the drawbacks
associated with the parent drugs. In recent years, synthesis of platinum(II) complexes
with biologically important ligands such as carbohydrates,82,83,115 amino acids,88
peptides,87,116 steroids,117 and folate118 have been explored because of their reduced
toxicity. Among these, glycoconjugation has received much attention. Carbohydrates are
important elements in many drugs that target DNA and RNA.119,120 There is recent
evidence to suggest that carbohydrate motifs are utilizing glucose transporters for
targeted delivery to cancer cells.83,121 Despite the fact that glycoconjugation reduces
overall toxicity of platinum drugs, leads to higher potency,82 and facilitates targeted
delivery83, the impact of the sugar motif on the mechanism of cell death is still largely
unknown. The ability of carbohydrates to form a number of hydrogen-bonding
interactions and presence of the larger sugar group within the Pt coordination sphere can
influence the reactivity of these molecules. To gain insight into the behavior of
glycoconjugated platinum(II) complexes compared to cisplatin, I utilized a cisplatin
derivative as a model compound as shown in Figure 1.17 (compound 5).82
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Figure 1.17. The structure of sugar-conjugated cisplatin derivative, compound 5.
The cisplatin derivative cis-dichlorido[(2--D-glucopyranosidyl)propane-1,3diammine]platinum(II) is shown.
I also carried out experiments to reveal the feasibility of using cisplatin as a probe
for RNA-ligand interactions. Aminoglycosides are cationic ligands that bind to RNA with
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moderate affinity and poor selectivity. In order to develop new antibiotics, it is of
importance to understand the structural mechanisms used by aminoglycosides to target
RNA. It is challenging to experimentally determine the electrostatic environments that
are involved in drug-RNA interactions; however, certain studies have shown the
importance of the high number of positive charges on aminoglycosides in binding to
RNA.122,123 Isothermal titration calorimetric studies of neomycin B binding to a RNA
stem loop revealed the contribution of hydrogen-bonding and electrostatic contacts.122
Salt-dependent variations in binding were attributed to electrostatic contacts. However,
there is still a lack of information on the relative contributions of electrostatic interactions
for aminoglycoside binding and techniques to evaluate the electrostatic interactions.
Experiments were carried out to achieve these goals with the following specific aims.
Aim 1: Determine the reactivity preferences, reaction rates, and the products
formed for the reaction between compound 5 and nucleosides
Many known platinum(II) complexes prefer binding to the guanine base, but there
are exceptions to this observation. For example, changing the non-leaving group ligand to
amino acids such as ornithine and lysine has been shown to alter the binding preference
to adenine.88 The first aim of this thesis work was to determine the binding preferences of
a carbohydrate-linked cisplatin analog (5) in the context of nucleosides. HPLC and LCMS techniques were utilized to characterize the reaction products and to obtain reaction
rates.
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Aim 2: Investigate the reaction rates, binding sites, and structural impacts of
compound 5 at the oligonucleotide level
Reactivity at the nucleoside level does not reflect influences of the nucleic acid
backbone. Therefore, it is important to analyze drug reactivity at biologically relevant
conditions to fully understand activity within the context of a cell. In this thesis work,
kinetic experiments were carried out to determine the reaction rates and characterize
DNA and RNA oligomers. Gel-based assays were used for the rate determination with
mono- and bisactivated compound 5 in comparison to cisplatin. Additionally, reaction
rates were obtained in the presence of varying salt conditions to understand the effect of
electrostatics and the role of the sugar moiety on the overall binding kinetics. Moreover,
the structural effects of binding were also evaluated using different gel-based assays in
the context of plasmid DNA and DNA oligomer.
Cisplatin anticancer activity is mainly associated with DNA binding. However,
with more mechanistic studies being done, this idea has been challenged and cisplatin
was shown to bind to other cellular targets such as RNA and proteins, which could also
disrupt cellular functions and lead to cell death.39,53,56 In particular, cellular RNA has
received increased attention in recent years.40,46,124 My hypothesis was that an attached
sugar group and overall positive charge would facilitate compound 5 accumulation on
RNA. The chemical probing technique was used to detect reactive sites on the
functionally important ribosome.
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Aim 3: Evaluate the cytotoxicity of compound 5 against cancer cell lines compared
to normal cells and quantify its accumulation levels
To explore the cytotoxicity of 5 towards various cancer cell lines, a series of MTT
(3-(4,5-dimethylthiaxol-2-yl)-2,5-diphenyltetrazolium bromide) assays were carried out
in this thesis work. Comparable cytotoxicity of compound 5 with cisplatin had previously
been reported for ovarian and melanoma cancer cell lines, but my goal was to expand this
study to other cancer cell lines (e.g., prostate) as well as the corresponding normal cell
lines. My hypothesis was that selective cancer cell targeting could be achieved by
utilizing a characteristic feature of certain cancer cells, specifically enhanced uptake of
glucose.125 This idea was previously explored with glycoconjugated oxaliplatin
derivatives, but not with cisplatin derivatives such as compound 5.83 Therefore, it was of
interest to explore the differential accumulation of compound 5 in cancer cells compared
to normal cells. As a proof of concept, the DU145 prostate cancer cell line was selected
for this comparison based on the higher glucose transporter expression levels,126 along
with the normal prostate cell line-RWPE1.83
Aim 4: Probe RNA-aminoglycoside interactions using cisplatin kinetics as a tool
Based on a previous study from our lab that showed salt-dependent cisplatin
coordination rates to RNA, we postulated that positively charged aminoglycosides could
also impact the platination rates by competing with cisplatin for the target. Herein, I
describe a kinetic method to monitor aminoglycoside interactions with RNA using
cisplatin coordination rates. A gel-based assay was used to obtain the cisplatin
coordination rates to RNA in the presence of various aminoglycosides.
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CHAPTER 2
BIOCHEMICAL METHODS, CELL STUDIES, AND DATA ANALYSIS
2.1 Abstract
The work discussed in this thesis largely focuses on understanding the underlying
mechanisms of platinum(II) complex activity and using certain features of these
anticancer drugs for chemical probing. A variety of biochemical, bio-analytical, and
molecular biology techniques were utilized for these purposes. Gel-based techniques
were used to analyze product formation with DNA and RNA to observe, nucleic acid
structural changes, and to obtain kinetic parameters for reactions between a carbohydratelinked Pt(II) complex (5) and the parent compound cisplatin. These methods include
agarose gel electrophoresis, as well as native and denaturing polyacrylamide gel
electrophoresis (PAGE). Radioactive labeling was employed for visualization of the
nucleic acids in the gels. In addition, high performance liquid chromatography (HPLC)
and mass spectrometry (MS) techniques such as matrix-assisted laser desorption
ionization (MALDI) and liquid chromatography mass spectrometry (LC-MS) were used
for product characterization (e.g., identity and quantity). Another goal of my thesis work
was to understand the cellular toxicity and accumulation of the carbohydrate-linked Pt(II)
compound (5) compared to the already known anticancer drug cisplatin. Cellular toxicity
was assessed using an MTT (3-(4,5-dimethylthiaxol-2-yl)-2,5-diphenyltetrazolium
bromide) assay, and Pt levels in the cell were determined by using inductively coupled
plasma mass spectrometry (ICP-MS). The methods describe in this chapter were utilized
to examine Pt-RNA or Pt-DNA interactions, but could also be employed with other small
molecule-nucleic acid complexes.
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2.2 Introduction
2.2.1 Reactivity and Pt(II) coordination rates with nucleosides and oligonucleotides
To evaluate the binding preferences of compound 5 with different RNA
nucleosides (Figure 2.1), the reactions were analyzed by reverse-phase HPLC on a C18
column. Depending on the observed product formation, only certain nucleosides such as
guanosine were selected for kinetic experiments. The rates of Pt(II) complex coordination
to guanosine (G) and deoxyguanosine (dG) were determined by using HPLC-based
assays as described in Section 2.4.4. The products were characterized by LC-MS.

Figure 2.1. The chemical structures of RNA and DNA nucleosides. Adenosine,
deoxyadenosine, guanosine, and deoxyguanosine have purine bases, whereas cytidine,
deoxycytidine, uridine, and thymidine have pyrimidine bases.
Experiments were carried out to compare the reactivity of Pt(II) complexes at the
oligonucleotide level (Section 2.4.9). Based on the reactivity at guanine bases, nucleic
acid sequences with guanosine residues were employed. To determine the platination rate
constants, an electrophoretic mobility shift assay (EMSA) technique was employed. The
kinetic experiments were carried out using mono- or bis-activated Pt(II) compounds for
comparison. Rates were obtained under different buffer conditions for the reactions
between DNA/RNA and mono-activated Pt(II) compounds. All of the experiments were
done in parallel to cisplatin reactions for comparison.
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For all of the kinetic experiments carried out in this thesis work, pseudo-firstorder conditions were maintained.51 More specifically, the concentration of the Pt(II)
complex was in large excess with respect to the other reactant (X= nucleoside, RNA or
DNA). As such, the Pt(II) concentration was included in the rate constant, which is the
pseudo-first-order rate constant or kobs.51 The reaction between Pt and X is second-order,
but a ≥50-fold excess is used. Therefore, kobs will be equal to the product of the Pt(II)
concentration and the apparent second-order rate constant, k2,app. The apparent secondorder rate constant, k2,app is then obtained by varying the platinum concentration.
2.2.2 Cisplatin coordination rates to H69 RNA in the presence of aminoglycosides
Cisplatin binding to the H69 RNA hairpin loop is well characterized.95 The H69
sequences with and without pseudouridine (ψ) modifications (Figure 2.2) were utilized
in this experiment to determine the effect of the modification on aminoglycoside binding.
Aminoglycosides such as neomycin and paromomycin (Figure 1.16) that are known to
show interactions with the H69 region (19-mer) were used, and compared to the nonbinding compound streptomycin.

Figure 2.2. Structures of RNA constructs used in the kinetic study. Modified ()
and unmodified (UUU) H69 rRNA constructs are shown, in which  is pseudouridine
(shown to the right).
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2.2.3 Structural effects of platinum compounds on DNA
Structural effects caused by complex 5 were evaluated by reacting it with plasmid
DNA and a duplex DNA oligomer (22-mer). As a comparison, reactions were done with
cisplatin. By reacting with plasmid DNA, global structural changes caused by cisplatin
and 5 were evaluated. The effect of a single platination event within a duplex DNA was
also evaluated using the small oligomer DNA.
2.2.4 Structure probing of RNA
Single-stranded RNAs form many secondary structures and adopt complex
scaffolds, which are important for its function.97 There are various interactions that can
occur between the bases, and with ions in the solution (e.g., Mg2+), that govern the
structure and are important for drug binding.127 Probing techniques are utilized to
understand the key structural features of RNA at the nucleotide level. The two main
probing techniques used for this purpose are chemical and enzymatic probing.128 Some
chemical probes are able to penetrate cell membranes and therefore can be used for in
vivo probing (e.g., DMS).99 These small molecules provide information about solventaccessible sites within complex, folded, tertiary structures of RNA.128 In contrast,
enzymatic probing provides less information about the folded RNA structure, due to the
bulkiness of the probe. RNases can be utilized to determine ligand-binding sites in in
vitro studies. Table 2.1 shows some commonly used chemical and enzymatic probes and
their targets. Depending on the size of the RNA, the detection method can vary.
Modification or cleavage sites for small RNA can be directly detected by radiolabeling
the RNA ends.99 For larger RNAs (over 200 nucleotides), primer extension is used to
determine the reactive sites.
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Table 2.1. Chemical and enzymatic probes and their RNA targets99,128
probe

target

RNase T1

Unpaired G

RNase T2

Unpaired A>C, U, G

RNase V1

Paired or stacked nucleotides

RNase U2

Unpaired A>G>>C>U

RNase H

RNA only from DNA-RNA hybrids

Nuclease S1

Unpaired nucleotides

Mung bean nuclease

Single-strand regions

DMS

N7-G, N1-A, N3-C

CMCT

N7-G, N3-U

DEPC

N7-A

kethoxal

N1, N2-G

Fe-EDTA (OH radicals)

Ribose C1 and C4

NMIA

2-OH of flexible nucleotides

Pb2+

Phosphodiester bonds in single-stranded
regions and unstable helices

in-line probing

Phosphodiester bonds

DMS: dimethyl sulfate; DEPC: diethylpyrocarbonate; CMCT: 1-cyclohexyl-3-(2morpholinoethyl) carbodiimide metho-p-toluene sulfonate; NMIA: N-methylisatoic
anhydride.
The use of cisplatin as a probe for RNA structure was reported recently.43 Reverse
transcription-based primer extension followed by gel electrophoresis was employed to
detect the cisplatin binding sites in RNA (Figure 2.3). The same method was exploited to
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find compound 5 coordination sites on rRNA in this study. The ribosomes were isolated
and platinated. Then, the rRNAs were extracted and used for primer extension reactions
with DNA primers designed for specific regions of the ribosome.

Figure 2.3. A schematic diagram showing the basic steps of cisplatin probing.
Denaturing gel electrophoresis is carried out after the reverse transcription-based primer
extension reactions. The resulting gel image will show the dideoxy sequencing lanes for
each nucleotide control, and cisplatin reaction lanes. The red color bands in the cisplatin
reaction lane depict the stop sites. The stop sites occur one nucleotide prior to the actual
modification site on the RNA.
2.2.5 Potency and accumulation of platinum(II) compounds in human cancer and
normal cell lines
The anticancer potency of 5 was tested by determining the IC50 values in several
human cancer cell lines using the MTT colorimetric assay.129 This assay relies on a color
change in which viable cells convert the yellow-colored MTT (3-(4,5-dimethylthiazol-2yl)-2,5-diphenyltetrazolium bromide) reagent into purple-colored formazan (Scheme
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2.1).130 The NAD(P)H-dependent cellular oxidoreductase enzymes in viable cells are
responsible for the color change, as they reduce the MTT reagent to produce insoluble
formazan.130 The color change can be monitored by a multi-well scanning
spectrophotometer/plate reader.
Scheme 2.1. The conversion of MTT to formazan. MTT is a yellow reagent and
formazan is purple.

mitochondrial
reductase

3-(4,5-dimethylthiazol-2-yl)-2,5diphenyltetrazolium bromide
(MTT)

(E,Z)-5-(4,5-dimethylthiazol-2-yl)1,3- diphenylformazan
(formazan)

2.3 Materials
2.3.1 Chemicals and supplies
Cisplatin (cis-diamminedichloridoplatinum(II)) was obtained from Alfa Aesar
(Wardhill, MA). Anhydrous dimethylformamide (DMF) (99.8% purity) was obtained
from EMD (Gibbstown, NJ). The HPLC grade acetonitrile, silver nitrate (AgNO3),
ammonium acetate (NH4OAc), sodium dihydrogen phosphate (NaH2PO4), disodium
hydrogen phosphate (Na2HPO4), KH2PO4, K2HPO4, magnesium chloride (MgCl2),
potassium chloride (KCl), sodium chloride (NaCl), agarose, bromophenol blue dye,
dimethyl sulfoxide (DMSO), 2-amino-2-hydroxymethyl propane-1,3-diol (Tris), phenolchloroform-isoamyl alcohol (25:24:1) (PCI), T4 DNA ligase, boric acid, phosphate buffer
saline, pH=7.4 (PBS), and Dulbecco’s Modified Eagle’s (DMEM) cell culture media

41
from Fisher Scientific (Fair Lawn, NJ) were used. The chemicals potassium
tetrachloroplatinate(II) (K2PtCl4), sodium perchlorate (NaClO4), acrylamide, glycerol,
xylene

cyanol

dye,

N,N'-methylenebisacrylamide,

urea,

4-(2-hydroxyethyl)-1-

piperazineethanesulfonic acid (HEPES), 2-mercaptoethanol (2-ME), 3-hydroxypicolinic
acid (3-HPA), ethylenediaminetetraacetic acid (EDTA), ammonium chloride (NH4Cl),
ethanol, neomycin B, paromomycin, streptomycin, penicillin-streptomycin (pen-strep),
fetal bovine serum (FBS), tissue culture dishes, and 96-well plates were purchased from
Sigma-Aldrich (St. Louis, MO). The chemicals Luria broth (LB) (BD medical
Technology, Franklin Lakes, NJ), deoxynucleoside triphosphates (dNTPs) (Genscript,
Piscataway, NJ), dideoxy nucleotide triphosphates (ddNTPs) (Roche, Indianapolis, IN),
nuclease- and protease-free sucrose (MP Biomedicals, Solon, OH) were used. DNase I
and ImPromII Reverse Transcriptase (RT) were purchased from Promega (Fitchburg,
WI). The enzymes T4 RNA ligase and T4 polynucleotide kinase from New England
Biolabs (Ipswich, MA) were employed in this study. The radiolabels [5'-32P] pCp and
[32-P] ATP were purchased from Perkin-Elmer Life Sciences, Inc. (Waltham, MA). The
Sep-pak C18 cartridges were purchased from Waters (Milford, MA). Keratinocyte-SFM
media, 0.25% trypsin-EDTA (Gibco, Pittsburgh, PA), and 10 ppm platinum solution in
2% HNO3 (High-purity standards, Charleston, NC) were used for the cell-based
experiments. RNase-free distilled, deionized water (ddH2O) was used for all experiments.
2.3.2 Nucleosides and oligonucleotides
Single RNA and DNA nucleosides were purchased from Sigma-Aldrich and stock
solutions were prepared by dissolving them in ddH2O to the desired concentration (The
difference in UV absorbance between phosphate buffer and water is less than 0.15%).131
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Concentrations of the nucleoside solutions were calculated by measuring the absorption
at maximum wavelengths and using published extinction coefficients (260 nm = 14,900 M1

cm-1 for adenosine, 253 nm= 13,600 M-1 cm-1 for guanosine, 271 nm= 9100 M-1 cm-1 for

cytidine and, 262nm= 10,100 M-1 cm-1 for uridine).132
DNA and RNA were purchased from Integrated DNA Technologies (Coralville,
IA) and GE Dharmacon (Lafayette, CO), respectively. The DNA and RNA were gel
purified as described in each method section. Concentrations of nucleic acid solutions
were calculated by using the absorbance at 260 nm and single-stranded extinction
coefficients (DNA1 260nm = 176,500 M-1cm-1, RNA1260nm = 190,700 M-1cm-1, H69
RNA 260nm = 189,400 M-1cm-1, H69 primer 260nm = 192,000 M-1cm-1, A site primer
260nm = 165,500 M-1cm-1, 790 primer 260nm = 173,900 M-1cm-1, PTC (peptidyl transferase
center) primer 260nm = 202,400 M-1cm-1).133 The pUC19 plasmids were isolated and
purified by using a plasmid maxi-prep kit from Qiagen (Germantown, MD).
DNA1: 5' TCTCCTTCTTGGTTCTCTTCTC 3'
DNA2: 5' GAAGAGAACCAAGAAGGAGAGA 3'
RNA1: 5' UCUCCUUCUUGGUUCUCUUCUC 3'
H69 RNA (UUU): 5' GGCCGUAACUAUAACGGUC 3'
H69 RNA (): 5' GGCCGAACAAACGGUC 3'
H69 primer: 5' CGACAAGGAATTTCGCTACC 3'
790 primer: 5' ACCAAGTCGACATCGTTT 3'
A-site primer: 5' GTTAAGCTACCTACTTCT 3'
PTC primer: 5' CACTTTAAATGGCGAACAGCC 3'
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2.3.3 Cell lines
The human cancer cell lines HeLa, H1299, MDA-MB-231, and MDA-MB-453
were obtained from Dr. Young-Hoon Ahn’s lab.134-137 The human prostate cancer cell
lines (DU145 and LNCaP) were obtained from Dr. K.V. Honn’s lab in the Chemistry
Department.138,139 The normal prostate cell line, RWPE-1, was received from Dr. Zhihui
Qin’s lab in the Eugene Applebaum College of Pharmacy and Health Sciences, Wayne
State University.140
2.3.4 Instrumentation
HPLC analysis was performed on a Waters 600 LC, with a 717 autosampler
(Waters, Milford, MA), UV-detector, and a Supelco Discovery C18 column (5 μm
particle diameter; 4.6 mm i.d. × 250 mm, Sigma-Aldrich, St. Louis, MO). The LC-MS
analysis

was

carried

out

on

a

Shimadzu

8040

Nexera

X2

Ultra

High

Performance/Pressure Liquid Chromatograph (UPLC) system with a quadrupole type
tandem mass spectrometer (Shimadzu, Columbia, MD). An Acquity UPLC HSS T T3
C18 column was (1.8 μm particle diameter, 2.1 × 100 mm, Waters, Milford, MA) was
used in LC-MS. The MALDI mass spectra were acquired on a Bruker UltrafleXtreme
TOF (Bruker Daltonics, Billerica, MA). Whole cell platinum levels were quantified by
using an Agilent 7700X ICP-MS, ASX-500 series ICP-MS autosampler with Agilent
MassHunter software (Santa Clara, CA). The gel images were obtained on a Typhoon
FLA 9500 instrument (GE Healthcare). The pH of the solutions was determined by using
a Mettler Toledo (Columbus, OH) pH meter with an Inlab Versatile Pro pH electrode
(electrolyte 3 mol/L KCl).
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2.4 Methods
2.4.1 Preparation of activated cisplatin complexes
Cisplatin (1 mg, 3.3 μmol) and AgNO3 (30 mg, 177 μmol) solutions were
prepared by dissolving separately in 333.3 μL and 353.2 μL anhydrous DMF volumes to
make 10 mM and 500 mM solutions, respectively.48 To a 200 μL of prepared cisplatin
solution 1 equivalent of AgNO3 was added to give a 9.8 mM solution of mono-activated
(aquated) cisplatin (compound 3). To obtain bis-activated complex, the solutions were
mixed in a 1:2 molar ratio. The reaction mixture was shaken at 37 C for 16 h in the dark
on a vortex mixer (Scheme 2.2). The resulting AgCl was precipitated by centrifugation at
14,000 rpm for 10 min, and the supernatant contained the desired mono-activated
cisplatin (3). Activated cisplatin was freshly prepared every time and diluted to
intermediate stock concentrations with ddH2O just prior to use.
Scheme 2.2. Generation of the mono-activated platinum species (3). One chlorido
ligand will be removed as AgCl to yield the mono-activated species, compound 3.

H 3N

Cl

1 eq. AgNO3

H 3N

Cl

37 C, 16 h

H 3N

Pt
H 3N
cisplatin

Pt

OH2
+ AgCl(s)

Cl

mono-activated cisplatin(3)

2.4.2 Synthesis and purification of cis-dichlorido[(2-β-D-glucopyranosidyl)propane1,3-diammine]platinum, compound 5
Synthesis of compound 5 was done as described previously from compound 4.82
Synthesis, purification, and NMR characterization of compound 4 (calculated mass 252
Da) was done by Amr Sonousi in Dr. David Crich’s lab, Department of Chemistry,
Wayne State University. Compound 4 (21 mg, 83 μmol) and K2PtCl4 (27 mg, 65 μmol)
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solutions were prepared by dissolving in 1 mL of ddH2O. To generate 5, they were mixed
(1:1 molar ratio, 65 μmol) and stirred at room temperature for 2 days in the dark. The
color of the solution changed from orange to light brown. One µL of the crude product
solution was mixed with 1 µL of saturated 3-hydroxypicolinic acid (3-HPA) matrix in
50% acetonitrile and analyzed by MALDI in the positive mode. The product was then
purified by HPLC on C18 (5 μm particle diameter; 4.6 mm i.d. × 250 mm, SigmaAldrich, St. Louis, MO) on a Waters 600 LC with a 717 autosampler (Waters, Milford,
MA) and UV-detector (Figure 2.4a). The mobile phases of 40 mM ammonium acetate,
pH 6.5 (NH4OAc) (buffer A), and 40% acetonitrile (buffer B) were used. The column
was equilibrated with 95% (v/v) buffer A and 5% (v/v) buffer B, and then the percentage
of buffer B was increased in a linear gradient from 5 to 35% over 30 min. The product
peak was collected, dried, and characterized by MALDI-MS (Figure 2.4b) and 1H-NMR
(D2O solvent, Agilent DD2-600 MHz NMR with Agilent (1H-19F/15N-31P) 5 mm PFG
One NMR Probe). The total dry weight of purified 5 (calculated mass 518 Da) was about
25 mg (~75% yield) and it was light yellow in color.
Scheme 2.3. Chemical synthesis, structure of the carbohydrate-linked cisplatin
analog
(cis-dichlorido[(2-β-D-glucopyranosidyl)propane-1,3-diammine]platinum
(5)), and activation step.

(4)

(5)

mono-activated 5
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Figure 2.4. Isolation and characterization of compound 5. (a) The HPLC trace (C18
column, eluted at 3.5 min with linear gradient of B from 5 to 35% over 30 min, flow rate
1 mL/min) for crude and purified 5. (b) The MALDI-MS spectrum for purified 5. The
calculated mass for [compound 5+K+] is 556.99 Da and the observed (3-HPA matrix,
positive detection mode) was 556.82 Da. The inset shows the isotopic distribution for
predicted and observed complex.
MALDI-MS spectrum showed a peak at 557 Da, which is the mass for 5 (518 Da)
associated with K+. The isotopic distribution observed on MALDI-MS as shown is the
inset of Figure 2.4b matched the predicted pattern as shown. Platinum has five stable
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isotopes,

192

Pt (0.7%), 194Pt (32.8%), 195Pt (33.7%), 196Pt (25%), and

has two stable isotopes,

35

Cl (75.8%) and

37

198

Pt (7%) and Cl

Cl (24.2%). Compound 5: 1H NMR (600

MHz, D2O): δ 4.36 (d, J(H1,H2) = 7.7 Hz, 1H;H1), 3.57 (m, 1H; H7), 3.72 (dd,
J(H6a,H6b) = 12.5 Hz, J(H5,H6a) = 2.4 Hz, 1H; H6a), 3.54 (dd, J(H6a, H6b) = 12.1 Hz,
J(H5, H6b) = 5.3 Hz, 1H; H6b), 3.10-3.33 (m, 4H; H2, H3, H4, H5), 2.51-2.61 (m, 2 ×
2H; H8, H9) (Appendix A, Figure A4).
Mono-activation of 5 was carried out in ddH2O. A 9.8 mM solution of 5 was
prepared by dissolving 6 mg (11.6 μmol) in 1.16 mL of ddH2O. The AgNO3 solution (500
mM) was prepared by dissolving 30 mg in 353.2 μL of ddH2O. To obtain the monoactivated complex, one equivalent of AgNO3 (11.6 μmol, 23.2 μL) was added to the
solution of 5 (Scheme 2.3). The activated complex was divided into 50 μL aliquots, dried
in a speed vac concentrator, stored in -80 °C, and redissolved in ddH2O just prior to use.
2.4.3 Reaction of mono-activated 5 with nucleosides
Adenosine, guanosine, cytidine, and uridine nucleoside solution stocks were
prepared by dissolving about 2 mg in 500 μL of water, and the exact concentrations were
determined by measuring the UV absorbance.131,132 The reactions were carried out by
mixing nucleoside (0.1 mM): mono-activated 5 (0.5 mM) in a 1:5 ratio at 37 °C for 16 h
in the dark. The reaction mixtures were quenched by adding 3 μL of 3 M NaCl and
vortexing. The quenched reaction mixtures were analyzed by reverse-phase HPLC on a
Supelco Discovery C18 column (5 μm particle diameter; 4.6 mm i.d. × 250 mm) on a
Waters 600 LC with a 717 autosampler and UV-detector. The mobile phases of buffer A
and buffer B were used. The column was equilibrated with 95% buffer A and 5% buffer
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B, and then the percentage of buffer B was increased in a linear gradient from 5 to 35%
over 30 min.
2.4.4 Kinetic parameters for the reaction between G and dG nucleosides with Pt(II)
complexes
For the kinetic measurements mono-activated cisplatin (3) and mono-activated
compound 5 were used. Reactions were carried out by mixing sodium phosphate buffer,
pH 7.0 (final concentration 25 mM) with freshly prepared and diluted nucleoside solution
(final concentration 0.1 mM) and mono-activated Pt(II) (final concentration 5 mM) in a
1:50 molar ratio. The total volume of the master reaction mixture was adjusted up to 300
μL by adding ddH2O. The reactions were vortexed and incubated at 37 °C in the dark up
to 6 h. At varying time points, 45 μL of sample was removed from the reaction mixture
and quenched by adding 3 μL of 3 M NaCl (final concentration 188 mM) and vortexing.
The quenched samples were immediately frozen on dry ice and stored at -80 °C until
further analysis. The quenching time points were 0.5, 1, 2, 3, 4 and 6 h. This procedure
was repeated three times for each nucleoside reaction. The samples were centrifuged at
10,000 rpm for 10 min before injection onto the HPLC. The same HPLC method
described in Section 2.4.3 was used, and 35 μL from each sample was injected onto the
column. The retention times for the nucleosides were confirmed by comparing to
standards and the peak areas (unreacted nucleoside and products) were calculated using
Empower software (Empower Software Solutions, Inc., Orlando, FL). The pseudo-firstorder rate constants were calculated by plotting the ratio of unreacted nucleotides over
quenching times. HPLC standard calibration curve for G (from Bett Kimutai) is shown in
Appendix A, Figure A1.
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Scheme 2.4 shows the kinetic model for a reaction between X (nucleoside, RNA,
or DNA) and Pt(II) under pseudo-first-order reaction conditions. The reaction between
the Pt(II) complex and X was considered to be a second-order reaction as shown in
Equation 2.1.51 To maintain pseudo-first-order conditions, high Pt(II) concentrations
were used, in which a ≥50-fold excess over X was used (the specific concentrations are
mentioned in the Methods section for each experiment).47 Therefore, kobs was equal to the
product of the Pt(II) concentration and apparent second-order rate constant, k2,app
(Equation 2.2). To experimentally obtain kobs, the unreacted RNA ratio [Xt]/[X0] and
time were plotted to fit an exponential decay (Equation 2.3), in which the m2
corresponded to kobs.
Scheme 2.4. Kinetic model for the reaction between Pt(II) complexes and X, in
which X can be nucleosides, RNA or DNA.
kapp
Pt(II) + X
Pt-X
X= nucleoside, RNA, or DNA
-d[X]/dt = kapp [Pt(II)] [X]

Equation 2.1

Under pseudo-first-order conditions,
kobs= kapp [Pt(II)]

Equation 2.2

-d[X]/dt = kobs [X]
ln[Xt]/ [X0] = - kobs t
The unreacted X ratio is [Xt]/[X0], and
[Xt]/ [X0]

= A e-kobst

Equation 2.3

Y= m1 exp (-m2X)+m3, in which Y= [Xt]/[X0], m2= kobs, m1= amplitude of the
reaction, m3= extent of the reaction
2.4.5 Product characterization by LC-MS
The dG or G and mono-activated 5 reaction mixtures from Section 2.4.4 (after 16
h reaction) were analyzed on LC-MS or by direct injection onto a mass spectrometer
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(details below). The analysis was carried out on a Shimadzu 8040 Nexera X2 Ultra High
Performance/Pressure Liquid Chromatograph (UPLC) system with a quadrupole type
tandem mass spectrometer (Shimadzu, Columbia, MD). The sample was introduced and
ionized by using an electrospray ionization (ESI) probe (nebulizing gas flow 3 L/min,
drying gas flow 15 L/min, interface 4.5 kV, heat block temperature 400 °C). An Acquity
UPLC HSS T T3 C18 column (1.8 μm particle diameter, 2.1 × 100 mm, Waters, Milford,
MA) was used, and the column oven was maintained at 40 °C. For the LC buffers, 10
mM NH4OAc, pH 5.2 (buffer C), and 10 mM NH4OAc (10%) in 10% acetonitrile (buffer
D) were used. Elution was carried out with a flow rate of 800 μL/min, from 100 to 67%
buffer C and increase in D from 0 to 33% over the course of a 17 min gradient. For direct
injection, 2 μL of the reaction mixture was introduced to the mass spectrometer with a
flow rate of 300 μL/min using buffer D. Peaks were identified by using LabSolutions
software.
2.4.6 Ethanol precipitation of nucleic acids
To a centrifuge tube containing nucleic acid solution (V volume), 2.5 V of 100%
ethanol and 0.1 V of 3 M NH4OAc were added and the sample was placed on dry ice for
45 min. The sample was then centrifuged at 14,000 rpm for 45 min at 4 °C. The
supernatant was carefully removed and 100 μL of 70% ethanol was added to the pellet.
The sample was placed on dry ice for 15 min and centrifuged at 14,000 rpm for 15 min at
4 °C. The supernatant was removed and the remaining pellet was dried in a speed vac
concentrator. The dried nucleic acid pellet was dissolved in 50 µL of ddH2O by
vortexing.
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2.4.7 Radiolabeling of the RNA at the 3' end and purification
The 3' end of each H69 RNA (UUU and ) was radiolabeled using [5'-32P]pCp and T4 RNA ligase.141 For the radiolabeling RNA (50 pmol per reaction), 10 μCi of
[5'-32P]-pCp, 30 units of T4 RNA ligase enzyme, 3 μL of 10× ligase buffer (50 mM TrisHCl, pH 7.5, 10 mM MgCl2, 1 mM dithiothreitol), 4 μL of DMSO, and ddH2O (total
volume is 30 μL) were used. Following a 16 h incubation time at 4 °C, the labeled RNA
was ethanol precipitated and gel purified on a 20% denaturing polyacrylamide gel (0.8
mm thick, acrylamide: bisacrylamide 19:1, 1× TBE). Following PAGE, the RNA bands
were visualized by autoradiography, excised, and eluted by the crush-and-soak method in
350 mM NaOAc, pH 5.3, 0.1 mM EDTA buffer overnight at 4 °C.142 Desalting of the
purified RNAs was carried out using Sep-pak C18 columns.132 The eluted RNA was dried
in a speed vac concentrator. The dried nucleic acid pellet was dissolved in 50 µL of
ddH2O by vortexing.
2.4.8 Radiolabeling of nucleic acids at the 5' end143
For the labeling of 50 pmol DNA or RNA, 10 μCi [γ-32P] ATP and 10 units T4
polynucleotide kinase were reacted in 3 μL of 10× T4 polynucleotide kinase buffer (50
mM Tris·HCl, pH 7.6, 10 mM MgCl2, 5 mM DTT, 0.1 mM spermidine, and 0.1 mM
EDTA). The total volume was adjusted to 30 μL with ddH2O and the sample was
incubated at 37 oC for 45 min. The labeled nucleic acid was isolated by gel purification as
described for 3' labeling followed by desalting.
2.4.9 Platination rates for the reactions with oligonucleotides
The DNA1 and RNA1 strands were used for kinetic experiments. The unlabeled
DNA or RNA (0.7 M) and corresponding 5'-radiolabeled DNA or RNA (50,000-60,000
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cpm) were mixed with buffer (final concentration of 12 mM K+ and 20 mM Na+, pH 6.2)
and ddH2O to a volume of 50 L in an 0.6 mL centrifuge tube, placed in a boiling water
bath for 2 min, and then on ice for 5 min. The reaction was then spun down and allowed
to reach room temperature before adding the Pt(II) compound. The sample was then
incubated with mono-activated Pt(II) complex (final concentration of 94 M) at 37 C in
the dark. The total volume of the reaction mixture was 60 μL. The reactions were
quenched at different time points by taking 5 μL aliquots and putting into a tube
containing 1 L of 2 M NaCl, followed by freezing of the samples on dry ice. A control
reaction was also carried out by adding water instead of the platinum compound. To each
reaction 0.4 L of loading buffer that contains 0.1% bromophenol blue, 0.1% xylene
cyanol, 1× Tris base, boric acid, EDTA, and 8 M urea was added, and the solutions were
loaded onto a 20% polyacrylamide gel (0.4 mm thick, acrylamide: bisacrylamide 19:1, 1×
TBE) and run at 48 V/cm for about 3 h. The gel image (illustrated in Figure 2.5a) was
analyzed and the unreacted nucleic acid was quantified using ImageQuantTM software
(GE Healthcare) using the following Equation 2.4.
Equation 2.4:
Fraction of unreacted RNA ([Xt]/[X0])

Kaleidograph 4.1 software was used to plot the fraction of unreacted nucleic acid
over time to obtain the platination rates (Figure 2.5b). Each reaction rate was obtained by
averaging three trials. For comparison, experiments were carried out with bis-activated
platinum complexes as well. To compare the salt-dependent reaction rates, reaction rates
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were obtained in a 12 mM K+ and 5 mM Na+, pH 6.2 buffer. Each reaction rate was
obtained as an average from three trials.

Figure 2.5. Schematic diagram of the gel and graph for kinetic experiments. (a) A
schematic of the electrophoretic mobility shift assay is shown. The quenched reactions
are loaded onto a 20% denaturing polyacrylamide gel and the products and reactants are
separated and quantified. The concentration of unreacted RNA decreases over time from
t0 to tt. (b) A representation of the exponential decay of the reactant over time.
2.4.10 Cisplatin coordination rates to H69 RNA in the presence of aminoglycosides
The basic kinetic experiment protocol described in Section 2.4.9 was followed for
this experiment. The labeled (50,000-60,000 cpm) and unlabeled H69 hairpins (final
concentration of 0.7 M) were incubated with freshly prepared aminoglycoside (final
concentration 1, 3, or 6 M) at 37 C for 30 min in buffer (final concentration of 12 mM
K+ and 20 mM Na+, pH 6.2) and water. This step was followed by incubation with monoactivated cisplatin (final concentration of 188 M) at 37 C in the dark as described
above. The final volume of the reaction mixture was 60 μL. The experiment was repeated
three times to obtain each rate for neomycin, paromomycin and streptomycin at 1, 3, and
6 M concentrations.
2.4.11 Platinum complex reaction with plasmid DNA
The pUC19 plasmids were isolated by QIAGEN Plasmid Maxi Kit following the
user protocol. Reaction tubes were prepared containing 0.5 µg of DNA plasmid, 10 mM
sodium phosphate buffer (pH 7.4), and water (final volume 10 µL). The plasmid was
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platinated with either freshly mono-activated cisplatin (final concentration of 160 µM) or
compound 5, separately. The reactions were incubated at 37 C in the dark for 24 h. At
varying time points, reactions were quenched by adding 3 µL of 3 mM NaCl and 1 µL of
loading dye (0.25% bromophneol blue, 0.25% xylene cyanol, 30% glycerol). A control
reaction was also prepared without adding Pt(II) compound. The quenched reactions were
then loaded on to a 1.2% agarose gel and ran at 75-80 V until the xylene cyanol dye band
has migrated off the gel.
2.4.12 Platinum complex reaction with duplex DNA oligomer
A model DNA was chosen to examine the impact of platination on DNA
bending.24 The DNA1 (3 nmol) was platinated with bis-activated cisplatin, or 5 (6 nmol),
by reacting in a 1:2 ratio, then the products were purified and desalted by using 20%
polyacrylamide gel electrophoresis and ethanol precipitation as described earlier.
Platinum adduct formation was confirmed by MALDI-MS. For that, 2 µL (300 pmol) of
platinated DNA was mixed with 1 µL of saturated 3-hydroxypicolinic acid (3-HPA)
matrix in 50% acetonitrile, spotted on a MALDI plate, and allowed to dry. The mass
spectra were acquired on a Bruker UltrafleXtreme TOF (Bruker Daltonics, Billerica,
MA) instrument in the positive-ion reflector mode.95
The 5' end of the DNA2 strand (50 pmol) was radiolabelled using [-32P] ATP,
gel purified, and desalted as described in Section 2.4.8. For the annealing reaction,
60,000-100,000 cpm from the radiolabelled DNA2 strand and 20 pmol from platinated
DNA1 strand were used. A control reaction was done with unplatinated DNA1 as well.
The total reaction volume was adjusted to 10 µL with deionized water and the reaction
was brought to 90 °C in a water bath. It was allowed to cool slowly to room temperature
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over 6 h, and then the temperature was further reduced to 4 °C and held constant for an
additional 2 h by keeping in the cold room. To the annealed oligomer (10 µL), 1 µL of 10
mM ATP, 2 µL of 10× T4 DNA ligase buffer (400 mM Tris-HCl, 100 mM MgCl2, 100
mM DTT, 5 mM ATP, pH 7.8), and 1 unit of T4 DNA ligase were added. After adjusting
the total volume to 20 µL with water, the ligation reaction was allowed to proceed for 1 h
at room temperature. The ligation reactions were loaded onto an 8% native
polyacrylamide gel (0.8 mm thick, mono:bisacrylamide ratio of 29:1, 1× TBE, 10 min
pre-run) and run (89 mM Tris-borate, 89 mM acid, 2 mM EDTA) at approximately 10
V/cm for 5 h until the bromophenol blue dye marker had migrated off the gel. A watercooled electrophoresis apparatus was used to maintain the temperature of the gel at room
temperature. Migration of all the DNA bands in the original autoradiogram was measured
manually and used for the bend angle calculations. A calibration curve for distance
migrated over the length (bp) was plotted for the unplatinated control. Using the
calibration curve, calculated lengths were obtained for the platinated oligomer bands with
reduced mobility. The relative mobility (RL) of the platinated DNA (the ratio between the
calculated length of the oligomer and actual length (L)) was calculated for the 110 or 132
bp sized oligomers. Determination of the DNA bend angle was performed using the
equation RL – 1 = (9.6 x 10-5 L2- 0.47) (RC), in which L represents the length of a
particular oligomer with relative mobility RL and RC is the curvature relative to DNA
bending of an A tract (A DNA with a known bend angle).24,144,145 The detailed
calculations with the results are discussed in Chapter 4.
2.4.13 Isolation of 70S ribosomes and ribosomal subunits
Bacterial ribosomes or ribosomal subunits were isolated from the E. coli DH5α
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strain by using the sucrose gradient method.146 E. coli was grown to 0.4 OD and the
culture was centrifuged at 6,000 g for 20 min to pellet the cells. The pellet was
resuspended in buffer A (20 mM HEPES-KOH, pH 7.5, 100 mM NH4Cl, 10 mM MgCl2,
and 0.5 mM EDTA) and lysed on a French Press. After adding DNase I (5 μg/mL), the
lysate was incubated on ice for 15 min. The lysate was centrifuged twice at 15,000 rpm
for 30 min and the supernatant was collected. After adjusting the NH4Cl concentration in
the supernatant to 500 mM, the sample was centrifuged at 42,000 rpm for 4 h to pellet the
crude ribosomes. The pellet was washed and resuspended in buffer B (20 mM HEPESKOH, pH 7.5, 200 mM NH4Cl, 1 mM MgCl2). The concentrations of the crude ribosomes
were determined by using a Nanodrop UV-visible spectrometer. About 30 OD of crude
ribosomes were layered on 40 mL of a 10-30% sucrose gradient in buffer B with 1 mM
MgCl2 and centrifuged in a swinging bucket rotor on a Sorvall WX 80 ultra centrifuge at
19,000 rpm for 19 h. The ribosomes and subunits were collected separately. Fractions of
the same type were combined and the Mg2+ concentration was raised to 10 mM.
Ribosomes were pelleted by centrifugation at 42,000 rpm for 24 h at 4 °C. Pure
ribosomes were redissolved in storage buffer (ribosome subunit stock buffer: 20 mM
HEPES-KOH, pH 7.5, 10 mM MgCl2, 30 mM KCl; full ribosome stock buffer: 20 mM
HEPES-KOH, pH 7.5, 6 mM MgCl2, 30 mM NH4Cl) and stored at -80 °C.
2.4.14 Platination of ribosomal RNA and rRNA purification
For each reaction, 15 pmol of ribosomes/subunits were used. Platination was
carried out by reacting mono-activated platinum(II) compounds with ribosomes/subunits
in 1:200 pmol ratio for 16 h at 37 °C in the dark (72 mM HEPES, pH 6.5, 3.6 mM
MgCl2, 88 mM KCl). Excess platinum(II) compound was removed by ethanol
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precipitation. Phenol-chloroform extraction with 10 mM EDTA was done to extract the
reacted rRNA followed by ethanol precipitation. Isolated rRNA was dissolved in ddH2O
and the concentration was determined using a Nanodrop UV-visible spectrometer (1 OD=
23.5 pmol of 70S rRNA, 1 OD= 69 pmol of 30S rRNA).
2.4.15 Reverse –transcription and primer extension reactions
The appropriate DNA primers were radiolabeled with [-32P] ATP at the 5' end as
described earlier. Platinated rRNA (500 ng) and 1 µL of radiolabeled primer (60,000100,000 cpm) were incubated together at 80 °C for 3 min and then allowed to cool down
to room temperature for 5 min. The master mixture for a reverse transcription reaction
was prepared by mixing 24 units of ImProm-II reverse transcriptase enzyme, 1 μL of 5×
reverse transcriptase reaction buffer, and 0.4 μL of 50 mM MgCl2. To the primerannealed platinated rRNA, 1.65 μL of the master mixture, 1 μL of dNTP (stock
concentration 10 mM), and ddH2O (total volume 5 μL) were added. Primer extension was
carried out at 43 °C for 1 h. For sequencing, total RNA was used with the corresponding
radiolabeled primer. For the sequencing reverse transcription reaction 1 μL of
dNTP:ddNTP 1:4 (0.5 mM:2 mM) was used instead of the dNTP mixture. Termination of
the reactions was done by heating the reaction mixture at 95 °C in a water bath for 2 min
after adding 2 μL of denaturing loading dye (80% formamide, 1× TBE, 0.02%
bromophenol blue, 0.02% xylene cyanol) and quickly placing on ice. Reactions (50,000
cpm per lane) were loaded into 10% denaturing polyacrylamide gels (0.4 mm thick,
acrylamide:bisacrylamide 19:1, 0.5× TBE, 7 M urea). Gels were run at 33 V/cm, for
approximately 3 h. Gels were exposed to a phosphor screen overnight and imaged on a
Molecular Dynamics Phosphorimager and analyzed using ImageQuant software.
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2.4.16 Initiate cell growth from a frozen stock
Autoclaved tips and tubes were used at all experiments. The experiments were
carried out in a Laminar floor hood under aseptic conditions to avoid contaminations.
Sterile media and solutions were used for the cell growth and assays and 70% ethanol
was used to wipe the surfaces. Cancer cells were grown in Dulbecco’s Modified Eagle’s
(DMEM) medium with heat inactivated 10% FBS and penicillin (5 units/mL) and
streptomycin (5 units/mL) as antibiotics. For the normal cells, keratinocyte media
containing prequalified human recombinant epidermal growth factor 1-53 (EGF 1-53)
and bovine pituitary extract (BPE) was used. The media, solutions, and the enzymes were
stored at 4 °C and thawed at 37 °C water bath prior to use. All of the cultures were
incubated in a humidified, 37 °C, 5% CO2 incubator.
Frozen vials containing the cells were removed from the liquid nitrogen freezer
and immediately thawed by placing in a 37 °C water bath for 1-2 min. The thawed cells
were transferred to a sterile centrifuge tube containing 1 mL medium and centrifuged for
5 min at 200 × g. The supernatant was discarded and the pellet was resuspended by
adding 1 mL medium. It was then transferred to a culture plate that contains appropriate
amount of medium and incubate at 37 °C to let the cells attach to the plate. The cells were
monitored and the medium was changed after 5-6 days. The cells were grown until they
reach confluency.
2.4.17 Trypsinizing and subculturing cells from a monolayer
After reaching 80-90% confluency, cells were dispersed by trypsin treatment and
reseeded onto new plates. The medium was removed from the primary culture and PBS
was added to wash the cells. Trypsin-EDTA solution (0.25% for cancer cells and 0.05%
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for normal cells) was added and incubated at 37 °C for about 10 min to dislodge the
adhered cells. Tapping on the culture dish facilitated dislodging as well. Cells were
observed under the microscope to ensure that the cells are detached. For cancer cells,
small volume of medium containing FBS was added to the plate to inactivate trypsin, and
mixed by pipetting to make a homogenous cell suspension. For normal cells, after adding
FBS containing medium, cells were transferred to a centrifuged tube and centrifuged for
2 min at 200 × g. Supernatant was removed and the pellet was resuspended in
keratinocyte media. Equal volume of the cell suspension was added to fresh plates with
media and incubated at 37 °C in a 5% CO2 incubator. The media was changed as needed
and the cells were grown to confluency.
2.4.18 The anticancer potency of compound 5 using MTT assay
After reaching the confluency, the cells were trypsinized and collected in a 15 mL
centrifuge tube. The total volume was adjusted to 5 mL by adding medium and mixed
well by pipetting. From the cell suspension 10 μL was taken and placed on the
hemocytometer to count the cell number under the microscope. Cancer cells
(10,000/well) were seeded in a transparent flat-bottom 96-well plate with medium. Cells
were grown for 24 h to allow them attached the plate. After that, the media was removed
and fresh media and varying concentrations of the platinum compounds were added to
the wells. Two controls were done with each experiment. A growth control well had cells
and media, but no platinum compounds, whereas blank control wells had only media.
After 72 h of incubation, 10 μL of MTT stock (5 mg/mL) was added to all the wells and
incubated for additional 4 h. Then media was removed and 200 μL of DMSO was added
to dissolve the formazan product formed by viable cells. After 10 min incubation, the
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optical density of each well was measured at 520 nm using a microplate reader (BioTek
synergy H1 hybrid reader BioTek instruments, Winooski, VT). For each drug
concentration, % cell viability was calculated using the following equation.
Equation 2.5:

The IC50 value was obtained by plotting the % viability against the drug
concentration, in which IC50 is the drug concentration that gives the 50% cell viability.
Each experiment was repeated two or more times in parallel to obtain the IC50 values.
2.4.19 Quantify the platinum levels in the cells by ICP-MS
Accumulated Pt in the human cells was quantified by using an Agilent
Technologies 7700 series ICP-MS instrument (Santa Clara, CA). Platinum levels in
human prostate cancer cell line, DU145 and normal prostate cell line, RWPE-1 were
quantified for comparison. The cells were grown in a monolayer until confluency,
trypsinized, and homogenized. From the cell suspension, an equal number of cells
(460,000) were seeded onto 6 cm culture dishes and grown for 18 h. The media was
removed and the cells were washed with PBS. To each plate, platinum compound
solution (final concentration of 50 μM) and keratinocyte media was added to give a
volume of 3 mL. The cells were incubated for 2 h at 37 °C. The media was removed,
cells were collected into centrifuge tubes by trypsinizing, and washed with PBS.
Homogenized cell solutions were prepared by mixing, and cell number in each tube was
counted by using a hemocytometer. Then, the cells were digested by adding 300 μL of
concentrated nitric acid and incubating at room temperature for 16 h. The samples were
diluted by adding ddH2O up to 3 mL prior to the analysis. A standard series of Pt
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solutions with 0.5, 1, 5, 10, 25, 50, 100, 200 ppb concentrations was prepared in 2%
HNO3 and 0.5% HCl solution for calibration. Two independent trials for each cell line
were carried out simultaneously for cisplatin and compound 5. The digested cell samples
were analyzed in the ICP-MS along with solvent blanks, no-drug blank, and standards
(plasma gas flow 15 L/min, nebulizer pump speed 0.3 rps, spectrum acquisition mode,
100 sweeps per sample, 3 replicates per sample, general purpose plasma mode). The
instrument was calibrated with 10 ppb internal standard solution that contains

209

Bi. The

recommended platinum isotope with the least polyatomic interferences for ICP-MS, 195Pt
was detected.147,148 The data were obtained under high energy He tune mode in which the
internal standard signal was stable and the R value for the calibration curve was 1.
Furthermore, 10 ppm validation standard was run after the samples for quality control.
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CHAPTER 3
CARBOHYDRATE-LINKED PLATINUM COMPOUND: PRODUCT
CHARACTERIZATION AND KINETIC STUDIES WITH NUCLEOSIDES
3.1 Abstract
When it comes to new drug development, an understanding of the mode of action
is needed to refine the therapeutic approaches to further enhance efficacy. This thesis
work focuses on a novel class of cisplatin-derivatives, carbohydrate-linked platinum
complexes, due to their reported higher cell potencies, tumor selectivity, and low toxicity.
To get insight into the behavior of glycoconjugated platinum(II) complexes compared to
cisplatin, cis-dichlorido[(2--D-glucopyranosidyl)propane-1,3-diammine] platinum(II)
(compound 5) was utilized. First, the binding preference of compound 5 was established
by reacting it with DNA and RNA nucleosides and analyzing the products by HPLC and
LC-MS. The compound reacted more with guanosine (G) and deoxyguanosine (dG) over
other nucleosides. To further characterize the differential reaction rates, HPLC-based
kinetic experiments were carried out with dG and G nucleosides and mono-activated 5
and compared to mono-activated cisplatin. Overall, 2.5-fold or lower reaction kinetics for
compound 5 were observed compared to cisplatin. The reduced coordination rates of 5
compared to cisplatin are likely the result of steric hindrance from the bulkier sugar group
at the site of reaction. Perhaps surprisingly, compound 5 showed a higher coordination
rate with the RNA nucleoside G compared to the corresponding DNA nucleoside dG.
This preference of 5 for G over dG is opposite of the preference of cisplatin for dG.
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3.2 Introduction
Chemotherapy along with radiation therapy is the most common way to treat
cancer.149 Chemotherapeutics include alkylating agents (e.g., busulfan, chlorambucil,
carmustine), hormones, antitumor antibiotics, and metal complexes such as cisplatin.150
Among them, cisplatin and platinum-based drugs have received much attention due to
their successful cure rates.7 As a result, a large number of Pt-based and other metalcontaining complexes have been synthesized in the hope of finding better drugs. 7 Most
studies are focused on finding drugs with low side effects, and compounds with higher
cytotoxicity, efficacy, and selectivity towards tumors compared to normal cells. A
characteristic feature of platinum-based complexes is that the leaving- and/or non-leaving
group ligands can be replaced with a variety of functional groups. These ligands
determine different aspects of the compound.73 Careful selection of the ligands facilitates
tuning of cytotoxic characteristics of the complex. Carbohydrates are a class of tunable
molecules that can serve as ligands and introduce a variety of favorable chemical
properties to platinum complexes.150,151
Carbohydrate moieties are components of antibiotics (e.g., aminoglycosides,
vancomycin), antivirals (e.g., ribavirin, stavudin), as well as antitumor (e.g., doxorubicin,
bleomycin) drugs.152,153 One of the reasons these functionalities are widely used in drugs
is that they help reduce toxicity and improve molecular targeting.150 The hydrogenbonding capability of carbohydrates leads to improved water solubility of the molecules.
Carbohydrates are essential molecules in biological systems and therefore tend to be
nontoxic. Carbohydrate attachments facilitate drug binding to specific targets such as
ribosomes.153 Additionally, cells have specific carbohydrate transporters that can
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facilitate drug uptake.154 Glucose and other monosaccharides in the body are transported
through cell membranes via facilitated diffusion by using a family of 14 transport
proteins called GLUTs.155 These transporters are highly expressed in metabolically active
cells such as cancer cells.126,156 Therefore, sugar pendants can direct the drugs to tumor
cells for higher uptake.83 One phenomenon that is crucial for tumor growth and
progression is cell-cell recognition through carbohydrate-protein interactions.157 Modified
carbohydrates can interfere with these interactions and inhibit cancer growth.157
Moreover, carbohydrates have functional groups that can be easily modified to introduce
amino, thiol, and carboxylato groups. Modifications allow carbohydrates to serve as
strong donor ligands that are capable of coordinating to metals. Specifically, in platinumbased anticancer agents, the non-leaving group ligands are usually N-donor ligands
(Figure 3.1). Thus, if the carbohydrates are to be attached as non-leaving groups, often
they are modified with an amino group that can be used to coordinate to a platinum
center.151 The nature of the ligand influences the activity of the drug against different
types of cancer, which will be briefly discussed in this section in regards to binding
preferences.
Interest in exploring sugar conjugation for platinum-based anticancer drug
development began about a decade after cisplatin was approved as a drug by the FDA. 84
Tsubomura and co-workers synthesized the first amino sugar-platinum complexes with
promising anticancer activity against Sarcoma 180 in mice (Figure 3.1a).84 Figure 3.1b
shows simple diaminosugar-platinum complexes with a 2,3-diamino-2,3-dideoxy-Dglucose non-leaving group and different leaving groups. The cytotoxicity of these
derivatives was mostly in the low micromolar range as determined by MTT assays with
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CH1 (ovarian), HeLa (cervical), SW480 (colon), and U2OS (bone) human cancer lines,
however the cytotoxicities were not significantly improved compared to clinically
available Pt-based drugs.158 More recently, polynuclear Pt(II) complexes with higher
water solubility and cytotoxicities compared to cisplatin have been reported (Figure
3.1c).159 The concept of attaching a known drug to sugar-platinum complexes has also
been explored to generate multifunctional drugs.160 This strategy was developed to
overcome resistance problems by linking two anticancer drugs such as doxorubicin and a
cisplatin derivative (Figure 3.1d); however, no advantage over the individual drugs was
observed in that case. To improve the drug-receptor interactions, sugars have also been
attached to the Pt center via linkers.161 Oxaliplatin derivatives with various linkers
attached to the 6th position of glucose (Figure 3.1e) have been shown to be taken up
selectively by GLUT1.83 In this study, longer linkers were shown to inhibit cell uptake, as
they could restrict the transporter conformational changes.83
Another class of carbohydrate-Pt complexes that were recently developed and
tested were Pt(IV) complexes. These complexes are kinetically inert and therefore more
stable for oral administration.162 With the axial ligands, more functionalities can be
introduced to the drug to increase cellular accumulation, reduce side effects, and drug
resistance.162 Recently, several glycoconjugated Pt(IV) complexes have been reported in
which sugar derivatives were introduced as axial ligands for targeted cancer therapy
(Figure 3.1f ).163,164 For an example, the compound shown in Figure 3.1f has shown
GLUT1 and OCT transporter-dependent selective accumulation in cancer cells over
normal cells and a significantly higher antitumor activity (over 150-fold) compared to
cisplatin, oxaliplatin, and satraplatin.164
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Figure 3.1. Examples of different types of sugar-platinum complexes. Structures of
diaminosugar-Pt(II) complexes (a and b), a polynuclear Pt(II) complex (c), Pt(II)doxorubicin complex (d), an oxaliplatin derivative with glucose attached to the Pt(II)
center via a methylene linker (e), a sugar-Pt(IV) complex (f ), and compound 5 (g) are
shown.
As explained with some examples in this section, a variety of glycoconjugated-Pt
complexes have been synthesized and studied extensively. These studies are mainly
confined to cellular cytotoxicity assays and have shown promising activity. A few
attempts have been made to elucidate the transporter dependence and cancer cell
selectivity of the glycoconjugated-Pt(II) complexes.81,83,115,121,165 Although these studies
show a promising strategy for cancer treatment, detailed reactivity and structural impacts
of a glycoconjugated-Pt complex with nucleic acids are mostly unknown. Therefore, the
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work described in this thesis attempts to understand the behavior of a glycoconjugatedPt(II) derivative in terms of the reactivity preferences with nucleosides, reaction rates
with nucleosides and oligonucleotides, and structural effects on DNA.
The

carbohydrate-linked

cisplatin

derivative,

cis-dichlorido[(2-β-D-

glucopyranosidyl)propane-1,3-diammine]platinum(II) that is been explored in this thesis
work has a short 2-propane-1,3-diamine linker between the sugar and the platinum center
(compound 5, Figure 3.1g).82 As observed in a crystal structure, the complex has a
normal square planar geometry for the Pt(II) center with usual (compared to cisplatin)
Pt−Cl and Pt−N distances (231 and 202 pm, respectively).82 Both the glucopyranose ring
and the chelate ring adopt a chair conformation. In another study, the solution structure of
5 was determined by NMR in D2O,161 revealing similar structures in both the solid and
solution states. Furthermore, the NMR study showed that the carbohydrate moiety is in
the axial position of the six-membered chelate ring.161 Compound 5 has a solubility of
>20 mg mL-1 at 25 °C, which is higher than that of cisplatin (2.5 mg mL-1).82
3.3 Objectives
Although many examples of platinum complexes bound to sugars are
known,150,151 only a few reports focus on the role of the carbohydrate moiety on the
reaction kinetics with nucleosides and target site identification on larger oligonucleotides.
In general, platinum(II) complexes show preferences towards guanine bases. However,
there are a few variants with known preferences towards the adenine base.88 One
objective of the work in this chapter was to conduct a study with nucleic acid building
blocks to evaluate the reactivity of compound 5 compared to cisplatin. After determining
the reactivity preference for G nucleosides, a kinetic study was done to compare the

68
reaction rates of mono-activated 5 towards DNA and RNA nucleosides, dG and G,
respectively. Another objective was to compare mono-activated compound 5 reaction
rates with that of cisplatin. Finally, the platination products were characterized by using
mass spectrometry to determine the adduct types (i.e., monoadducts vs. biadducts).
Overall, in this work I investigated the kinetics and binding stoichiometry of a
carbohydrate-linked platinum(II) complex (5) with the nucleic acid building blocks.
3.4 Results and discussion
Compound 5 was synthesized and characterized as described previously (Chapter
2, Section 2.4.2). The MALDI-MS spectrum show a peak at 557 Da, which is the
predicted mass for 5 (518 Da) associated with K+. The peak patterns in the 1H-NMR
spectra for the ligand (compound 4) and Pt(II) complex (5) are consistent with the
literature (Figure 3.2, Appendix A, Figure A2-A4).82,161 Clear peak shifts are observed
after coordination for protons at C7 (4.20 to 3.57 ppm), and C8 and C9 (2.96-3.20 to 2.55
ppm), which correspond to a shift of 0.63 ppm and 0.41-0.65 ppm, respectively. In the
six-membered chelate ring, the C7, C8, and C9 protons are closer to the Pt center;
therefore, electron localization causes the protons to be shielded more in 5 than in the free
ligand, 4, leading to the observed upfield shifts and supporting complex formation. Minor
peak shifts are observed for the other protons.

69

Figure 3.2. The 1H-NMR spectra of (a) compound 4 and (b) compound 5 in D2O
(600 MHz). The C atoms are numbered in the chemical structures (left) and the
corresponding proton signals are shown in the spectra. Signals that show significant peak
shifts are marked with an asterisk (*).
3.4.1 Reactivity with nucleosides
Cisplatin and many other platinum-based drugs are known to react with purine
bases, adenine and guanine.166 Higher reactivity is usually observed with guanine.
Initially G and dG were reacted with a 5-fold excess of mono-activated 5 for 5 h at 37 °C
in ddH2O, pH 7.6 to detect the reactivity, and a higher peak intensity (compared to when
buffer was used) with G was observed compared to dG. Therefore, RNA nucleosides
were used to identify the reactivity preference; mono-activated 5 was reacted with
adenosine (A), guanosine (G), cytidine (C), and uridine (U) under identical conditions.
The nucleoside solutions were reacted with 5-fold excess of mono-activated 5 and
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quenched with NaCl after 16 h, and then the products were analyzed by HPLC (Figure
3.3).

Figure 3.3. HPLC analysis of RNA nucleoside reactions with mono-activated
compound 5. HPLC spectra (C18 column; buffer A: 40 mM ammonium acetate, pH 6.5;
buffer B: 40% acetonitrile; linear gradient of B from 5 to 35% over 30 min; flow rate 1
mL/min) for control (top) and reactions (bottom) with (a) guanosine, (b) adenosine, (c)
cytidine, and (d) uridine nucleosides are shown. Arrows show the possible adducts for the
reactions.
Additional peak formation at higher retention times is mainly observed with G but
not with other nucleosides, A, C, and U. For the reaction with G, four major peaks
corresponding to possible platinum adducts are detected with 20.4, 22.4 (two unresolved
peaks), and 27.5 min retention times with minor peaks at 19.7 and 24.2 min. Product
formation with 5 is observed with A (27-28 min) and C (4.2 min) to a minor extent, but
not with U. Based on the overall results, compound 5 appears to form multiple adducts
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with G to a higher level than with other nucleosides. The presence of multiple adducts
could

be

the

result

of

mono-substitution

([Pt(C9H20O6N2)G(Cl)]+,

or

[Pt(C9H20O6N2)G(H2O)]2+), or bis-substitution. For cisplatin, the dG binding preference
at the N7 position was explained by the ability to form a hydrogen bond between the
ammine-NH of cisplatin and the O6 of guanine base, which stabilizes the adduct.167 The
bidentate sugar ligand of compound 5 has two H-donor ammine groups that can engage
in hydrogen bond formation with the O6 of guanine. Therefore, as with cisplatin, we
propose that compound 5 binding to the N7 position of guanine would be preferred over
other nucleosides based on the potential hydrogen-bonding interaction with the O6 of
guanine.
3.4.2 Kinetic experiment with G and dG nucleosides
Cisplatin is well known to bind to DNA, and the direct coordination step is under
kinetic control.15 Preference in reactivity may be governed by the non-leaving ligand,
size, and charge. As shown by the initial reactions, compound 5 appears to have preferred
reactivity towards G over the other RNA nucleosides, A, C and U. Therefore, HPLC
analysis was used to quantify the coordination rates for G compared to dG. The rates for
dG or G reactions with mono-activated 5 were compared to those with cisplatin. The
kinetic reactions were carried out under pseudo-first-order conditions, in which the Pt(II)
concentration was 50 times higher than the nucleoside concentration (Chapter 2, Section
2.4.4).47 The reactions were quenched at 0.5, 1, 2, 3, 4, and 6 h time points with NaCl
(final concentration 188 μM).47 The HPLC traces are shown in Figure 3.4a. The products
had longer retention times than the unreacted nucleosides.
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The disappearance of nucleosides was quantified rather than appearance of
products since multiple products are observed. The fraction of unreacted nucleoside (y=
unreacted nucleoside/total nucleoside) was obtained by integrating the peak areas of the
products and reactant nucleosides. The fraction of unreacted nucleoside was plotted with
quenching times and fit to Equation 2.3 (y= A e-kobst) (Figure 3.4b) to obtain the pseudofirst-order rate constants (Table 3.1).

Figure 3.4. Results for the kinetic experiments with mono-activated Pt(II) and dG
and G. (a) HPLC traces for the kinetic experiments with mono-activated 5 are shown.
The reactions ([nucleoside]= 0.1 mM, [Pt(II)]= 5 mM, 25 mM Na2HPO4/NaH2PO4, pH 7,
37 °C) were quenched at 0.5, 1, 2, 3, 4, and 6 h and injected onto the HPLC (C18
column, linear gradient of B from 5 to 35% over 30 min, flow rate 1 mL/min). (b) Plots
of the fraction of unreacted nucleoside (y) over time with fits to y= A e-kobst equation are
given. The errors were calculated from three (two for cisplatin) independent experiments.
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Table 3.1. Pseudo-first-order rates for the reactions of mono-activated Pt(II)
complexes with nucleosides
mono-activated
cisplatin
kobs (s-1) × 10-6

monoactivated 5
kobs (s-1) × 10-6

dG

49 ± 1

5 ± 0.2

G

28 ± 2

11 ± 0.8

The errors were calculated from three independent
experiments.
Overall, mono-activated compound 5 show lower reaction kinetics compared to
cisplatin; for dG, the rate is 9.8-fold lower, and for G it is 2.5-fold lower (Table 3.1).
Slower kinetics have been observed previously for platinum(II) compounds with larger
ligands, likely due to crowding at the platinum center.51,168 Activated square planar Pt(II)
complex coordination at dG residues has been explained by an associative substitution
mechanism (Scheme 3.1).168 The incoming ligand coordinates as a fifth ligand to form a
trigonal-bipyramidal intermediate, after which the aqua ligand dissociates. The bulkier
sugar moiety could slow down the rate-determining first step of associative substitution
of activated compound, in which the dG residue coordinates to the Pt center.168 Activated
compound 5 could have different steric and ligand-exchange characteristics compared to
activated cisplatin, as supported by the slower reactions with both dG and G. Slower
reaction kinetics is a desirable property in anticancer drugs because it minimizes offtarget binding.168 In fact, bidentate or tridentate N-donor ligands in platinum-based drugs
add stability to the platinum complexes and decrease the possibility of undesired
substitution reactions.90,169
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Scheme 3.1. Steps of the associative substitution mechanism of a nucleophile binding
to mono-activated cisplatin. Platinum interactions with the incoming nucleophile and
the aqua leaving group in the trigonal bipyramidal transition state are shown.

mono-activated
cisplatin

trigonal bipyramidal
transition state

mono-substituted
cisplatin

Between dG and G, mono-activated compound 5 is more reactive towards G.
Compound 5 show 2.2-fold greater reactivity towards G over dG, whereas cisplatin
display a 2-fold higher rate for dG (Table 3.1). The G nucleoside has an additional
hydroxyl group at the 2 position of the ribose-sugar compared to dG, which could be
involved in forming an additional hydrogen bond with the carbohydrate moiety of the
Pt(II) compound, although this type of interaction was not verified in this thesis work. In
an associative mechanism with a trigonal-bipyramidal transition state, the ligand cis to
the leaving group becomes axial to the trigonal plane (Figure 3.5).167,168 When the
carbohydrate group becomes axial, it has the ability to interact with the entering and
leaving groups at an angle of 90°. Therefore, I propose that the transition state is
stabilized by an additional hydrogen bond with the incoming G and carbohydrate moiety
of 5, thus favoring the reaction with G as opposed to dG.
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Figure 3.5. Possible trigonal-bipyramidal transition state for the mono-activated 5
reaction with G nucleoside. The aqua ligand, adenine base, and one –NH2 of the
carbohydrate ligand are in the trigonal plane. The other –NH2 group of the carbohydrate
ligand and the chlorido group become axial to the trigonal plane as shown. In this
structure, the carbohydrate group of 5 and the ribose sugar group exist above the plane,
which brings the sugar moiety of 5 closer to the ribose for additional hydrogenbonding.161,167
3.4.3 Mass analysis of products (LC-MS)
The mixtures of products that are generated from the reactions between G or dG
and mono-activated 5 were analyzed by using mass spectrometry, with either LC-MS or a
direct injection method, to identify the adducts (Chapter 2, Section 2.4.5). The m/z of all
the possible adducts were calculated and a specific mass range (calculated m/z ± 8 Da)
was selected in the MS for adduct identification. Both mono- and bis-substituted adducts
were detected in the reaction mixtures after 16 h.
Analysis of the guanosine-5 reaction mixture by LC-MS (Figure 3.6 and 3.7)
supports the product identities as [Pt(C9H20O6N2)G(Cl)]+, [Pt(C9H20O6N2)G(H2O)]2+, and
bis-substituted adduct [Pt(C9H20O6N2)G2]2+. The calculated exact masses for the monosubstituted [Pt(C9H20O6N2)G(Cl)]+ and [Pt(C9H20O6N2)G(H2O)]2+ are 765 Da and 748
Da, respectively. The isotopic distribution due to Pt and Cl was observed in the LC-MS
spectra and matched the predicted spectra as shown in Figure 3.6 and 3.7. The bissubstituted product, [Pt(C9H20O6N2)G2]2+, has a calculated mass of 1,013 Da; the major
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peak in the spectrum appeared at 1,010 Da [M-3H+]- in the negative mode. The retention
times

for

the

[Pt(C9H20O6N2)G(H2O)]2+,

[Pt(C9H20O6N2)G(Cl)]+,

and

[Pt(C9H20O6N2)G2]2+ adducts in the LC-MS are 1.5, 4.2, and 4.3 min, respectively.

Figure 3.6. The predicted and experimental mass spectra for compound 5G monosubstituted adducts with possible structures. (a) The calculated and observed (positive
mode) m/z for [Pt(C9H20O6N2)G(Cl)]+ were 765 Da. (b) The calculated mass for
[Pt(C9H20O6N2)G(H2O)]2+ was 748 Da and the observed (positive mode) m/z for
[Pt(C9H20O6N2)G(H2O)-H+]+ was 747 Da.
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Figure 3.7. The predicted and experimental mass spectra for compound 5G bissubstituted adduct with possible structure. The calculated mass for
[Pt(C9H20O6N2)2G]2+ was 1013 Da and the observed (negative mode) m/z for
[Pt(C9H20O6N2)2G-3H+]- was 1010 Da.
The dG reaction mixtures were analyzed by using mass spectrometry with direct
injection of the sample. Figure 3.8 depicts the mass spectra obtained for mono- and bissubstituted adducts with the isotropic distribution. The calculated exact masses for
[Pt(C9H20O6N2)dG(Cl)]+, [Pt(C9H20O6N2)dG(H2O)]2+, and [Pt(C9H20O6N2)(dG)2]2+ were
749 Da , 732 Da, and 981 Da, respectively. The observed peaks are similar to the
predicted

spectra

in

the

positive

mode

with

the

masses

749

Da

for

[Pt(C9H20O6N2)dG(Cl)]+, 731 Da for [Pt(C9H20O6N2)dG(H2O)-H+]+, and 980 Da for
[Pt(C9H20O6N2)(dG)2-H+]+.
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Figure 3.8. The predicted and experimental mass spectra for compound 5dG
adducts with possible structures. (a) The calculated and observed (positive mode) m/z
for [Pt(C9H20O6N2)dG(Cl)]+ was 749 Da. (b) The calculated mass for
[Pt(C9H20O6N2)G(H2O)]2+ was 732 Da and [Pt(C9H20O6N2)dG(H2O)-H+]+ was observed
(positive mode) at 731 Da. (c) The alculated mass for [Pt(C9H20O6N2)(dG)2]2+ was 981
Da and [Pt(C9H20O6N2)(dG)2-H+]+ was observed (positive mode) at 980 Da.
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In this chapter, experimental results were presented for nucleoside-monoactivated compound 5 reactions and adduct identification. By using the nucleosides, the
reactivity was evaluated with minimum complexity as opposed to the reactions with
nucleic acids. The reactivity rates of mono-activated 5 were compared to that of cisplatin,
and showed preferred binding to G over dG. However, the overall reaction kinetics were
low for 5 compared to cisplatin, with a 2.5-fold lower rate for the reaction with G. The
reactivity differences between mono-activated 5 and cisplatin may arise from the
presence of different non-leaving group ligands. The lower reaction rates of monoactivated 5 could be due to the bulkiness of the sugar moiety, which sterically hinders the
reactivity with nucleosides. Reactivity differences of 5 compared to cisplatin could afford
unique biological consequences such as limited off-target binding, avoiding recognition
by repair enzymes, or altering downstream biological pathways. Further experiments
could be carried out to explore the reactivity differences and gain new perspectives for a
rational design of new platinum antitumor drugs.
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CHAPTER 4
REACTIVITY OF A CARBOHYDRATE-LINKED PLATINUM COMPOUND
WITH NUCLEIC ACIDS
4.1 Abstract
This chapter describes the reaction kinetics and structural impacts caused by
compound 5 (cis-dichlorido[(2--D-glucopyranosidyl)propane-1,3-diammine]platinum
(II)) at the oligonucleotide level in order to obtain some mechanistic insight into how it
works. With the guanosine ribonucleoside binding preference of 5 as described in
Chapter 3, it was of interest to explore the reaction kinetics at the nucleic acid level to
mimic the cellular targets. A series of gel-based kinetic experiments was carried out,
comparing 5 and cisplatin reactions with DNA and RNA, using both mono- and bisactivated complexes. A salt-dependent kinetic study was also carried out to understand
the contribution of RNA electrostatics on the reactivity of 5. The DNA structural changes
that occur upon mono-activated compound 5 binding were evaluated by using plasmid
and small oligomer DNAs. A reverse transcription-based primer extension technique was
used to analyze compound 5 binding sites on ribosomal RNA (rRNA). All of these
experiments were done in parallel with cisplatin. Compound 5 and cisplatin both formed
platinum adducts that lead to DNA bending. Slow reaction rates were observed for 5 for
oligonucleotides compared to cisplatin (≥3.7-fold), which was similar to the reactions
with nucleosides. These findings reveal the impact of the carbohydrate ligand on reaction
kinetics and target selectivity. These results agree with the fact that by changing the size
and nature of the non-leaving group ligands, a controlled activity can be achieved.
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4.2 Introduction
Certain aspects of nucleic acid interactions have been studied at great lengths to
understand the reaction mechanism of cisplatin.17,170,171 DNA has long been the subject of
intense investigation, but RNA has received more attention in recent years.170 These
studies include locating the platination sites, evaluating the stabilizing (or destablizing)
and structural effects of cisplatin on nucleic acids, kinetic measurements, understanding
sequence dependence of the compounds, and examining their impact on cellular
function.17,47,51,170,171
4.2.1 Kinetic studies of cisplatin-nucleic acid reactions
Cisplatin binding to nucleic acids is a kinetically controlled reaction.15 The
chlorido ligand of cisplatin is not directly displaced by the purine base, rather it happens
through a solvent-assisted mechanism.172 Therefore, the rate-limiting step in the reaction
is the initial cisplatin hydrolysis, which is a first-order reaction.172 However, activated
complexes have been used for studying the subsequent steps of platination in vitro
without the interference from the initial rate-determining step. Kinetic studies have been
done to get insight into the mechanism, primary reactive species, and sequencedependent reactivity of cisplatin with DNA.172 By directly using the activated complex,
the role of the non-leaving group ligands can be elucidated as well. Sequence-dependent
studies have identified that dGs in the context of -d(GG)- or -d(AG)- are more reactive
towards cisplatin than other dGs, and the adduct formation is dependent on whether the
sequence is in a single- or double-stranded region.12,166,173 Furthermore, flanking bases
have been shown to play a role in platination.174,175 Importance of the location of the
target site has also been shown with kinetic experiments, in which the target sites located
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at the ends of an oligomer are platinated more slowly compared to those in the
middle.176,177 Moreover, the intial platination step was faster at the 5'dG than at 3'dG for
5'-d(GG)-3' target sites.175 Platination rates are also affected by the ions present in the
microenvironment of the nucleic acid, as well as the pH. Higher concentrations of cations
and increasing pH reduce the platination rates for DNA.47,177 Several kinetic studies for
Pt(II)-RNA interactions have been reported.44,48,51 One such study showed a kinetic
preference of cisplatin for G-C-rich and wobble base-pair regions on full-length tRNA.44
A comparison between Pt(II) compound coordination to DNA and RNA revealed a more
pronounced salt-dependent reactivity with RNA.51 Moreover, the effect of pH, salt, and
RNA sequence on platination was studied in our lab by Dr. Dedduwa-Mudalige for her
thesis work.50
4.2.2 Structural impacts of Pt(II)-nucleic acid interactions
DNA adducts of cisplatin and some other Pt(II) complexes have been extensively
characterized by X-ray crystallography and NMR spectroscopy.171 The physical effects of
Pt(II) binding to DNA have been discussed in detail, as this has been identified as the
main event to initiate cell apoptosis.171 Mainly, the effects are categorized as unwinding,
shortening, and bending of the double-helical DNA structure.171 Intercalating Pt reagents
such as [Pt(terpy)(HET)]+ are known to lengthen and stiffen the DNA double helix,
whereas cisplatin and transplatin binding shorten the DNA.178 Cisplatin binding to DNA
in a bidentate fashion has a large structural impact because the complex is able to kink
the double helix at the binding site. 171 With mono-functional adducts, this effect is not as
pronounced.179 The DNA-bending angle for cisplatin has been quantified in several
studies, but the values varied.24,145,180,181 A molecular mechanics study revealed that
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cisplatin binding to form a cis-d(GG) intrastrand cross-link on duplex oligomer bent the
DNA about 60.182 By using a gel electrophoresis mobility shift assay, the cis-d(GG)
bend angle was estimated to be about 40°.180 Using a similar method in another study, the
bend angles for cis-d(GG) and cis-d(AG) adducts were 32° and 34°, respectively.24 In the
case of the cis-d(GTG) 1,3 adduct, an angle of 35° was reported.24 A crystal structure of
cisplatin bound to duplex DNA showed a bend angle of 26°, which is smaller than what
was obtained from the gel and solution studies.183 The effect of flanking bases on DNA
bending was evaluated in a recent study, in which the bend angles were found to be about
32-34° regardless of what the flanking bases are at the platinated d(GG) site.25
Bending causes the neighboring region to be destabilized and the Watson-Crick
base pairing to be weakened.171 The neighboring bases unstack and the sugar puckering
changes from C2'-endo to C3'-endo; thus, the standard B-DNA conformation is changed
to A-form DNA.171 Changes in UV and circular dichroism spectra supported the idea of
base unstacking within the helix.179 Furthermore, a decrease in melting temperature upon
cisplatin binding revealed destabilization of the DNA structure.179 Alkylation at the N7
position of purines is known to destabilize the glycosidic bond and facilitate
depurination.184 However, with cisplatin binding, the glycosidic (N9-C1') linkage is
stabilized, probably due to the better distribution of the positive charge over the Pt
atom.184 Lowering the pKa of the N1 position of the purine ring from ≈ 10 to ≈ 8 upon
platination supports this idea as well.185 Therefore, the anticancer activity of platinum
compounds is often correlated with distortion of the DNA structure, which affects regular
biological functions in the cell.171
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4.3 Objectives
In order to develop next-generation platinum anticancer drugs with less off-target
effects, low resistance, and higher potency, it is important to understand their reactivity at
the biomolecular level. Although clinically available platinum(II) drugs have been
studied extensively, the biochemistry of other cisplatin derivatives is poorly understood.
The purpose of this chapter is to evaluate the reaction kinetics of 5 with oligonucleotides,
as well as its structural impacts on DNA and nucleotide preferences for rRNA binding to
understand the effects of the carbohydrate ligand.
From Chapter 3, it was clear that the kinetics are different for 5 compared to
cisplatin at the nucleoside level, in which the overall reactivity was low for 5 and the
guanosine ribonucleotide binding was preferred. It was of interest to evaluate the
reactivity on DNA and RNA oligonucleotides as well as the mononucleotides. Therefore,
the first objective of this section was to evaluate the reaction kinetics of 5 with
oligonucleotides to compare their binding preferences, and to gain insights into the basis
of these differences. Kinetic studies with mono- and bis-activated compound 5 were done
to compare the reaction rates with DNA and RNA oligonucleotides. Salt-dependent
kinetic rates were also obtained for the reaction between mono-activated 5 with DNA and
RNA to understand the electrostatic contributions on the reactivity. Similar experiments
were carried out with cisplatin for comparison.
After establishing the reactivity with oligonucleotides, the next question to ask
was what is the impact of binding on the nucleic acid structure? If a potentially active
molecule does not distort the nucleic acid structure or inhibit a nucleic acid-related
functions, its activity may not be the result of targeting nucleic acids.171 Therefore, the
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second objective of this study was to determine the structural changes caused by monoactivated 5 on DNA in comparison to cisplatin.
Previous studies showed that cisplatin’s anticancer activity correlates with DNA
binding. However, with more mechanistic studies available, this idea has been challenged
and cisplatin has been shown to bind to other cellular targets such as RNA and
proteins.39,186,187 In particular, cellular RNA has received some attention in recent
years.187 Considering the abundance, accessibility, and functional importance, rRNA can
be considered as one of the potential targets of Pt(II) compounds.187 Furthermore, the
biologically active compound 5 showed higher reactivity towards the guanosine
ribonucleoside compared to the corresponding deoxy nucleoside. Therefore, the third
objective was to evaluate the nucleotide preferences of 5 binding to rRNA. The effects of
the carbohydrate ligand on structural and kinetic properties are clues in understanding the
biological activities of glycoconjugated molecules. Overall, this chapter aims to provide
information about steric, electronic, and hydrogen-bonding properties of compound 5 that
influence nucleic acid binding and kinetics of the molecule.
4.4 Results and discussion
4.4.1 Kinetic studies for mono-activated 5 and nucleic acid reactions
Kinetics are crucial to the antitumor properties of a drug. Chapter 3 evaluates the
binding kinetics with the building blocks of nucleic acids in a simplified environment.
However, it is important to compare these data to kinetic parameters of nucleic acids to
get a better view of the activity of platinum compounds. More complex secondary and
tertiary structures of nucleic acids, cations and solvents in the microenvironment, and
electrostatic and hydrogen-bonding ability of the ligands are some of the factors that
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determine the drug-nucleic acid interactions.188 Kinetic, thermodynamic, and structural
preferences of the drug are governed by these parameters.188
The DNA and RNA strands used for my kinetic experiments are similar in length
(22-mer), sequence (except for T in DNA and U in RNA), and have only one -GG- site
for platination (DNA1 and RNA1). The single-stranded nucleic acids were radiolabeled
at the 5 end for visualization during gel electrophoresis. The first hydrolysis of cisplatin
is the rate-limiting step. Therefore, by using mono-activated platinum complexes, factors
influencing the direct coordination step could be rapidly evaluated without interference
from the first hydrolysis. Under excess Pt(II) concentration, this reaction was expected to
obey pseudo-first-order conditions. The pseudo-first-order rate constant, kobs, for the
reaction between different concentrations of mono-activated 5 and DNA were obtained as
described in Chapter 2, Section 2.4.9. The Pt(II) compound was maintained at a 134fold higher concentration than that of the oligonucleotide. This condition maintained the
pseudo-first-order rate. Specifically, the final concentration of the added mono-activated
Pt(II) complex was 94 μM. This procedure was repeated with RNA for direct
comparison. The experiment was also carried out with mono-activated cisplatin to
compare the rates to those of the carbohydrate complex.
Results obtained with DNA are shown in Figure 4.1 and the results obtained with
RNA are shown in Figure 4.2. As shown in Figure 4.1a and b, addition of monoactivated 5 and cisplatin to nucleic acids results in a decrease of unplatinated nucleic acid
in a time-dependent manner as observed on denaturing polyacrylamide gel images.
Slower migrating product bands are observed on the gels. The fraction of unreacted
nucleic acid over time is fitted to a single exponential decay (Equation 2.3 and Equation
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2.4) to obtain the kobs. Standard errors were calculated from three independent
experiments.

Figure 4.1. Representative results for the kinetic experiment between DNA and
mono-activated Pt(II) complexes. The gel images for the reactions between DNA with
mono-activated (a) compound 5 and (b) cisplatin showed the time-dependent decay of
unreacted DNA and formation of the products ([DNA] = 0.7 μM, [Pt(II)] = 94 μM; 10
mM K2HPO4/KH2PO4, pH 6.2, with 20 mM NaClO4, 37 °C). The fraction of unreacted
DNA over time for the mono-activated (C) compound 5 and (d) cisplatin showed
exponential decay.
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Figure 4.2. Representative results for the kinetic experiment between RNA and
mono-activated Pt(II) complexes. The gel images for the reactions between RNA with
mono-activated (a) compound 5 and (b) cisplatin showed the time-dependent decay of
unreacted RNA and formation of the products ([RNA] = 0.7 μM, [Pt(II)] = 94 μM; 10
mM K2HPO4/KH2PO4, pH 6.2, with 20 mM NaClO4, 37 °C). The fraction of unreacted
RNA over time for the mono-activated (c) compound 5 and (d) cisplatin showed
exponential decay.
For the reaction of mono-activated compound 5 with DNA, the rate is 14-fold
lower than that of cisplatin (Table 4.1). For RNA, the rate is 3.7-fold lower. Therefore,
mono-activated 5 shows slower reactivity with oligonucleotides compared to cisplatin,
similar to the reactions with nucleosides in Chapter 3. This difference could be due to
the steric hindrance caused by the larger carbohydrate group of 5 when approaching the
target site because the carbohydrate group is in the axial position of the six-membered
chelate ring.161 Furthermore, the six-membered ring between the Pt and the carbohydrate
ligand has the ability to accommodate different conformations (i.e., boat and twist-boat)
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during the coordination reaction. That difference could cause slower reactivity of monoactivated 5. This effect is also observed for carboplatin, in which the bidentate leaving
group ligand accommodates a boat configuration, which blocks reactions with the
incoming nucleophiles.189 Moreover, the Pt(II)-based anticancer compound picoline has
also shown reduced reactivity due to steric effects caused by the non-leaving group
ligand compared to cisplatin.190 This characteristic has been considered beneficial in
anticancer drugs in terms of minimizing the off-target reactions with glutathione or other
cellular thiols.191
Table 4.1. Pseudo-first-order rate constants, kobs for the reactions of mono-activated
Pt(II) complexes with DNA, RNA
mono-activated
cisplatin
kobs (s-1) × 10-4

mono-activated 5
kobs (s-1) × 10-4

DNA

7.4 ± 0.8

0.54 ± 0.05

RNA

3.3 ± 0.7

0.9 ± 0.1

As shown in Table 4.1, mono-activated cisplatin shows a 2.2-fold preference for
DNA over RNA, whereas 5 shows a 1.7-fold preference for RNA. Therefore, the RNA
preference of mono-activated compound 5 is also present at the oligonucleotide level,
similar to the nucleosides. The geometric environment of the DNA and RNA might
influence electrostatics of the nucleic acids, and subsequently the kinetics of Pt(II)
interactions. The RNA structure creates multiple electrostatic pockets for metal
binding.192 In biology, Mg2+ is associated with the RNA regions to modulate electrostatic
potentials.127 In contrast to DNA, RNA adopts an A-form structure and the major groove
is shown to be more electronegative than the minor groove.192,193 This property may
explain the preference of cationic drugs such as compound 5 for RNA over DNA. Sugar-
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derived small molecules such as aminoglycosides preferably target RNA based on
hydrogen-bonding capabilities of the drug.122 Therefore, specific hydrogen-bonding
interactions between the multiple sugar –OH groups of the carbohydrate ligand and RNA
could be one of the reasons that the mono-activated 5 has preferred reactivity towards
RNA compared to cisplatin.
4.4.2 Kinetic studies for bis-activated 5 and nucleic acid reactions
There could be various reasons for the observed low coordination rates of monoactivated compound 5 with DNA and RNA compared to cisplatin. The experiments were
carried out with mono-activated Pt(II) compounds; therefore, the effect of the ratelimiting first hydrolysis step (10.2 × 10-5 s-1) is not the reason for slow coordination.16
The mono-activated compound can react with nucleosides or undergo second hydrolysis
to produce the bis-activated complex. These competing reactions may impact the
observed slow rates for the mono-activated compound 5. Therefore, by using bisactivated compounds, we could analyze the effect of the structure or role of the overall
charge of the complex (+1 vs. +2) on the reaction rate. As shown in Table 4.2 and
Appendix B-Figure A1, the experiment was carried out with both DNA and RNA.
Table 4.2. Pseudo-first-order rate constants, kobs for the reactions of bis-activated
Pt(II) complexes with DNA, RNA
bis-activated cisplatin
kobs (s-1) × 10-4

bis-activated 5
kobs (s-1) × 10-4

DNA

17 ± 2.7

0.2 ± 0.09

RNA

5.2 ± 1.6

0.3 ± 0.05

The same reactivity patterns are observed, similar to the mono-activated cisplatin, in
which DNA is the preferred target with (3.2-fold) faster reactivity compared to RNA for
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the bis-activated cisplatin. For bis-activated 5, a significant difference between the rates
for DNA and RNA is not observed.

Figure 4.3. Comparison of reaction rates obtained from DNA and RNA with monoand bis-activated Pt(II) complexes. The rate comparisons for (a) cisplatin and (b)
compound 5 are shown. The errors were calculated from three independent experiments.
The obtained rates for mono- and bis-activated form of each compound are
compared and summarized in Figure 4.3. Higher reaction rates for the bis-activated
cisplatin (compared to mono-activated) are observed for both DNA and RNA.167,194 This
result also agrees with previously reported data, in which bis-activated cisplatin had a
higher reaction rate than the mono-activated complex with DNA.174,194 There are a few
explanations to the observed higher rates for the bis-activated cisplatin. Compared to the
monocation, the dication would facilitate the compound to be attracted more towards
polyanionic nucleic acids and therefore increase the reaction rate. Moreover, the oxygen
on the aqua ligand is less electronegative compared to the chlorido ligand, which would
strengthen a hydrogen bond between the –NH3 ligand and O6 of the guanine base. This
interaction would increase the reaction rate of bis-activated cisplatin by stabilizing the
transition state and decreasing the activation energy. In contrast, bis-activated 5 show a 3fold decreased rate with both DNA and RNA compared to the mono-activated form. This
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effect may be due to the larger carbohydrate non-leaving group near the Pt(II) reactive
center as explained in the Section 4.4.1 (so charge effect is reduced due to steric bulk).
4.4.3. Salt-dependent kinetic studies of 5 with nucleic acids
Coordination reactions between activated Pt(II) complexes with nucleic acids
occur in two steps.195 In the first step, the Pt(II) compound associates with DNA or RNA
by displacing a fraction of surface-bound cations. The second step is direct coordination
to the target. Activated-Pt(II) complexes are positively charged; therefore, the first
association step is affected by cations in the media. Therefore, a salt-dependent kinetic
study was carried out with mono-activated 5 in comparison to cisplatin with DNA and
RNA to evaluate the contribution of electrostatics on the reaction. The platination rates
were obtained from reactions in two buffer conditions, in which both had 12 mM K+.
Additionally, one condition was 5 mM Na+, whereas the other was 20 mM Na+. The
comparative results are shown in Table 4.3, Figure 4.4, and Appendix A-Figure A3.
Table 4.3. Pseudo-first-order rate constants, kobs for the reactions of mono-activated
Pt(II) complexes with DNA, RNA in different buffer conditions
buffer
condition
12 mM K+

nucleic
acid

monoactivated
cisplatin
kobs (s-1) × 10-4

monoactivated 5
kobs (s-1) × 10-4

fold change
(cisplatin/comp 5)

DNA

24 ± 5

2 ± 0.4

12

RNA

33 ± 10

1.4 ± 0.3

23.6

DNA

7.4 ± 0.8

0.54 ± 0.05

13.7

RNA

3.3 ± 0.7

0.9 ± 0.1

3.7

5 mM Na+

20 mM Na+

At the low salt concentration (5 mM Na+), the reaction rate differences between
DNA and RNA are less prominent for both monoactivated-cisplatin and 5. However, at
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the high salt concentration (20 mM Na+), mono-activated cisplatin shows a 2.2-fold
preference for DNA over RNA, whereas 5 shows a 1.7-fold preference for RNA. This
shows that the target preference can vary depending on the cations in the environment. 51
With increasing salt, the reaction rates decrease for both mono-activated cisplatin and 5,
likely due to increased competition for binding to the target. This result agrees with
previous reports.50 With DNA, both mono-activated compounds show a decline in the
reactivity with increasing salt concentration (3.2-fold for cisplatin and 3.7-fold for 5,
respectively). A more pronounced salt effect was observed for the RNA and monoactivated cisplatin reaction (10-fold) in the two buffer conditions. However, only a 1.5fold rate difference was observed for the reaction with mono-activated 5 and RNA at the
two buffer conditions, suggesting that electrostatics play a less significant role in RNA-5
interactions.

Figure 4.4. Comparison of salt-dependent reaction rates obtained for monoactivated (a) cisplatin and (b) compound 5 with DNA and RNA. The errors were
calculated from three independent experiments.
Taken together, these kinetic data suggest that compound 5 has a slight preference
for RNA over DNA. The size of the molecule may also play a role in governing the
reaction. These results agree with previous studies, in which it was shown that large
differences in rates occur when ligands occupying the Pt(II) coordination sphere are
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changed.189 These observations may influence the design of new carbohydrate-Pt(II)
drugs that have reduced off-target binding. Additionally, compound 5 may favor RNA
binding and therefore, future studies can be done to evaluate the reactivity of 5 with
RNA.
4.4.4 Structural impacts of mono-activated 5 on plasmid DNA
Early studies with cisplatin and transplatin were done with plasmid DNA.178
Plasmid DNA is topologically constrained, so that if there are any alterations causing
changes in the number of helical turns, that effect is reflected on the DNA
superhelicity.178 Unwinding can be deduced by the changes in the superhelicity, which
can be monitored by gel electrophoresis. Initial experiments to evaluate the structural
effects of mono-activated 5 were carried out with pUC19 plasmid and compared to
results with mono-activated cisplatin. Mono-activated 5 or cisplatin (160 μM each) were
incubated with plasmid (0.5 μg) for different time periods as described in Chapter 2,
Section 2.4.11. The reactions were quenched and analyzed on agarose gels (Figure 4.5).

Figure 4.5. The gel images of the plasmid DNAs platinated by mono-activated (a)
cisplatin and b) compound 5. ([DNA] = 0.5 μg, [Pt(II)] = 160 μM; 10 mM
Na2HPO4/NaH2PO4, pH 7.4, 37 °C). The reactions were quenched at the time points
indicated at the bottom of the images. The cartoon figures on the right show the
topological forms of the closed circular DNA.
The bands corresponding to the supercoiled plasmid DNA exhibit different gel
migration distances over various time points as adducts form with either mono-activated
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cisplatin or compound 5. The differing gel migration distances are caused by bending and
unwinding of the plasmid DNA induced by the platinum adduct. The supercoiled plasmid
platinated by mono-activated Pt(II) complexes becomes more relaxed, decreasing the
electrophoretic mobility of the DNA. Upon further incubation with mono-activated
cisplatin, relaxed plasmid DNA appears to rewind in the opposite direction to be
supercoiled (30 min- 24 h time period). In contrast, the supercoiled region of plasmid
platinated by mono-activated compound 5 is only seem to become more relaxed during
the same incubation period. This suggests that compound 5 has a kinetically slower effect
on the DNA plasmid structure than cisplatin.
4.4.5 Structural impacts of 5 on short duplex DNA oligomer
While the reactions with plasmid DNA allowed us to investigate more of the
global structural changes, a DNA bending study was carried out with a short DNA duplex
with a single -d(GG)- site as described in Chapter 2, Section 2.4.12 to understand the
structural impact at the local binding site. Depending on the binding mode the effect on
the secondary structure can vary. A gel electrophoresis mobility shift assay that was
reported in the literature for quantifying the DNA-bending angle was utilized in this
study to evaluate the effect of 5.24 This method was developed based on a previous
method that was used to study DNA bending at naturally occurring d(A5T5)2 sequences
known as A-tracts.196 Presence of this sequence in the center of a DNA leads to bending
of the DNA structure, thereby causing reduced mobility in a gel. Moreover, it has been
shown that if there are multiple A-tracts in a DNA, the bends will be phased
constructively if they are located ~10.5 helical turns apart.145,196 Other spacings caused
the bending to cancel out with no change in the mobility. The DNA duplex used for my
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Pt bending studies was designed keeping the above facts in mind, in particular the
spacing of the d(GG) site.
My experiments were carried out with a 22-base pair DNA duplex molecule
(Scheme 4.1) that was used previously with cisplatin (top and bottom strands are referred
to as DNA1 and DNA2).24,144 The sequences were designed to have a two-nucleotide
overhang on each end to facilitate ligation in only one orientation. DNA1 has a 5'
phosphate and a single -d(GG)- site for platinum coordination. DNA2 is complementary
to DNA1 and has hydroxyl groups at both the 3' and 5' ends, in which the 5' ends were
radiolabeled using [32-P]-ATP.
Scheme 4.1. Sequences of DNA used in the bending experiments.
DNA1:
5' p-TCT CCT TCT TGG TTC TCT TC TC-OH 3'
DNA2: 3' HO-AG AGA GGA AGA ACC AAG AGA AG-OH 5'
To facilitate the efficient platination of DNA1, it was reacted with a 1:2 ratio
(DNA:Pt) of bis-aquated Pt(II) complexes (Figure 4.6a). The MALDI-MS spectra
confirmed single platination of DNA1 in the gel-purified product (Figure 4.6b and c).
The mass of DNA1 was calculated to be 6,640 Da and after coordination to cisplatin, the
mass of the DNA1-Pt product was 6,868 Da, which corresponds to single platination
most likely at the –d(GG)- site. For 5 coordinated to DNA1, the mass was 7086 Da with a
shift of 447 Da that corresponds to bidentate coordination for a single adduct.
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Figure 4.6. The platination of DNA1. (a) The DNA1 sequence with a single platination
site and MALDI-MS spectra for the reaction of DNA with (b) cisplatin and (b) compound
5 are shown. The spectra were obtained in positive-ion reflector mode (3-HPA matrix).
The calculated mass of the single-stranded DNA (M) is 6640 Da. The masses of the
DNA1-Pt products correspond to bidentate coordination for a single adduct ([DNA1Pt(NH3)2]+/2+ for cisplatin and [DNA1-Pt(C9H20O6N2)+/2+ for compound 5).
Initial experiments were carried out with cisplatin to verify the DNA bending
method and compare to published data.24 The platinated and unplatinated DNA1 strands
were annealed and ligated with bottom strand (DNA2) in separate reactions. The effects
of platination on the DNA structure were determined by analyzing the reaction mixtures
on 8% native polyacrylamide gels. The ligation of duplex monomers leads to the
formation of DNA oligomers. Initially, different ligation times were tested. Figure 4.7a
shows the results for one and 16 h ligations. Both conditions show the same results of
ligation; therefore, future ligations were done for 1 h at room temperature.
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Figure 4.7. Results for DNA bending caused by cisplatin. (a) The 8% native
polyacrylamide gel image for DNA bending experiments with and without cisplatin is
shown. (L= linear ligated DNA oligomers, C= circular ligated DNA oligomers; the
numbers 2, 3, 4, etc. correspond to the number of duplex monomers that are ligated
together. Lanes 5-7 contain reaction mixtures treated with thiourea to remove the Pt
adduct. Reactions 8-10 are controls (separate gel). (b) A schematic diagram of the DNA
ligation with and without cisplatin, and (c) the calibration curve constructed for the (-)
cisplatin DNA are shown.
In the reaction with unplatinated DNA1, the duplex monomers were expected to
ligate to give linear oligomers, which is indeed observed in Figure 4.7a (for example, L4
represents a linear oligomer with four monomers ligated together). In contrast, the
platinated DNA has a reduced mobility on the gel as seen in Figure 4.7a. We believe this
effect is due to the bending effect of the cisplatin adduct on the DNA structure (Figure
4.7b). For the platinated DNA, migration retardation is observed particularly for the
larger multimers. A decrease in gel mobility may result from a decrease in the end-to-end
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distance of the ligated DNAs due to curvature introduced by the platinum adducts.24 The
chosen DNA sequence predicts the bends to be spaced evenly, such that constructive
addition of bends leads to circular DNA. With an increasing number of bends that are
added together, the gel mobility of the DNA products decrease. Similar to previous
studies done with cisplatin,24,25,144 the circularization occurs when five double-stranded
monomers are ligated together (C5-110 bp) and the resulting circle comigrates with L6.
As reported by Bellon and Lippard, the difference in the migration of the
platinated DNA relative to the unplatinated DNA can be used to quantify the bend angle
caused by cisplatin.145,197The migration distances of the bands on the gel corresponding to
unplatinated DNA (lanes 1 and 3) were measured manually and a calibration curve was
constructed between the log size of the DNA and migrated distance (Figure 4.7c). From
the plot, the calculated length for a particular linear platinated DNA can be obtained. The
calculated length is based on an oligomer’s mobility. Using the equation obtained from
the calibration curve (y = -0.0947x + 3.038), the calculated lengths (y) were determined,
in which x is the migration distance for the linear platinated DNA (Table 4.4).
Table 4.4. Calculated lengths and relative mobilities for the cisplatin-modified DNA
nucleic
acid

DNA distance
migrated (cm)

y = -0.0947x
+ 3.0378

calculated
length
(bp)

measured
length (bp)

relative
mobility
(RL)

L2

14.9

1.63

42

44

0.95

L3

12.5

1.85

71

66

1.1

L4

11.0

1.99

99

88

1.1

L5

8.6

2.22

167

110

1.5

The relative mobility (RL) of the platinated DNA is the ratio between the
calculated length of the oligomer and actual length. Since unplatinated DNA has the same
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calculated length and actual length, the RL is 1 for all points. With higher curvature in the
DNA structure, mobility retardation is higher and results in higher R L values. As shown
in Table 4.4, the platinated DNA has RL>1 for longer oligomers (≥L3). Determination of
the DNA bend angle caused by cisplatin is performed using Equation 4.1, in which L
represents the length of a particular oligomer with relative mobility R L and RC is the
curvature relative to DNA bending of an A tract (A DNA with a known bend
angle).24,144,145 Application of Equation 4.1 to the 110-bp multimer composed of the 22bp platinated monomers gives a curvature of 0.85. To determine the average bend angle
in degrees, the RC value is multiplied by the absolute value of two A6 tract (40°).197,198
The result predicts the bend induced by the cisplatin 1,2-d(GG) intrastrand crosslink to be
34°, which corresponds well with previous studies.24 The experiment was repeated three
times and the bending angle was calculated using the 110-mer to be 34 ± 1°.
RL – 1 = (9.6 x 10-5 L2- 0.47) (RC)2

Equation 4.1

After establishing the protocol with cisplatin, the same experiment was carried out
with DNA platinated by bis-activated compound 5 (Figure 4.8). Similar bands are
observed with reduced mobility, together with bands corresponding to circular products.
The band corresponding to linear 5-mer, which is used for quantification, is more
prominent in cisplatin than for compound 5, which suggests the rate of cyclization could
be different for the two compounds. Therefore, the 6-mer (132 bp) band was used to
quantify the bend angle for compound 5. The band migration distances were measured
and the DNA-bending angle was computed to be 36 ± 1° (two trials), which is similar to
that of cisplatin modified DNA.
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Figure 4.8. Results for DNA bending caused by 5. (a) The 8% native polyacrylamide
gel image for DNA bending experiments with and without compound 5 is shown. (L=
linear ligated DNA oligomers, C= circular ligated DNA oligomers; the numbers 2, 3, 4,
etc. correspond to the number of duplex monomers that are ligated together. Lanes 3 and
4 are reactions treated with thiourea to remove the Pt adduct. (b) The calibration curve
constructed for the (-) Pt DNA is shown.
To show that the mobility change is due to platinum adduct formation, saturated
thiourea was used to reverse the platination.199 When the ligation products modified with
cisplatin and 5 were incubated with saturated thiourea (0.2, 0.5, or 1 μL) for 72 h at 37 °C
(lanes 5-7 in Figure 4.7 and lanes 3-4 in Figure 4.8), the linear platinated DNA bands
show similar migration patterns as the unplatinated DNA (lane 1). Even after removing
the Pt, the upper bands (corresponding to C5-C8)) in the gel have slower mobility,
supporting a model in which the Pt binding has caused circularization. Presence of

102
circular products is evidence for the ability of 5 to significantly bend the DNA structure
so that the ends will come closer together for ligation.
Figure 4.9 shows crystal structures of cisplatin and oxaliplatin bound DNA, in
which the adducts are located in the major groove of DNA.181,200 The crystal structures
consist of a DNA dodecamer duplex with a sequence of 5-CCTCTGGTCTCC.181,200
There is only one platination site in the middle of the sequence. Irrespective of the length,
this DNA duplex is very similar to the one used in my study. Thus, it is a good
representation of the platinum adducts bound to duplex DNA. Compound 5 adduct was
modeled onto the crystal structure of oxaliplatin to represent the binding. Although the
positioning of the sugar pendent may slightly vary in an actual structure, this model
structure gives an indication of how compound 5 sits in the major groove of a DNA
duplex. The adduct of 5 is bulkier than cisplatin and oxaliplatin, and it likely sits in the
DNA pocket with the sugar group protruded outside, similar to oxaliplatin.
(b)
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Figure 4.9. Crystal structures of Pt(II) complex-bound DNA duplex. The DNA
dodecamer duplex has a single GG-site for platination with (a) cisplatin (PDB: 1AIO), (b)
oxaliplatin (PDB: 1IHH) and (c) compound 5.181,200 The other nucleotides in the duplex
are C and T. Platinum atom is shown is dark blue color and the chemical structure of the
Pt(II) complex is shown below each crystal structure. The crystal structure for 5 was
modeled based on the oxaliplatin-DNA structure.
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Depending on the Pt(II) adduct, the effect on DNA structure varies. For example,
monofunctional or intercalating adducts unwind DNA, whereas cis intra- and interstrand
bifunctional adducts unwind and bend the DNA.201 Moreover, trans-1,3-intrastrand
adducts cause the middle nucleotide to bulge out.171 Furthermore, trans adducts cause a
hinge joint at the locus, which does not lead to cooperative bending. Previous studies
showed that the formation of 1,2-d(GG) instrastrand cross-links by cisplatin leads to
DNA bending towards the major groove and unwinding of the DNA.183 Taken together,
my results support the hypothesis that compound 5 makes a 1,2-d(GG) intrastrand crosslink with DNA that leads to DNA bending as well. Appearance of similar circular bands
for cisplatin and compound 5 further suggests similar DNA bending caused by platination
on duplex DNA. The calculated bend angles are in the same range as previously reported
bend angles from similar gel-based assays (32-40°). In fact, additional hydrogen-bonding
interactions of 5 could further restrain the DNA duplex and orient it for faster ligation
than cisplatin. Such interactions has been shown with oxaliplatin where additional
hydrogen-bonding interactions are present between the NH of the (R, R)-DACH ligand
and the O6 atom of the 3′-dG of the d(GG) lesion.200 The search for a better anticancer
drug might include molecules that can form hydrogen bonds directly to DNA in the
vicinity of the lesion, similar to oxaliplatin. Therefore, it may be promising to use
compounds related to 5 that have similar hydrogen-bonding properties. The toxicity of
cisplatin comes from these lesions on DNA; therefore, it was of interest to compare the
biological effects of cisplatin and 5 as well. This will be further discussed in Chapter 5.
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4.4.6 Evaluation of structural and sequence specificity of mono-activated 5 by
probing ribosomal RNA
The size and charge of the non-leaving group ligands can affect the binding
selectivity to oligonucleotides. With previous experiments, compound 5 binding to d(GG)
sites of DNA has been shown. With the observed kinetic preference of mono-activated
compound 5 for RNA over DNA, it was of interest to further explore the RNA binding
aspects of compound 5. Amino-sugar derived drugs are largely known to interact with
RNA,120 specifically rRNA, due to their capability of hydrogen bonding with the target.
Furthermore, the ribosome has specific binding pockets to accommodate different ligands
as a part of its normal biological role.97 The ribosome is a ribonucleoprotein complex that
plays a significant role in the protein translation process.97 The ribosome is a highly
abundant, complex structure that is a common drug target.97 With the similarity between
DNA and RNA purine nucleotides, the ribosome and other functionally important RNAs
can be secondary targets for platinum drugs. There have been previous efforts to study
cisplatin binding to RNA. These studies have included probing of rRNA to identify
platination sites,43 localization studies to show where cisplatin is accumulating in the
cell,46 and kinetic studies to determine the rates of RNA platination.51 A crystal structure
of the T. Thermophilus 70S ribosome modified with cisplatin is also available.40 In this
study, structural and sequence specificity of mono-activated compound 5 binding to
rRNA was evaluated in the context of the ribosome. The method is included in Chapter
2, Section 2.4.13-2.4.15 (this work was done in collaboration with Dr. Nisansala
Muthunayake). Considering the bulky sugar ligand of 5 compared to the simple ammines
of cisplatin, it was of interest to evaluate the preferred binding sites for each compound.
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Certain regions in the ribosome are critical for its biological function, namely
translation. Based on a recently published cisplatin-bound ribosome crystal structure,40
h24 (790 loop), h44, h43, and the peptidyltransferase center (PTC) were chosen to map
the binding sites of mono-activated 5 on the rRNA. Additionally, H69 has been
extensively studied as a cisplatin-binding site in our lab; therefore, it was of interest to
probe H69 as well. Out of the probed functionally important rRNA regions, h24, h44, and
h43 are located in the small subunit of the ribosome, whereas the PTC region and H69
are located in the large subunit. The DNA primers were designed to anneal to
complementary regions of RNA, upstream of the site of interest. For example, the
radiolabeled primer for the 790 region anneals at positions 831-814 of 16S rRNA (E. coli
numbering) and extends towards the 790 region during reverse transcription. The
platinum-modified nucleotide locations can be detected by reverse transcriptase stops on
the 3' side of the adduct. There are some stop sites visible in the control lane due to RNA
secondary structures that block reverse transcriptase. Dideoxy sequencing was done in
parallel to compare with the reverse transcription reactions. Band intensities at the stop
sites were quantified and normalized to standard bands to achieve the % reactivity. The
bands with ≥50% were considered as major stop sites, whereas the ones below 50% were
considered as minor sites.
Figure 4.10 shows the result for probing the 790 loop, which is part of helix 24
(h24) in the small subunit, with mono-activated cisplatin and 5.202 There is a prominent
stop site at U801 for cisplatin, which is consistent with previously published data from
our lab.43 As shown in the secondary structure map, this site is in the internal loop region
and adjacent to two consecutive G residues, G799 and G800. Several other stop sites are
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observed at A792, A777, and C770, and a minor stop site at C795 for cisplatin, where all
residues are located 3' to purine reactive sites. Minor stop sites are observed for 5 at all of
the above-mentioned residues. Nucleotides A792, A777, and C770 are proposed to
participate in adduct formation with neighboring G residues, similar to cisplatin. In
contrast, the stop at C795 suggests adduct formation at the adjacent A residue.

Figure 4.10. Probing result for ribosomal h24 (790 loop) region with mono-activated
cisplatin and 5. (a)The autoradiogram shows reverse transcription mapping of in vitro
reactive sites of mono-activated cisplatin and 5 on 70S ribosomes in a 1:200 molar ratio.
The stop sites for cisplatin () and 5 () are shown with symbols (,major, ,minor
adduct). Dideoxy sequencing lanes are labeled as U, C, A, and G. (b) The rRNA
secondary structure with the corresponding platinum-reactive sites is shown. The primer
binding site is shown with an arrow.
The 790 loop is located near the ribosome decoding site. Chemical and enzymatic
probing, as well as mutagenesis and structure studies, have revealed this region to be
exposed on the surface of the 30S subunit, and directly involved in subunit association, as
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well as playing a key role in translation initiation.203 Notably, the Pt(II) modification site
at A790 and G791 is at the mRNA channel, where the rRNA directly contacts the bound
mRNA.40 Cisplatin has been shown to coordinate to A790 and mRNA in a recent x-ray
structure, and therefore may prevent mRNA translocation.40 Furthermore, Pt(II) binding
at A794 could affect P-site binding of tRNA, similar to the antibiotic edeine.103
Therefore, platination at these positions could potentially prevent protein synthesis.

Figure 4.11. Probing result for ribosomal h44 (A site) and h43 regions with monoactivated cisplatin and 5. (a) The autoradiogram shows reverse transcription mapping of
in vitro reactive sites of mono-activated cisplatin and 5 on 70S ribosomes in a 1:200
molar ratio. The stop sites for cisplatin () and 5 () are shown with symbols
(,major, ,minor adduct). Dideoxy sequencing lanes are labeled as U, C, A, and G.
(b) The rRNA secondary structure with the corresponding platinum-reactive sites is
shown. The primer binding site is shown with an arrow.
The ribosomal decoding site (A site) is in h44 of 16S rRNA, and it is involved in
maintaining translation fidelity.103 Many antibiotics exert their activity by binding to the
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A site (e.g., neomycin and kanamycin) or regions near A site (hygromycin B) and thereby
prevent the translocation of mRNA and tRNA on the ribosome.204 Cisplatin and 5 show
multiple coordination sites between the A1415 and G1423 region, which has many
wobble pairs (Figure 4.11). A strong 5 binding site is located at G1334, next to a wobble
pair and another minor binding is detected at G1370 of the h43 region.

Figure 4.12. Probing result for the ribosomal H69 region with mono-activated
cisplatin and 5. (a)The autoradiogram shows reverse transcription mapping of in vitro
reactive sites of mono-activated cisplatin and 5 on 70S ribosomes in a 1:200 molar ratio.
The stop sites for cisplatin () and 5 () are shown with symbols (,major, ,minor
adduct). Dideoxy sequencing lanes are labeled as U, C, A, and G. (b) The rRNA
secondary structure with the corresponding platinum-reactive sites is shown. The primer
binding site is shown with an arrow.
Mono-activated compound 5 binding to H69 region of the 23S rRNA is observed
as shown in Figure 4.12. Platination is observed for both cisplatin and 5 at G1921-22
residues, which are next to a wobble pair. In vitro studies with model H69 hairpin loop
have confirmed the cisplatin binding at G1921 and G1922 as well.95 H69 region forms
the intersubunit bridge B2a with h44 in the 70S ribosome.205 This region undergoes
conformational changes to facilitate translation initiation and ribosome recycling.206
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Therefore, it is likely that Pt(II) drug binding to these dynamic motifs could inhibit
protein translation.

Figure 4.13. Probing result for ribosomal PTC region with mono-activated cisplatin
and 5. (a)The autoradiogram shows reverse transcription mapping of in vitro reactive
sites of mono-activated cisplatin and 5 on 70S ribosomes in a 1:200 molar ratio. The stop
sites for cisplatin () and 5 () are shown with symbols (,major, ,minor adduct).
Dideoxy sequencing lanes are labeled as U, C, A, and G. (b) The rRNA secondary
structure with the corresponding platinum-reactive sites is shown. The primer binding site
is shown with an arrow.
The PTC region of the 23S large subunit of the ribosome is another targeted
region for multiple drugs. My probing results reveal cisplatin binding sites at the PTC
region, but none for 5 (Figure 4.13). Similar to the published crystal structure with the
platinum-modified ribosome, strong stop sites at the A2530-G2535 region suggest
cisplatin binding. This region interacts with the ribosomal protein L6, and therefore, the
C-terminus of the protein is likely to interact with the Pt adduct.40 These contacts at the
GTPase activating center could affect possibly GTP hydrolysis or EF-G binding.40 Larger
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drugs such as macrolides and peptides are known to bind to the upper exit channel of the
PTC region.207 Preliminary probing data show interactions at A2058-2059, which are
residues in the macrolide binding pocket (data not shown).207
The sequence preference for cisplatin binding to DNA is well characterized.
Cisplatin prefers binding to G-C rich DNA sequences. The adducts mostly form at –
d(GG)- or –d(AG)- sequences.166 Furthermore, the flanking bases also play a role in
platination.174,175 The main factor governing the structural specificity of cisplatin is
accessibility of the N7 of guanine base for reactions with aquated cisplatin. One study
with a DNA hairpin, d(CGCGTTGTTCGCG) showed that guanine located in the loop is
preferred for reactivity over guanines in the stem region due to the increased solvent
accessibility.47 Some of the types of adducts formed in RNA are similar to DNA.43,208
Reactivity studies with RNA have also shown cisplatin binding at loop regions, A
residues, G-C-rich, and wobble base-pair regions using full-length tRNA and ribosomal
RNA.44,208 The reactive sites observed in my probing studies showed similar trends as
with the above-mentioned sequences and secondary structures. The adducts occur at
purine residues in the context of –d(GG)- or –d(AG)- sequences. Furthermore, we
observed that Pt(II) compounds seem to prefer binding to non-standard duplex regions,
such as mismatches. Only a few adducts were located at the residues involved in
canonical base pairing with a standard A-form helix. All other sites were involved with
bulges, internal loops, hairpin loops, or GU wobble pairs. Interestingly, many of the
major binding sites of mono-activated 5 were at or next to wobble pairs. Wobble pairs
have been implicated in RNA functioning in some studies.127 The GU wobble pair is the
most common non-Watson-Crick pair in RNA.209 Regions with tandem GU pairs in the
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major groove of RNA have more negative surface potentials, which may play a role in
metal binding.209,210 In the rRNA probing, some of the positively charged cisplatin and 5
binding sites were at GU wobble pair sites, probably due to the high negative potential
at those sites.
My results suggest that cisplatin and 5 have some similar reactive sites. But compared
to cisplatin, 5 showed overall lower band intensities at the reactive sites. Irrespective of
the bulky carbohydrate ligand of 5, it is noteworthy to observe 5 reactivity at most of the
cisplatin reactive sites. This agrees with the RNA preference of mono-activated 5 and
implies that sugar conjugation has altered the target specificity of the platinum
compound.
Overall, the data in this chapter shows the reactivity of compound 5 compared to
cisplatin. The two compounds have different non-leaving group ligands, and by
comparing similarly activated compounds side by side, we could evaluate the role of the
ligands on the activity. My data show that carbohydrate conjugation reduces the reaction
rates of compound 5 relative to the parent cisplatin, likely due to steric effects and
restricted flexibility of the carbohydrate moiety. These key structural differences in the
compound may help minimize off-target binding. The DNA structural changes caused by
compound 5 binding were also analyzed by using plasmid and short oligomer DNAs.
Compound 5 caused unwinding and bending of the DNA, similar to cisplatin, even
though the binding event appeared to be slower than cisplatin. Kinetic studies of monoactivated compound 5 showed preference towards RNA over DNA. Furthermore,
ribosome-binding studies showed that the compound 5 binding sites overlap with
cisplatin and other common drug-binding sites, suggesting that the binding could
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potentially disrupt the protein translation process. Therefore, further efforts towards the
design of carbohydrate-linked platinum analogs for the treatment of specific cancers
might include RNA as a potential target.
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CHAPTER 5
POTENCY AND ACCUMULATION OF A CARBOHYDRATE-LINKED
PLATINUM COMPOUND IN HUMAN CELL LINES
5.1 Abstract
Different platinum anticancer drugs have different levels of potency in different
cancer types. To explore the cytotoxicity of the carbohydrate-platinum compound (5)
towards various cancer cell lines, a series of MTT assays were carried out. Comparable
cytotoxicities of compound 5 and cisplatin in ovarian and melanoma cancer cell lines was
reported previously. In this work, we expanded the study to include several other cancer
cell lines and to show low micromolar potency (4 μM) in a prostate cancer cell line,
DU145. Despite previous success, a common problem associated with platinum
compounds is their side effects originating from a lack of tumor selectivity. Selective
targeting can be achieved by utilizing characteristic features of the cancer cells, such as
enhanced glucose uptake. Therefore, it was of interest to examine compound 5 uptake
and compare cytotoxicities (IC50 values) for DU145 prostate cancer and the
corresponding normal cells. Compound 5 showed an 18-fold higher potency towards
DU145 compared to normal cells, suggesting selectivity towards the cancer cells. A
quantitative analysis of Pt levels in the cells was carried out using inductively coupled
plasma mass spectrometry (ICP-MS), to determine whether the biological differences
were due to higher accumulation of compound 5 in the cells or some other factor. There
is a 24-fold higher accumulation of 5 in cancer cells over normal cells, whereas for
cisplatin it is 18-fold. Therefore, these findings suggest the potential of using
glycoconjugated platinum complexes as lead compounds for selective tumor targeting.
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5.2 Introduction
The drawbacks associated with the antitumor drugs have stimulated the search for
new compounds with improved pharmacological properties. In the search for new
compounds, one of the first steps is testing their antitumor activity against a panel of
cancer cells.7,201,211 This approach will facilitate identification of tumor cells that are
targeted as well as determine the level of selectivity of the chosen compounds. The cell
studies together with biochemical assays will give insight into the mechanism and
facilitate the development of compounds with an improved spectrum of activity.
Although most of the existing anticancer drugs are believed to have a similar mechanism
of action for cancer cell apoptosis by binding to DNA, their potency towards different
cancer types varies.7 This difference could be due to the inherent properties of the cancer
cells, such as membrane components, in combination with the different properties of the
drugs.7
5.2.1 The MTT assay
There are several ways to quantify viable cells following drug treatment.
Traditional methods include counting cells using a hemocytometer and colony
counting.212 However, these methods can be tedious and time consuming. Another widely
used method is the radionuclide incorporation assay, which can be expensive and timeconsuming.212 Compared to these methods, the MTT assay is a quantitative, sensitive,
and reliable assay for cell viability measurements.129,213 It is a colorimetric assay to
indicate the cellular metabolic activity. MTT is a yellow-colored, water-soluble dye that
can readily undergo reduction, primarily by mitochondrial dehydrogenases, to produce
purple colored formazan crystals.213 This conversion takes place in the presence of live
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cells, in which MTT is taken up through endocytosis, and the formazan product is
transported and crystallized on the cell surface.214 The intensity of the color is therefore
correlated with the number of live cells present. The absorbance is read (usually between
500 and 600 nm) after dissolving the formazan crystals in DMSO.130 The absorbance is
compared to the controls and normalized to calculate the percent survival of cells. The
cytotoxicity of the drugs is given as the IC50 value after exposing the cells to different
concentrations of the drug. The IC50 value is the drug concentration at which half of the
cell activity is inhibited.215 This value is obtained from a graph plotted against the percent
survival and the relevant drug concentrations. Although used for cell viability, this assay
can also be used to analyze cell proliferation.213 The MTT assay has been widely adopted
due to its simplicity and sensitivity. However, certain parameters have to be taken into
consideration when optimizing the assay to obtain the best signal intensity. These include
the number of cells and their metabolic activity, the concentration of MTT, and the length
of incubation.213 There are other tetrazolium reduction assays that are similar to MTT.130
The most commonly used tetrazolium compounds include MTS (3-(4,5-dimethylthiazol2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium), XTT (2,3-bis-(2methoxy-4-nitro-5-sulfophenyl)-2H-tetrazolium-5-carboxanilide),

and

WST

(2-(2-

methoxy-4-nitrophenyl)-3-(4-nitrophenyl)-5-(2,4-disulfophenyl)-2H-tetrazolium).215
Resazurin reduction assay and trypan blue assays are also commonly used for cell
viability.130,215
5.2.2 Potency of major platinum-based drugs in human cancer cell lines
Cisplatin, oxaliplatin, and carboplatin are FDA-approved, platinum-based
anticancer drugs that are used around the globe.17 These compounds exhibit a broad
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spectrum of activity.59 Their potency has been widely documented with different cancer
cell lines using the above-mentioned methods.216,217 The IC50 value for a drug in the same
cell line can vary depending on many parameters, including the assay type and treatment
period.215 Table 5.1 summarizes the IC50 values that have been reported for the major
platinum-based anticancer drugs in several human cancer cell lines.
Table 5.1. IC50 values of cisplatin, oxaliplatin, and carboplatin in human cancer cell
lines
IC50 (μM)
cell line

cisplatin

oxaliplatin

carboplatin

MDA-MB-231

1.4 ± 0.2 (120 h*)216

23 ± 0.1 (72 h*)217

MDA-MB-435

5.8 ± 4 (24 h*)191

12.7 ± 5.6 (24 h*)191

H1299

21.4 ± 4 (72 h*)218

-

19.3 ± 3 (5 days*)219

DU145

3 (72 h*)220

-

10 ± 0.7 (5 days*)219

LNCaP

15.9 ± 4.7 (72 h)221

>50 (24 h*)222

IGROV1

5.6 ± 1.3 (24 h*)191

8.08 ± 2.9 (24 h*)191

A549

2.7 ± 0.5 (120 h*)216

0.86 ± 0.09 (72 h*)165

HOP-92

3.6 ± 3.2 (24 h*)191

2.70 ± 0.6 (24 h*)191

-

COLO205

16.7 ±7.2 (24 h*)191

2.8 ± 0.64 (24 h*)191

69 (72 h)

MCF7

15.6 ± 6.4 (24 h*)191

1.7 ± 0.54 (24 h*)191

62.2 (72 h)

HeLa

30. 4 ± 11 (24 h*)224

11.8 ± 1.4 (72 h*)225

5.4 ± 1.5 (96 h*)151

8.3 ± 0.3 (120 h*)216
-

>100 (72 h)221
49 ± 15 (96 h)223
20 ± 0.9 (120 h*)216

The drug treatment times are given in parenthesis. The IC50 values were determined by
*the MTT or MTS assay, 
, or  cell survival assay.
MDA-MB, IGROV1: ovarian cancer; H1299: lung cancer; DU145, LNCaP: prostate
cancer; A549: lung cancer; HOP: non small cell lung cancer; COLO205: colorectal
cancer; MCF7: breast cancer; HeLa: cervical cancer
5.2.3 Potency of carbohydrate-derived platinum(II) analogs
Several challenges such as low water solubility and high toxicity for normal cells
in the traditional platinum-based drugs can be overcome by tuning the ligands.151
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Carbohydrates are a class of bioavailable ligands that are non-toxic, inexpensive, and
easy to modulate in order to introduce desirable properties for drug applications.151
Multiple attempts have been made to synthesize platinum(II) and (IV) complexes with
carbohydrates ligands, as described in the previous chapters of this thesis.121,151,158,211 In
this chapter, only the activities of platinum(II)-carbohydrate complexes will be discussed.
Carbohydrate conjugation has been shown to help overcome some of the abovementioned drawbacks associated with traditional drugs. For example, a series of
glycoconjugated oxaliplatin derivatives were shown to have 50- to 120-fold increases in
water solubility at 25 C compared to the parent compound oxaliplatin.211 Another
feature that has been explored with glycoconjugated Pt(II) complexes is their selectivity
towards tumors.81,165,211 According to the Warburg effect, tumor cells have a higher
metabolism, which is necessary to promote tumor growth, proliferation, and
survival.226,227 An outcome of this increased metabolism is increased glucose uptake and
higher glucose transporter (GLUT) expression on the cell membrane to facilitate the
uptake.156,165 Therefore, this is a feature of malignant cells that can be exploited when
designing glycoconjugated platinum complexes for selective targeting. There are 12
members of the glucose transporter gene family, in which GLUT1 is ubiquitously
expressed in all tissue types.154 Other than for achieving selectivity, glycoconjugation can
also be used as a strategy to overcome cross-resistance due to decreased drug uptake.165
Tables 5.2 and 5.3 show potencies of a few glycoconjugated platinum(II) analogs
with promising activity in comparison to clinically available platinum(II) drugs. Figure
5.1a shows glucose, mannose, and galactose-conjugated oxaliplatin derivatives, in which
the sugar group is attached as the leaving group ligand. These compounds show improved
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water solubility and comparable cytotoxicity to oxaliplatin (Table 5.2) in the tested
human cancer cell lines.165,211 Additionally, GLUT1-dependent uptake of these
derivatives was observed in HT29 cells that overexpress glucose transporters.165,211 The
structure of a simple diaminosugar-platinum(II) complex with a 2,3-diamino-2,3dideoxy-D-glucose non-leaving group ligand and different leaving group ligands are
shown in Figure 5.1b.158 The cytotoxicity for these derivatives was determined in human
cancer cell lines using the MTT assay and shown to have low micromolar range IC50
values (≤10 μM) as given in Table 5.3.
(b)

(a)

Figure 5.1. The chemical structures of sugar-conjugated platinum(II) complexes.
(a) Sugar-conjugated (trans-R,R-cyclohexane-1,2-diammine)-2-flouromalonato
platinum(II) and (b) a diaminosugar-platinum(II) complex with different leaving group
ligands are shown.
Table 5.2. Cytotoxicity of sugar-conjugated oxaliplatin derivatives (Figure 5.1a) in
human cancer cell lines compared to oxaliplatin165
IC50 (μM)
compound

DU145

MCF7

HT29

H460

A

5.9 ± 0.16

0.61 ± 0.13

0.53 ± 0.16

11 ± 0.11

B

2.6 ± 0.18

0.41 ± 0.09

2.2 ± 0.18

10 ± 0.15

C

5.1 ± 0.14

0.41 ± 0.09

1.1 ± 0.12

10 ± 0.15

oxaliplatin

2.1 ± 0.16

0.79 ± 0.11

5.1 ± 0.20

22 ± 0.17

The IC50 values were determined by the MTS assay for 72 h. DU145: prostate cancer;
MCF7: breast cancer; HT29: colon cancer; H460: lung cancer
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Table 5.3. Cytotoxicity of diaminosugar-platinum(II) complexes (Figure 5.1b) in
human cancer cell lines compared to carboplatin and oxaliplatin158
IC50 (μM)
compound

CH1

HeLa

D

5.1 ± 0.3

7.3 ± 0.8

E

4.1 ± 0.1

10 ± 1

F

6.3 ± 0.4

23 ± 7

carboplatin

0.52 ± 0.01

5.4 ± 1.5

oxaliplatin

0.34 ± 0.09

0.3 ± 0.08

 The IC50 values were determined by the MTT assay
for 96 h. CH1: ovarian cancer; HeLa: cervical cancer
5.3 Objectives
Platinum-based drugs are widely used in cancer therapy. Successful drug
candidates are expected to show improved cytotoxicity, reduced side effects, and/or
different mechanisms of action compared to the currently available drugs.7 One purpose
of this study was to evaluate the cytotoxicity of 5 in human cancer cell lines using the
MTT assay (in collaboration with Dr. Fidelis Ndombera and Bett Kimutai). The percent
survival of the cell lines was measured in response to compound 5 compared to the parent
platinum drug, cisplatin. High cytotoxicity in tumor cell cultures doesn’t necessarily
mean a compound is only cytotoxic towards the cancer cells; it could be toxic for normal
cells as well. Therefore, one of the goals of this thesis was to discriminate between toxic
and antitumor effects of 5 by parallel testing on normal cells. I hypothesized that the
sugar group in 5 would facilitate selective uptake of the complex in cancer cells due to
the higher GLUT1 transporter expression compared to normal cells. Therefore, the
second objective of this study was to determine the level of selectivity of the compound
in cancer cells compared to normal cells. For that, the IC50 values were determined and
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compared by using the MTT assay. Thirdly, the platinum levels were quantified in cancer
and normal prostate cells to compare the cellular uptake levels of 5.
5.4 Results and discussion
5.4.1 Cytotoxicity of 5 in human cancer cell lines
The in vitro antitumor activity of compound 5 was previously reported for two
human carcinoma cell lines, A2780S and MeWo, in comparison to cisplatin (Table
5.4).82
Table 5.4. In vitro antitumor activity of compound 582
median effect dose (μM)
cell line

compound 5

cisplatin

A2780S

2.5

3.3

MeWo

11.2

8

A2780S: ovarian cancer; MeWo: human melanoma
 Cytotoxicity was measured by clonogenic survival
assay.228
Previously, compound 5 showed comparable cytotoxicity as cisplatin with
A2780S and MeWo cell lines.82 The reported low micromolar potency of 5 encouraged
me to evaluate its cytotoxicity in several other cancer cell lines with different origins in
order to relate the molecular structure of 5 with cytotoxicity, as compared to cisplatin.
The IC50 values were determined by the dose dependence of cell viability after exposure
to 5 and cisplatin (Figures 5.2 and 5.3) for 48 to 72 h (Chapter 2, Section 2.4.18). The
treatment time was increased from 48 h to 72 h in the prostate cell lines to compare the
values with literature. The data are given in Table 5.5. The IC50 values are the averages
of at least two trials (except for 5 with MDA-MB-453 and LNCaP cell lines, in which
IC50 values were calculated from one trial).

121
(a)

HeLa

HeLa
150

80

% cell viability

% cell viability

100

60
40

100

50

20
0

0
0

100

300

0

200

[comp 5] mM

LNCaP

LNCaP
100

80

80

% cell viability

100

60
40
20

300

60
40
20

0
0

20

40

0

60

0

[cisplatin] mM

(c)

20

40

60

[comp 5] mM

DU-145

DU-145
150
% cell viability

150
% cell viability

100

[cisplatin] mM

(b)

% cell viability

200

100

50

100

50

0

0
0

50

100

[cisplatin] mM

150

0

50

100

150

[comp 5] mM

Figure 5.2. Dose-response curves for cisplatin and compound 5 by using the MTT
assay for human cancer cell lines. The drug concentration that gives the 50% cell
viability (IC50 values) and the errors were obtained by a nonlinear regression curve fitting
by using the GraphPad software.
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Figure 5.3. Dose-response curves for cisplatin and compound 5 by using the MTT
assay for human cancer cell lines. The drug concentrations that give the 50% cell
viability (IC50 values) and the errors were obtained by a nonlinear regression curve fitting
by using the GraphPad software.
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Table 5.5. The IC50 values for compound 5 and cisplatin in human cancer cell lines
as evaluated by the MTT assay
IC50 (μM)

treatment
cell line

cancer type

time

compound 5

cisplatin

HeLa

cervical

48 h

184 ± 41

23 ± 1.4

LNCaP

prostate

64 h

63

4 ± 0.6

DU145

prostate

72 h

4 ± 0.7

2 ± 0.7

H1299

non small cell lung

48 h

131 ± 8

33 ± 3

MDA-MB-231

breast

48 h

106 ± 30

17 ± 4

MDA-MB-453

breast

64 h

53

10 ± 0.7

Notably, in the prostate cancer cell line DU145, compound 5 has comparable
cytotoxicity to cisplatin with an IC50 value of 4 ± 0.7 μM. It is interesting to see a higher
potency of 5 in DU145 cells irrespective of the previously observed slower reaction
kinetics. This result suggests that DU145 cells are more sensitive to 5 compared to other
tested cell lines. Multiple cancers have shown characteristic overexpression of genes that
are related to glycolysis.156 Prostate cancer is one of them, and the cells are particularly
prone to overexpression of GLUT1, which is responsible for sugar uptake.156 The DU145
cell line has been previously used for cell uptake studies with glycoconjugated
platinum(II) complexes due to this reason.83,165 Thus, higher sensitivity of DU145
towards glycoconjugated 5 compared to other cancer cells may be partly due to the higher
accumulation of the compound in the cells, which will be discussed later.
The IC50 values of 5, however, are higher than that of cisplatin in all the other cell
lines tested (Table 5.5). Cervical, breast, and lung cancer cell lines do not overexpress
the GLUT1 gene,156 which is also reflective in the cell toxicity assay data with higher
IC50 values (Table 5.5). There can be various other reasons for low potency of a drug.
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The activity of cancer drugs depends on many factors, including cell entry, drug
activation, binding to targets, and inhibition of function.211 These factors vary depending
on the characteristics of the tumor, drug-resistance mechanisms, and features of the drug
itself, and therefore, mediate the potency of the drug in a certain cell line. Additionally,
the assay type and the treatment times also affect the IC50 values. Considering the slower
kinetics of 5, increased treatment times would result in better cytotoxicity. In a previous
study, a similar trend was seen for carboplatin in which a higher cytotoxicity was
observed after a 24 h exposure period compared to a 1 h exposure period in six human
ovarian cell lines.212 Overall, compound 5 could be considered as a lead compound for
treating cancers with higher GLUT expression. Future studies can be carried out to test
the potency of compound 5 on other cancer cells lines that overexpress GLUT.
5.4.2 Cytotoxicity of 5 in normal human prostate cell line
MTT assays were carried out to investigate the selectivity of compound 5 towards
the cancer cells over normal cells. Since 5 exhibited more cytotoxicity towards DU145
prostate cancer cells, the corresponding normal prostate epithelial cell line, RPWE1, was
used to test for selectivity. Furthermore, DU145 cells have been shown to overexpress
GLUT, which is not the case for RPWE1. The hypothesis is that 5 would show higher
cytotoxicity against DU145 than RWPE1 due to GLUT-dependent uptake of the
compound. In fact, the IC50 values obtained from the MTT assays for 5 show an 18-fold
higher cytotoxicity towards DU145, whereas cisplatin did not show such a difference
(Table 5.6). The higher toxicity and selectivity of 5 towards the DU145 cancer cell line
compared to the normal cell line could be due to its higher accumulation in the cell,
which will be discussed later.
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Table 5.6. In vitro cytotoxicity of 5 and cisplatin on prostate cell lines as evaluated
by the MTT assay
cell line

cell type

IC50 (μM)

treatment
time

compound 5

cisplatin

DU145

prostate cancer

72 h

4 ± 0.7

2 ± 0.7

RWPE1

normal prostate

72 h

72 ± 2.6

4 ± 0.1

5.4.3 Quantification of 5 in cells using ICP-MS
In order to evaluate whether the cytotoxicity difference observed in Section 5.4.2
is due to Pt accumulation differences in the cells, whole cell Pt levels were quantified
after treatment. This was done by ICP-MS. First, the experimental protocol for sample
preparation and ICP-MS analysis method were optimized to obtain reproducible data to
evaluate the platinum content in the whole cell.229 The experiment was started with the
same cell number (4.6×105) in each plate (Chapter 2, Section 2.4.19). To minimize the
effects from the media, both cell lines were incubated in the same keratinocyte media
during the drug treatment. Cells were treated with 50 μM Pt(II) compounds for 2 h and
the cells were washed several times with PBS to remove excess Pt. Cells were
trypsinized, pelleted, and digested with nitric acid (16 h), and then the total cellular
platinum content was determined by ICP-MS. As shown in Figure 5.4, compound 5
displays a level of 31.5 nmol Pt per 106 cells in cancer cells, which is 24-fold higher
compared to the level in normal cells. Compared to cisplatin, 5 shows a 1.3-fold selective
accumulation in cancer cells over normal cells after 2 h treatment. Although cisplatin
accumulation levels in cancer over normal cells show an 18-fold difference, the
cytotoxicity is similar in the two cell lines. This may be due to the increased activity of
cisplatin in the cancer cells.
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Figure 5.4. Accumulation of Pt(II) compounds in prostate cancer (DU145) and
normal (RPWE1) cells. The cells were treated with 50 μM compound for 2 h and the Pt
levels were quantified by ICP-MS. The errors were calculated from two independent
trials.
The strategy of glycoconjugation for targeted delivery via glucose transporters has
been explored previously with oxaliplatin derivatives;83,121,165,211 however, this effect has
not been examined with cisplatin derivatives such as 5. A recent study from the Lippard
group focused on glucose-platinum(II) conjugates for cancer cell targeting.83 In that
study, glucose-oxaliplatin derivative uptake levels were compared between DU145 and
RWPE2 and showed a 4-fold preference for cancer cells, which was discussed by the
authors as a significant difference.83 Moreover, the same compound showed a 2-fold
reduced cancer cell viability compared to the normal cells. In comparison, we were able
to show that compound 5 has better selectivity towards DU145 cells with a significant
difference in the Pt uptake (23-fold) and cytotoxicity (18-fold) compared to RPWE1.
While the overall results from this study showed the potential of compound 5 in DU145
cell line, it is worth exploring ways to improve the activity and selectivity towards other
cancer types as well. Glycoconjugated compounds can be synthesized with modifications
to the sugar, varying linker sizes, and with different leaving group ligands to optimize the
activity and selectivity towards cancer cells. This study not only identifies the potential of
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glycoconjugated anticancer agents for selective targeting, but also sheds light on the
design of more potent sterically hindered platinum(II) complexes.
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CHAPTER 6
RNA-AMINOGLYCOSIDE INTERACTIONS PROBED THROUGH
PLATINATION KINETICS
6.1 Abstract
Electrostatics play an important role in RNA-drug interactions; however, studying
these interactions experimentally in solution can be challenging. Positively charged drug
molecules such as aminoglycosides are attracted to the negatively charged RNA. Other
ions present in the environment affect the electrostatic properties and influence these
interactions. Based on a previous study from our lab that showed salt-dependent cisplatin
coordination rates to RNA, we postulated that positively charged aminoglycosides could
change the platination rates by competing with mono-activated cisplatin for the target
(H69 RNA). Herein, we describe a kinetic method to monitor aminoglycoside
interactions with RNA using cisplatin coordination rates. The platination rate was found
to decrease significantly in the presence of aminoglycosides. This change in monoactivated cisplatin reaction rates indicated the involvement of electrostatics in
aminoglycoside-RNA interactions. In addition, we postulated that the pseudouridine (Ψ)
modifications present in a rRNA construct used in this report were perhaps important for
the binding of the aminoglycosides. However, a significant difference between modified
and unmodified H69 RNA constructs was not observed when probed with the platination
kinetics. Overall, these findings are important for providing information on drug-RNA
interaction mechanisms, improving cationic drugs for nucleic acids, identifying unique
RNA drug targets, and developing tools to investigate RNA microenvironments.
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6.2 Introduction
The phosphate backbone of nucleic acids makes them highly charged, anionic
biopolymers.230 Therefore, electrostatics play an important role in various ligand-nucleic
acid interactions. Specifically, electrostatic microenvironments created by RNA folding
are important for their biological function, stability, and ligand interactions.192 For
example, local electrostatic pockets created by the ribosome are important for its key
interactions with mRNA and tRNA.231 Furthermore, RNA-protein interactions are
governed by electrostatic interactions,232 which has been established in numerous
examples, including transcription activating (Tat) protein binding to trans-active
responsive element (TAR) RNA and Rev-peptide binding to Rev-response element
(RRE) RNA.232,233 Additionally, some drugs that target the ribosome rely on the
electrostatic interactions to bind to their target sites.120 For example, the aminoglycoside
antibiotics, including compounds neomycin, kanamycin, and paromomycin (Figure 6.1),
bind to the ribosome and interfere with various steps in protein synthesis in bacteria.120
Neomycin and paromomycin, which are the focus of this chapter, interact with the h44
region of the 16S rRNA to induce codon misreading and decrease translation
fidelity.108,109 Crystal structures have also revealed a secondary binding site for neomycin
and paromomycin at H69 of 23S rRNA.106,110,111 Interactions in the H69 major groove are
believed to inhibit the recycling and translocation steps of protein synthesis.112 The
positively charged amine groups of aminoglycosides form electrostatic interactions with
RNA.122,123 In addition, anticancer drugs such as cisplatin are also shown to bind to
RNA.234 Once cisplatin enters the cell, it undergoes aquation to produce cationic reactive
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species. Electrostatic interactions between the positively charged cisplatin and the
negatively charged RNA attract the two species for the coordination reaction to occur.

Figure 6.1. Chemical structures of aminoglycosides at pH 7. The structures of
neomycin, paromomycin, and streptomycin at pH 7 with the pKa values of amino and
guanidinium groups are shown.
As mentioned before, RNA microenvironments and their interactions with other
ligands are important for RNA biology. Inside living cells, biological molecules,
including RNA are in constant contact with cations.230,235 Cations such as Na+ and Mg2+
neutralize the negative charge of RNA and facilitate folding and stabilizing.235,236 They
also play an important role in ligand interactions.230,235 Numerous studies have shown
salt-dependent binding and rate constants for RNA-ligand interactions.122,237-243
Additionally, a broad kinetic study done by Dr. Dedduwa-Mudalige determined the saltdependent coordination rates and electrostatics in cationic metal complexes-rRNA
reactions using mono-activated cisplatin.50 The salt-dependent nature of mono-activated
cisplatin coordination to RNA suggested the possibility of using the cisplatin kinetics as a
tool to investigate other cationic ligand-rRNA interactions. In a previous study, weakly
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bound aminoglycosides with the Rev-responsive element (RRE) of HIV-1 mRNA were
shown to readily dissociate from the mRNA at relatively high salt concentrations.244 We
hypothesized that, under pseudo-first-order conditions, positively charged cisplatin would
compete and cause dissociation of aminoglycosides in a similar fashion, and then
coordinate to RNA to block further interactions. Depending on the charge state and
binding mode of the drug, the degree of competition could vary, potentially being
reflected through the cisplatin coordination rate. This knowledge was employed in
developing a tool to monitor positively charged aminoglycoside binding to H69.
Computational studies can predict the varying electrostatic potentials on RNA and
potential locations of ligand interactions.192,245,246 However, there is a lack of methods to
evaluate the role of electrostatics in RNA-ligand interactions experimentally. This
chapter describes a method to monitor the RNA-aminoglycoside interactions by using
platination kinetics, and therefore elucidate the electrostatic involvement in drug binding
to RNA.
6.3 Objectives
The ribosome is an important drug target due to its abundance, accessibility, lack
of repair mechanisms, and vital biological function in the cell.97 One of the common
features of the drugs that target RNA is their positive charge, which facilitates the initial
binding step through electrostatic contacts. A lack of experimental methods to support the
role of electrostatic interactions between RNA and drugs delays the drug development
process against resistant pathogens. The primary objective of this work was to use of
cisplatin kinetics to probe and determine the electrostatic dependence of polycationic
drugs such as aminoglycosides in binding to RNA.
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Two model H69 rRNA hairpins (Figure 6.2) were chosen for this study. The H69
RNA hairpin possesses three pseudouridine nucleotides (Figure 6.2) that have been
shown to be involved in regulating the H69 structure, stability, and function.247-250 The
contribution of pseudouridines to the electrostatics of nucleic acids have been reported
previously.251 Therefore, two H69 constructs containing either uridines (unmodified H69)
or pseudouridines (modified H69) were studied in order to understand the influence of
the modifications on electrostatics and aminoglycoside binding of rRNA.

Figure 6.2. Structures of RNA constructs used in the kinetic study. Modified ()
and unmodified (UUU) H69 rRNA constructs are shown, in which  is pseudouridine
(shown to the right).
6.4 Results and discussion
The mono-activated cisplatin coordination rates to H69 were obtained in the
presence of 1, 3, and 6 µM neomycin, paromomycin, and streptomycin as described in
Chapter 2, Section 2.4.10. A representative result for the kinetic experiment in the
presence of 1 µM neomycin is shown in Figure 6.3a. The fraction of unreacted RNA was
plotted over times to obtain the platination rates in the presence of aminoglycoside
(Figure 6.3c). The control platination reaction contained no aminoglycosides (Figure
6.3b and d). Streptomycin does not bind with H69 RNA; therefore, streptomycin was
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used as a negative control.112 The disappearance of RNA was quantified rather than
appearance of products since multiple products are observed.

Figure 6.3. Reaction kinetics of mono-activated cisplatin and RNA constructs in the
presence and absence of aminoglycoside. Autoradiograms for unmodified and modified
H69 (a) in the presence of 1 μM neomycin and (b) absence of aminoglycoside are shown
([RNA] = 0.7 μM, [mono-activated cisplatin] = 188 μM; 10 mM K2HPO4/KH2PO4, pH
6.2, with 20 mM NaClO4, 37 °C). Single-exponential-decay fits for the disappearance of
unreacted RNA (c) in the presence of 1 μM neomycin and (d) absence of aminoglycoside
as a function of time (min) are shown.
The kobs and k2,app values for both modified and unmodified H69 in the presence of
different aminoglycosides are summarized in Table 6.1. The platination rates decrease in
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the presence of neomycin (>2-fold) and paromomycin (>1.3-fold) compared to the no
aminoglycoside control, revealing that cisplatin-RNA interactions are competing with the
aminoglycosides.
Table 6.1. Observed pseudo-first-order rate constants, kobs, and the second-order
rate constants, k2,app for the reactions of mono-activated cisplatin with H69 RNA in
the presence of varying concentrations of aminoglycosides
oligonucleotide

aminoglycoside

[aminoglycoside]
(μM)

no aminoglycoside

0

14.8 ± 2.9

7.9 ± 1.6

1

6.0 ± 1.1

3.2 ± 0.6

3

2.3 ± 0.4

1.2 ± 0.2

6

0.7 ± 0.1

0.4 ± 0.05

1

10.8 ± 2.7

5.8 ± 1.4

3

4.2 ± 1.0

2.2 ± 0.5

6

3.0 ± 0.9

1.6 ± 0.5

1

17.0 ± 3.7

9.0 ± 1.9

3

15.3 ± 2.4

8.1 ± 1.3

6

18.0 ± 1.9

9.6 ± 1.1

0

14.1 ± 3.1

7.5 ± 1.7

1

3.9 ± 0.9

2.1 ± 0.5

3

1.8 ± 0.3

0.9 ± 0.2

6

1.0 ± 0.2

0.5 ± 0.1

1

8.8 ± 1.7

4.7 ± 0.9

3

1.5 ± 0.7

1.1 ± 0.4

6

1.6 ± 0.5

0.9 ± 0.3

1

13.6 ± 2.1

7.2 ± 1.1

3

12.1 ± 2.1

6.4 ± 1.1

6

18.2 ± 2.4

9.7 ± 1.3

neomycin
unmodified
H69

paromomycin

streptomycin

no aminoglycoside

neomycin

modified H69

paromomycin

streptomycin

kobs (10-4 s-1) k2,app (M-1s-1)

[RNA] = 0.7 μM, [cisplatin] = 188 μM; 10 mM K2HPO4/KH2PO4, pH 6.2, with 20 mM
NaClO4, 37 °C
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Figure 6.4. A comparison of platination rates in the presence and absence of
aminoglycosides. The platination rates obtained with unmodified H69 (UUU) and
modified H69 (ΨΨΨ) are shown. Reaction conditions: [RNA] = 0.7 μM, [mono-activated
cisplatin] = 188 μM, [aminoglycoside] = 1, 3, or 6; 10 mM K2HPO4/KH2PO4, pH 6.2,
with 20 mM NaClO4, 37 °C.
The platination rate differences in the presence of varying aminoglycosides for
unmodified H69 construct are summarized in Figure 6.4. Both RNA constructs show a
decrease in cisplatin reactivity as the aminoglycoside concentration increases. Analogous
to the impact of salts on cisplatin-RNA interactions as reported previously,50 a similar
influence can be expected for coordination of mono-activated cisplatin in the presence of
positively charged aminoglycosides. Association of positively charged aminoglycosides
with H69 screens the negative charges on RNA. Therefore, neutralizing effects by
positively charged ligands decrease the cisplatin reactivity on RNA.50 Specifically,
between 1 and 6 μM neomycin concentrations, there is an 8-fold decrease in the
platination rate compared to a 3.6-fold decrease for paromomycin with unmodified H69.
Comparison between neomycin and paromomycin at every concentration level shows
higher cisplatin reactivity for paromomycin (about a 2-fold difference) compared to the
no aminoglycoside control. The changes in the platination rates in the presence of
aminoglycosides could be explained by differing electrostatic interactions. Neomycin has
six amino groups, of which five are positively charged at the chosen experimental
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conditions (pH=6.2) (Figure 6.1).252 Paromomycin has four out of five amino groups that
are positively charged at pH 6.2. The observed cisplatin kinetics differences for neomycin
and paromomycin can be rationalized by the different charges of the aminoglycosides, in
which neomycin has one extra positive charge that can screen the RNA more effectively
than paromomycin, thus decreasing the reactivity of cisplatin. The differences in
platination rates correlate well with aminoglycoside binding preferences to H69. For
instance, neomycin has tighter binding to unmodified H69 than paromomycin (Kd values
of 0.3 and 5.4 μM, respectively). Cisplatin binding rates are proportional to the Kd values
of tested aminoglycosides.
The streptomycin control has the highest platination rates. Streptomycin has two
guanidinium groups with pKa values of 12.5, which are positively charged at the given
conditions, but this molecule has been reported previously to not bind to the H69
region.112 Thus, in the presence of streptomycin, the cisplatin-binding rate does not
change significantly from the rate in the absence of aminoglycoside. These results
indicate that electrostatic contacts are likely to be important for aminoglycoside binding
to RNA. Therefore, as the overall positive charge of the aminoglycoside is decreased, the
competitive effect of mono-activated cisplatin increases.
Aminoglycoside dependent platination rates were determined in a buffer
containing 32 mM (12 mM K+ + 20 mM Na+) total monovalent cations. In the previous
salt-dependent studies,50 as the total cation concentration increased from 32 to 112 mM,
the platination rate (k2) decreased 6-fold for unmodified H69.102 This is analogous to the
decrease in the platination rate with increasing aminoglycoside concentration from 0 to 6
μM (20-fold decrease for neomycin-unmodified H69). For modified H69, a 4-fold (salt-
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dependent kinetic data) and 15-fold (neomycin-dependent kinetic data) decrease is
observed. This result indicated that in the presence of aminoglycosides (as low as 6 μM),
the decrease in platination rate is more prominent than in the presence of higher salt
concentration (112 mM). Since the kinetic model for platination kinetics involves a
preassociation step and a coordination step,235 aminoglycosides would likely interfere
with not only the preassociation step but also the direct coordination step due to
overlapping binding locations. In fact, previous studies have shown cisplatin and
aminoglycosides binding at the H69 stem.95,111 Specifically, RNase T1 probing, MALDI
MS, and dimethylsulfate (DMS) mapping revealed platination at G1921-G1922 and
G1906-G1907.95 Neomycin and paromomycin binding interactions at the H69 stem has
been shown by Dr. Sakakibara by using DMS footprinting.253 These results were also
consistent with bacterial 70S ribosome X-ray crystal structures with neomycin bound to
the H69 stem region near residues G1906, G1921, and G1922.111 Therefore, the observed
prominent aminoglycoside-dependent rate changes could be the result of increased
competition that cisplatin faces when coordinating to RNA. Overall, the results
demonstrated that platination rate variations can be used as an indication of
aminoglycoside or other cationic compound interactions with RNA.
In aminoglycoside-dependent studies, platination rate differences between
modified and unmodified H69 were not observed, implying that pseudouridine
modification does not impact aminoglycoside interactions with H69. This result also
correlates with the similar Kd values for the two RNA constructs as determined by ESI
MS.254 This could be due to minimal influence of Ψ modifications on the global
electrostatics for H69 under the experimental conditions used to evaluate with Brønsted-
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Debye-Hückel and polyelectrolyte theories in a previous study by Dr. Gayani DedduwaMudalige.50
In conclusion, this study showed the utility of coordinating compounds, such as
cisplatin, as probes to obtain information about cationic, non-metallic ligand interactions
with RNA. As hypothesized, the effects of the bound aminoglycosides were to slow
down the cisplatin coordination rates, thereby reflecting different affinities of
aminoglycosides to H69. This method was sensitive enough to detect differences in RNA
binding by neomycin and paromomycin, which differ by a single charge. Moreover,
cisplatin kinetics could be used to evaluate the effects of varying pH on cationic drugRNA interactions. This tool could also be expanded to probe aminoglycoside binding to
other RNA or DNA targets. Overall, this study highlighted the importance of electrostatic
interactions in drug binding, and therefore provides insight into drug binding modes that
can be used to improve their affinity and efficacy.
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CHAPTER 7
OVERALL CONCLUSIONS AND FUTURE DIRECTIONS
7.1 Overall conclusions
With the discovery of cisplatin anticancer activity, a large number of platinumbased compounds have been developed and tested for their activity. Only a few of those
have entered the clinic. Even 40 years after the discovery of cisplatin, there are still wide
gaps in our understanding of its mechanism of action.3 Also, the clinical success of these
drugs has been limited due to the intrinsic and acquired resistance and side effects.255
However, a deeper understanding of how these drugs work has opened the door to
explore new platinum-based anticancer drugs.7,90 Many researchers are investigating the
biochemical and biomolecular aspects of platinum-based drug mechanism in the hope of
identifying properties that could enhance the efficacy or minimize the drawbacks of the
currently available drugs.3,90
A characteristic feature of platinum-based complexes is the ability to replace the
leaving- and/or non-leaving group ligands with a variety of functional groups. These
ligands determine different aspects of the compound activity.73 Careful selection of the
ligands facilitates tuning of cytotoxic characteristics of the complexes. Since one of the
drawbacks associated with the current platinum anticancer drugs is off-target reactions
and resistance through increased cytosolic deactivation, researchers have aimed at
decreasing reactivity through the introduction of bulky non-leaving group ligands.255
Decreased reactivity was also expected to reduce the toxicity, as was the case with
carboplatin.74 Another approach is to introduce ligands with other biological roles in the
cell to reduce the toxicity and improve selectivity.255 The work discussed in the first part
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of this thesis focused on studying a carbohydrate-linked cisplatin analog, cisdichlorido[(2-β-D-glucopyranosidyl)propane-1,3-diammine] platinum(II) (compound 5),
which has a bulky, biologically active non-leaving group ligand. Although there were
multiple cellular studies with such complexes, biochemical studies to understand the
reactivity, structural effects, and impact of the non-leaving group ligand were lacking.
Therefore, studies in this thesis work were carried out to investigate the reaction kinetics
and selectivity of compound 5 with nucleosides and oligonucleotides in order to
understand the impact of the carbohydrate non-leaving group ligand on its reactivity.
One of the main goals of this thesis was to identify the kinetics of carbohydratelinked platinum(II) compound, 5, in the context of nucleic acids and their building blocks
(e.g., nucleosides). Impact of the carbohydrate moiety of compound 5 on the reaction
kinetics and nucleic acid binding preference were discussed in Chapter 3 and 4, in the
context of steric and electrostatic properties. A comparison was made with the parent
compound, cisplatin, which is sterically less crowded. Mono-activated compound 5
showed ≥2.5-fold slower reaction kinetics compared to mono-activated cisplatin with
nucleosides, a DNA oligonucleotide (13.7-fold slower), and an RNA oligonucleotide
(3.6-fold slower). The slower kinetic effect can be attributed to the bulkier carbohydrate
moiety of the complex, in which the reactivity may be reduced due to the crowding at the
Pt reactive center. This observation suggests that compound 5 might have reduced offtarget binding.
Furthermore, mono-activated 5 showed preference towards RNA over DNA (1.7fold) in contrast to cisplatin, which preferred DNA. Ribosome-targeting drugs such as
aminoglycosides have sugar moieties with multiple hydrogen-bonding sites. With the
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RNA-binding preference and multiple hydrogen-bond donating and accepting sites,
compound 5 may have target sites within the ribosome. Therefore, ribosome-probing
studies were carried out to locate the ribosome binding sites of the compound. Compound
5 showed binding at functionally important regions of ribosomal RNA such as the A site,
the 790 loop, and H69. The binding sites overlapped with cisplatin and other common
drug binding sites, suggesting that the binding could potentially disrupt the protein
translation process. Therefore, further efforts towards the design of carbohydrate-linked
platinum analogs for the treatment of cancers might include the RNA as a potential
target. The structural effects caused by compound 5 binding were also analyzed using
plasmid and short oligomer DNA as described in Chapter 4. Compound 5 showed
unwinding and bending of DNA, similar to cisplatin, even though the kinetics appeared
to be slower than cisplatin. To best of our knowledge, this is the first attempt to determine
reaction kinetics and structural effects at the oligonucleotide level for a carbohydratelinked Pt(II) compound. Our studies were carried out to understand the influence of the
sugar moiety on the reactivity.
A large number of new Pt-based compounds have been synthesized and tested
over the past few decades.7,150,162 Unfortunately, very few have entered clinical trials, and
some very promising drug candidates were abandoned due to their toxic effects.255 One of
the reasons for this is that testing in model cell lines poorly reflects the clinical situation.
For example, high cytotoxicity in tumor cells doesn’t necessarily mean it is only
cytotoxic towards the cancer cells; the compound could be toxic to normal cells as well.
Therefore, one of the goals of this thesis work was to discriminate between toxic and
antitumor effects of 5 by parallel testing on normal cells. The high potency of 5 towards
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DU145 prostate cancer cells against normal prostate cells provided evidence for the
targeted effect of glycoconjugation as described in Chapter 5. This effect could be due to
the utilization of highly expressed glucose transporters (GLUT) on DU145 cells for
compound 5 uptake as opposed to normal cells, in which the GLUT expression is low.165
Platinum levels upon compound treatment were quantified by using ICP-MS to further
suggest the selective accumulation of 5 on cancer cells vs. normal cells. Compound 5
showed higher accumulation (24-fold) in DU145 cancer cells compared to normal cells,
which makes 5 a promising candidate for targeted delivery compared to cisplatin.
Modifying existing drugs to use them as tools to obtain information about drugtarget interactions is another approach. Chapter 6 describes an attempt to establish
cisplatin as a tool to predict the RNA-cationic drug interactions. Both cisplatin and
aminoglycosides use electrostatic interactions to bind to their target. Therefore, cisplatin
binding rates were sensitive to the cationic aminoglycoside binding to RNA, identifying
drugs that interact with RNA. Furthermore, this tool can be expanded to monitor other
charged-small molecule-RNA interactions.
In conclusion, to gain clinical success of drugs, it is important to understand the
fundamental biochemistry behind their activity. These factors contribute to the
improvement of existing drugs and also to the rational design of new drugs with few
drawbacks. During the search for new anticancer drug candidates, biological ligands such
as carbohydrates have received more attention. This thesis work provides evidence for
carbohydrate-linked Pt(II) derivatives to act as promising anticancer drug candidates with
tunable steric, electronic, and/or H-bonding properties for nucleic acid binding.
Furthermore, carbohydrate-linked platinum compound studied in this thesis showed
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comparable structural effects and potency (in DU145 cancer cells) as cisplatin, also with
selectivity towards cancer cells. Overall, this study provided new perspectives for a future
design of carbohydrate-linked platinum(II) antitumor compounds.
Techniques and tools to understand how existing drugs work are likely to
influence drug development to a similar extent as the development process of new drugs.
This thesis work also demonstrated cisplatin’s ability to act as an electrostatic probe in
giving information about other cationic drug binding to RNA. It was successfully shown
to predict the aminoglycoside binding to RNA based on the changes in the cisplatin
reaction rates that are sensitive to the cationic molecules in the environment. It could be
used to evaluate environmental and other factors that influence the drug-target
interactions and therefore likely to shape future drug development.
7.2 Future directions
7.2.1 Evaluate the reactivity of compound 5 with thiol-containing molecules
One of the mechanisms for cancers to develop resistance towards Pt-based drugs
is through deactivating the compounds by binding with thiol-containing molecules in the
cell (e.g., glutathione, sulfur-containing peptides, and proteins).59 The slower reaction
kinetics of 5 suggested that it could have limited off-target binding, which could be
advantageous for avoiding drug resistance. To evaluate the binding kinetics of 5 with a
sulfur-containing ligand, an HPLC-based kinetic study could be carried out with
glutathione. Furthermore, a competition assay with guanosine or deoxyguanosine
nucleosides with glutathione by using the same method could be used to compare the
binding rates of each target.
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7.2.2 Characterize the adducts of compound 5
Multiple products were observed for compound 5 reaction with G and dG
nucleosides. In rRNA probing experiments, compound 5 coordinating to G and A
residues were observed. In this thesis work, only the adducts with G and dG nucleosides
were identified by mass spectrometry. However, the coordination site of compound 5 on
the nucleobases was not identified in this work. This can be done by using 1H-NMR
analysis of 5-purine nucleobase adducts. Furthermore, computational modeling and
energy calculations can be used to identify the reactivity preferences of 5 and understand
the roles of the carbohydrate ligand.
7.2.3 Translation inhibition assay
Ribosome probing data showed compound 5 binding at functionally important
regions of the ribosome. Furthermore, some binding sites were overlapping with wellknown drug binding sites. Therefore, the next step would be to analyze the effects of
binding on the protein translation process. There are commercial in vitro protein
translation kits that could be easily used to obtain such information. For example, the
translation level of a marker protein (e.g., green fluorescence protein) could be measured
to evaluate the ribosome function upon treatment with compound 5. Cisplatin treated
ribosomes could be used as a positive control in such an experiment.
7.2.4 Study cellular uptake mechanism of compound 5
Cellular assays in this study showed higher potency and compound 5
accumulations in GLUT-overexpressing cancer cells compared to normal cells. To
confirm the GLUT-dependent compound 5 uptake, a competition study could be carried
out in the presence of glucose. The optimized protocol used in this thesis work could be
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used to quantify the Pt accumulation levels by using ICP-MS. The cells could be treated
with compound 5 in the presence and absence of the competitor (glucose), and the in vivo
Pt level then quantified. Furthermore, to confirm the transporter as GLUT1, the MTT
assay could be carried out in the presence and absence of a GLUT inhibitor such as EDG
(4,6-O-ethylidene-α-D-glucose).83
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APPENDIX A

Figure A1. HPLC standard curve for G.
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Figure A2. 1H-NMR spectrum of compound 4.
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Figure A3. HSQC spectrum of compound 4.
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Figure A4. 1H-NMR spectrum of compound 5.
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APPENDIX B

Figure B1. Representative results for the reactions of bis-activated Pt(II) complexes
with DNA, RNA. Plots and gels for the reactions of bis-activated Pt(II) complexes with
(a) DNA and (b) RNA are shown. The fraction of unreacted nucleic acid over time
showed an exponential decay. ([DNA or RNA] = 0.7 μM, [Pt(II)] = 94 μM; 10 mM
K2HPO4/KH2PO4, pH 6.2, with 20 mM NaClO4, 37 °C).
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Figure B2. Representative results for the salt-dependent kinetic experiment of
mono-activated Pt(II) complexes with DNA, RNA. Plots and gels for the reactions of
bis-activated Pt(II) complexes with (a) DNA and (b) RNA are shown. The fraction of
unreacted nucleic acid over time showed an exponential decay. The experiments were
carried out with lower Na+ concentration with [DNA or RNA] = 0.7 μM, [Pt(II)] = 94
μM; 10 mM K2HPO4/KH2PO4, pH 6.2, with 5 mM NaClO4 at 37 °C.
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With the discovery of cisplatin in the 1960s, it has been widely studied as a
precursor for anticancer drug development. Despite its effectiveness against certain
cancers, clinical usage of cisplatin is restricted by a number of side effects and resistance.
In the past decade, scientists have been exploring biologically important ligands such as
sugar derivatives in the hope of overcoming such challenges. Attachment of a sugar
moiety could facilitate lower accumulation of platinum drugs in the body as well as
enhance cellular uptake. In this study, a carbohydrate-linked cisplatin analog, cisdichlorido[(2-β-D-glucopyranosidyl)propane-1,3-diammine]platinum

(5)

has

been

studied. The aim was to evaluate the impact of the carbohydrate moiety on the reaction
kinetics

with

nucleosides,

target

site

identification,

structural

impacts

on

oligonucleotides, and selective cancer cell targeting. All of the experiments in this thesis
work were carried out in comparison to the parent compound cisplatin. Compound 5 was
synthesized and a reactivity study was carried out with deoxy-/ribonucleosides and
oligonucleotides using high performance liquid chromatography (HPLC) and liquid
chromatography mass spectrometry (LC-MS). A series of gel-based kinetic experiment
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was carried out comparing 5 and cisplatin with DNA and RNA oligos, with mono- and
bis-activated complexes. A salt dependence kinetic study was also carried out to
understand the contribution of electrostatics on the reactivity. A study was done to
analyze the effects of compound 5 on DNA duplex structure by measuring the bending
angles. Furthermore, probing studies on ribosomal RNA (rRNA) showed compound 5
localization on rRNA. The potency of the compound was assessed by MTT assays.
Overall, mono-activated compound 5 showed preferred binding to G over dG, which is
opposite of the preference of cisplatin for dG. A similar trend was observed for monoactivated 5 at the oligonucleotide level, in which RNA binding was preferred over DNA.
However, in all the experiments, the reaction rate for mono- or bis-activated 5 was lower
(≥2.5-fold) than that of aquated cisplatin. Data from the kinetic experiments suggest that
the bulky carbohydrate ligand may play a role in reducing the reactivity of compound 5.
Salt dependence kinetic data suggested the RNA binding preference of 5 may come from
its ability to form additional hydrogen-bonding interactions with the target compared to
cisplatin. Therefore, glycoconjugation alters target specificity of the platinum compound.
Furthermore, compound 5 formed platinum adducts that bend the DNA structure in a
manner similar to cisplatin. Cell-based assays showed that 5 has selectivity towards
glucose transporter (GLUT) overexpressing cancer cells (DU145) over normal cells
(RWPE1). Overall, these findings support the potential of using glycoconjugated
platinum complexes as lead compounds for anticancer drug development with controlled
activity and target selectivity.
Electrostatics play an important role in RNA-ligand interactions. Positively
charged drug molecules and other ligands are attracted to the negatively charged RNA.
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Monovalent and divalent ions affect the electrostatic properties and influence these
interactions; however, few methods exist to study these interactions in solution. This
work focused on the use of cationic transition metal complexes as tools to study the
electrostatic contributions of drug-RNA interactions. More specifically, positively
charged mono-activated cisplatin and small model rRNA constructs were employed. The
rates of the platination were determined by using gel shift analysis in the presence of
different aminoglycosides. The rates of platination with RNA were shown to decrease in
the presence of aminoglycosides, suggesting a competition between cisplatin and
aminoglycosides to bind to the RNA. This work demonstrated the utility of monoaquated
cisplatin kinetics as a tool to study RNA-aminoglycoside interactions. Overall, these
findings are important for providing details on drug-RNA interactions, improving
cationic drugs for nucleic acids, identifying unique RNA drug targets, and developing
tools to investigate RNA microenvironments.
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